#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Sensory and cross-network contributions to response inhibition in patients with schizophrenia
#Text=Patients with schizophrenia show response inhibition deficits equal to or greater than those seen in impulse-control disorders, and these deficits contribute to poor outcome.
1-1	0-7	Sensory	_
1-2	8-11	and	_
1-3	12-25	cross-network	_
1-4	26-39	contributions	_
1-5	40-42	to	_
1-6	43-51	response	_
1-7	52-62	inhibition	_
1-8	63-65	in	_
1-9	66-74	patients	_
1-10	75-79	with	_
1-11	80-93	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	94-102	Patients	_
1-13	103-107	with	_
1-14	108-121	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	122-126	show	_
1-16	127-135	response	_
1-17	136-146	inhibition	_
1-18	147-155	deficits	_
1-19	156-161	equal	_
1-20	162-164	to	_
1-21	165-167	or	_
1-22	168-175	greater	_
1-23	176-180	than	_
1-24	181-186	those	_
1-25	187-191	seen	_
1-26	192-194	in	_
1-27	195-210	impulse-control	_
1-28	211-220	disorders	_
1-29	220-221	,	_
1-30	222-225	and	_
1-31	226-231	these	_
1-32	232-240	deficits	_
1-33	241-251	contribute	_
1-34	252-254	to	_
1-35	255-259	poor	_
1-36	260-267	outcome	_
1-37	267-268	.	_

#Text=However, little is known about the circuit abnormalities underlying this impairment.
2-1	269-276	However	_
2-2	276-277	,	_
2-3	278-284	little	_
2-4	285-287	is	_
2-5	288-293	known	_
2-6	294-299	about	_
2-7	300-303	the	_
2-8	304-311	circuit	_
2-9	312-325	abnormalities	_
2-10	326-336	underlying	_
2-11	337-341	this	_
2-12	342-352	impairment	_
2-13	352-353	.	_

#Text=To address this, we examined stop signal task performance in 21 patients with schizophrenia and 21 healthy controls using event related potential (ERP) and resting state functional connectivity.
3-1	354-356	To	_
3-2	357-364	address	_
3-3	365-369	this	_
3-4	369-370	,	_
3-5	371-373	we	_
3-6	374-382	examined	_
3-7	383-387	stop	_
3-8	388-394	signal	_
3-9	395-399	task	_
3-10	400-411	performance	_
3-11	412-414	in	_
3-12	415-417	21	_
3-13	418-426	patients	_
3-14	427-431	with	_
3-15	432-445	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-16	446-449	and	_
3-17	450-452	21	_
3-18	453-460	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-19	461-469	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-20	470-475	using	_
3-21	476-481	event	_
3-22	482-489	related	_
3-23	490-499	potential	_
3-24	500-501	(	_
3-25	501-504	ERP	_
3-26	504-505	)	_
3-27	506-509	and	_
3-28	510-517	resting	_
3-29	518-523	state	_
3-30	524-534	functional	_
3-31	535-547	connectivity	_
3-32	547-548	.	_

#Text=Patients showed prolonged stop signal reaction time (SSRT) and reduced N1, N2, and P3 amplitudes compared to controls.
4-1	549-557	Patients	_
4-2	558-564	showed	_
4-3	565-574	prolonged	_
4-4	575-579	stop	_
4-5	580-586	signal	_
4-6	587-595	reaction	_
4-7	596-600	time	_
4-8	601-602	(	_
4-9	602-606	SSRT	_
4-10	606-607	)	_
4-11	608-611	and	_
4-12	612-619	reduced	_
4-13	620-622	N1	_
4-14	622-623	,	_
4-15	624-626	N2	_
4-16	626-627	,	_
4-17	628-631	and	_
4-18	632-634	P3	_
4-19	635-645	amplitudes	_
4-20	646-654	compared	_
4-21	655-657	to	_
4-22	658-666	controls	_
4-23	666-667	.	_

#Text=Across groups, P3 amplitudes were maximal after SSRT (i.e., after the time associated with the decision to stop occurred), suggesting that this component indexed response monitoring.
5-1	668-674	Across	_
5-2	675-681	groups	_
5-3	681-682	,	_
5-4	683-685	P3	_
5-5	686-696	amplitudes	_
5-6	697-701	were	_
5-7	702-709	maximal	_
5-8	710-715	after	_
5-9	716-720	SSRT	_
5-10	721-722	(	_
5-11	722-725	i.e	_
5-12	725-726	.	_
5-13	726-727	,	_
5-14	728-733	after	_
5-15	734-737	the	_
5-16	738-742	time	_
5-17	743-753	associated	_
5-18	754-758	with	_
5-19	759-762	the	_
5-20	763-771	decision	_
5-21	772-774	to	_
5-22	775-779	stop	_
5-23	780-788	occurred	_
5-24	788-789	)	_
5-25	789-790	,	_
5-26	791-801	suggesting	_
5-27	802-806	that	_
5-28	807-811	this	_
5-29	812-821	component	_
5-30	822-829	indexed	_
5-31	830-838	response	_
5-32	839-849	monitoring	_
5-33	849-850	.	_

#Text=Multiple regression analyses showed that longer SSRTs were independently related to 1) patient status, 2) reduced N1 amplitude on successful stop trials and 3) reduced anticorrelated resting state functional connectivity between visual and frontoparietal cortical networks.
6-1	851-859	Multiple	_
6-2	860-870	regression	_
6-3	871-879	analyses	_
6-4	880-886	showed	_
6-5	887-891	that	_
6-6	892-898	longer	_
6-7	899-904	SSRTs	_
6-8	905-909	were	_
6-9	910-923	independently	_
6-10	924-931	related	_
6-11	932-934	to	_
6-12	935-936	1	_
6-13	936-937	)	_
6-14	938-945	patient	_
6-15	946-952	status	_
6-16	952-953	,	_
6-17	954-955	2	_
6-18	955-956	)	_
6-19	957-964	reduced	_
6-20	965-967	N1	_
6-21	968-977	amplitude	_
6-22	978-980	on	_
6-23	981-991	successful	_
6-24	992-996	stop	_
6-25	997-1003	trials	_
6-26	1004-1007	and	_
6-27	1008-1009	3	_
6-28	1009-1010	)	_
6-29	1011-1018	reduced	_
6-30	1019-1033	anticorrelated	_
6-31	1034-1041	resting	_
6-32	1042-1047	state	_
6-33	1048-1058	functional	_
6-34	1059-1071	connectivity	_
6-35	1072-1079	between	_
6-36	1080-1086	visual	_
6-37	1087-1090	and	_
6-38	1091-1105	frontoparietal	_
6-39	1106-1114	cortical	_
6-40	1115-1123	networks	_
6-41	1123-1124	.	_

#Text=This study used a combined multimodal imaging approach to better understand the network abnormalities that underlie response inhibition in schizophrenia.
7-1	1125-1129	This	_
7-2	1130-1135	study	_
7-3	1136-1140	used	_
7-4	1141-1142	a	_
7-5	1143-1151	combined	_
7-6	1152-1162	multimodal	_
7-7	1163-1170	imaging	_
7-8	1171-1179	approach	_
7-9	1180-1182	to	_
7-10	1183-1189	better	_
7-11	1190-1200	understand	_
7-12	1201-1204	the	_
7-13	1205-1212	network	_
7-14	1213-1226	abnormalities	_
7-15	1227-1231	that	_
7-16	1232-1240	underlie	_
7-17	1241-1249	response	_
7-18	1250-1260	inhibition	_
7-19	1261-1263	in	_
7-20	1264-1277	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-21	1277-1278	.	_

#Text=It is the first of its kind to specifically assess the brain's resting state functional architecture in combination with behavioral and ERP methods to investigate response inhibition in schizophrenia.
8-1	1279-1281	It	_
8-2	1282-1284	is	_
8-3	1285-1288	the	_
8-4	1289-1294	first	_
8-5	1295-1297	of	_
8-6	1298-1301	its	_
8-7	1302-1306	kind	_
8-8	1307-1309	to	_
8-9	1310-1322	specifically	_
8-10	1323-1329	assess	_
8-11	1330-1333	the	_
8-12	1334-1341	brain's	_
8-13	1342-1349	resting	_
8-14	1350-1355	state	_
8-15	1356-1366	functional	_
8-16	1367-1379	architecture	_
8-17	1380-1382	in	_
8-18	1383-1394	combination	_
8-19	1395-1399	with	_
8-20	1400-1410	behavioral	_
8-21	1411-1414	and	_
8-22	1415-1418	ERP	_
8-23	1419-1426	methods	_
8-24	1427-1429	to	_
8-25	1430-1441	investigate	_
8-26	1442-1450	response	_
8-27	1451-1461	inhibition	_
8-28	1462-1464	in	_
8-29	1465-1478	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-30	1478-1479	.	_

#Text=Highlights
#Text=People with schizophrenia show deficits in response inhibition measured using behavioral and ERP methods.
9-1	1480-1490	Highlights	_
9-2	1491-1497	People	_
9-3	1498-1502	with	_
9-4	1503-1516	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-5	1517-1521	show	_
9-6	1522-1530	deficits	_
9-7	1531-1533	in	_
9-8	1534-1542	response	_
9-9	1543-1553	inhibition	_
9-10	1554-1562	measured	_
9-11	1563-1568	using	_
9-12	1569-1579	behavioral	_
9-13	1580-1583	and	_
9-14	1584-1587	ERP	_
9-15	1588-1595	methods	_
9-16	1595-1596	.	_

#Text=Behavioral and ERP measures of response inhibition are correlated.
10-1	1597-1607	Behavioral	_
10-2	1608-1611	and	_
10-3	1612-1615	ERP	_
10-4	1616-1624	measures	_
10-5	1625-1627	of	_
10-6	1628-1636	response	_
10-7	1637-1647	inhibition	_
10-8	1648-1651	are	_
10-9	1652-1662	correlated	_
10-10	1662-1663	.	_

#Text=Patient status, reduced N1, and higher resting state functional connectivity separately predicted poorer response inhibition.
11-1	1664-1671	Patient	_
11-2	1672-1678	status	_
11-3	1678-1679	,	_
11-4	1680-1687	reduced	_
11-5	1688-1690	N1	_
11-6	1690-1691	,	_
11-7	1692-1695	and	_
11-8	1696-1702	higher	_
11-9	1703-1710	resting	_
11-10	1711-1716	state	_
11-11	1717-1727	functional	_
11-12	1728-1740	connectivity	_
11-13	1741-1751	separately	_
11-14	1752-1761	predicted	_
11-15	1762-1768	poorer	_
11-16	1769-1777	response	_
11-17	1778-1788	inhibition	_
11-18	1788-1789	.	_

#Text=This study underscores the value of using multimodal imaging to understand response inhibition deficits in schizophrenia.
12-1	1790-1794	This	_
12-2	1795-1800	study	_
12-3	1801-1812	underscores	_
12-4	1813-1816	the	_
12-5	1817-1822	value	_
12-6	1823-1825	of	_
12-7	1826-1831	using	_
12-8	1832-1842	multimodal	_
12-9	1843-1850	imaging	_
12-10	1851-1853	to	_
12-11	1854-1864	understand	_
12-12	1865-1873	response	_
12-13	1874-1884	inhibition	_
12-14	1885-1893	deficits	_
12-15	1894-1896	in	_
12-16	1897-1910	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-17	1910-1911	.	_

#Text=Introduction
#Text=Response inhibition is impaired in schizophrenia (Sz) (;;;;).
13-1	1912-1924	Introduction	_
13-2	1925-1933	Response	_
13-3	1934-1944	inhibition	_
13-4	1945-1947	is	_
13-5	1948-1956	impaired	_
13-6	1957-1959	in	_
13-7	1960-1973	schizophrenia	_
13-8	1974-1975	(	_
13-9	1975-1977	Sz	_
13-10	1977-1978	)	_
13-11	1979-1980	(	_
13-12	1980-1981	;	_
13-13	1981-1982	;	_
13-14	1982-1983	;	_
13-15	1983-1984	;	_
13-16	1984-1985	)	_
13-17	1985-1986	.	_

#Text=This is problematic because response inhibition is inversely related to impulsive behavior, and has been shown to be associated with poor outcomes in Sz.
14-1	1987-1991	This	_
14-2	1992-1994	is	_
14-3	1995-2006	problematic	_
14-4	2007-2014	because	_
14-5	2015-2023	response	_
14-6	2024-2034	inhibition	_
14-7	2035-2037	is	_
14-8	2038-2047	inversely	_
14-9	2048-2055	related	_
14-10	2056-2058	to	_
14-11	2059-2068	impulsive	_
14-12	2069-2077	behavior	_
14-13	2077-2078	,	_
14-14	2079-2082	and	_
14-15	2083-2086	has	_
14-16	2087-2091	been	_
14-17	2092-2097	shown	_
14-18	2098-2100	to	_
14-19	2101-2103	be	_
14-20	2104-2114	associated	_
14-21	2115-2119	with	_
14-22	2120-2124	poor	_
14-23	2125-2133	outcomes	_
14-24	2134-2136	in	_
14-25	2137-2139	Sz	_
14-26	2139-2140	.	_

#Text=Further, response inhibition is included in the Research Domain Criteria framework under the Response Selection: Inhibition/Suppression domain.
15-1	2141-2148	Further	_
15-2	2148-2149	,	_
15-3	2150-2158	response	_
15-4	2159-2169	inhibition	_
15-5	2170-2172	is	_
15-6	2173-2181	included	_
15-7	2182-2184	in	_
15-8	2185-2188	the	_
15-9	2189-2197	Research	_
15-10	2198-2204	Domain	_
15-11	2205-2213	Criteria	_
15-12	2214-2223	framework	_
15-13	2224-2229	under	_
15-14	2230-2233	the	_
15-15	2234-2242	Response	_
15-16	2243-2252	Selection	_
15-17	2252-2253	:	_
15-18	2254-2264	Inhibition	_
15-19	2264-2265	/	_
15-20	2265-2276	Suppression	_
15-21	2277-2283	domain	_
15-22	2283-2284	.	_

#Text=Effect sizes of impaired response inhibition in Sz as indexed by the stop signal task are greater than in impulse-control disorders such as attention deficit hyperactivity disorder (ADHD).
16-1	2285-2291	Effect	_
16-2	2292-2297	sizes	_
16-3	2298-2300	of	_
16-4	2301-2309	impaired	_
16-5	2310-2318	response	_
16-6	2319-2329	inhibition	_
16-7	2330-2332	in	_
16-8	2333-2335	Sz	_
16-9	2336-2338	as	_
16-10	2339-2346	indexed	_
16-11	2347-2349	by	_
16-12	2350-2353	the	_
16-13	2354-2358	stop	_
16-14	2359-2365	signal	_
16-15	2366-2370	task	_
16-16	2371-2374	are	_
16-17	2375-2382	greater	_
16-18	2383-2387	than	_
16-19	2388-2390	in	_
16-20	2391-2406	impulse-control	_
16-21	2407-2416	disorders	_
16-22	2417-2421	such	_
16-23	2422-2424	as	_
16-24	2425-2434	attention	_
16-25	2435-2442	deficit	_
16-26	2443-2456	hyperactivity	_
16-27	2457-2465	disorder	_
16-28	2466-2467	(	_
16-29	2467-2471	ADHD	_
16-30	2471-2472	)	_
16-31	2472-2473	.	_

#Text=Frontostriatal circuits are thought to play an important role in response inhibition, but the network abnormalities that underlie response inhibition pathology in Sz have not been well-characterized.
17-1	2474-2488	Frontostriatal	_
17-2	2489-2497	circuits	_
17-3	2498-2501	are	_
17-4	2502-2509	thought	_
17-5	2510-2512	to	_
17-6	2513-2517	play	_
17-7	2518-2520	an	_
17-8	2521-2530	important	_
17-9	2531-2535	role	_
17-10	2536-2538	in	_
17-11	2539-2547	response	_
17-12	2548-2558	inhibition	_
17-13	2558-2559	,	_
17-14	2560-2563	but	_
17-15	2564-2567	the	_
17-16	2568-2575	network	_
17-17	2576-2589	abnormalities	_
17-18	2590-2594	that	_
17-19	2595-2603	underlie	_
17-20	2604-2612	response	_
17-21	2613-2623	inhibition	_
17-22	2624-2633	pathology	_
17-23	2634-2636	in	_
17-24	2637-2639	Sz	_
17-25	2640-2644	have	_
17-26	2645-2648	not	_
17-27	2649-2653	been	_
17-28	2654-2672	well-characterized	_
17-29	2672-2673	.	_

#Text=Response inhibition deficits correlate with poorer outcomes in Sz, and we have previously found correlations between SSRT deficits and aggression.
18-1	2674-2682	Response	_
18-2	2683-2693	inhibition	_
18-3	2694-2702	deficits	_
18-4	2703-2712	correlate	_
18-5	2713-2717	with	_
18-6	2718-2724	poorer	_
18-7	2725-2733	outcomes	_
18-8	2734-2736	in	_
18-9	2737-2739	Sz	_
18-10	2739-2740	,	_
18-11	2741-2744	and	_
18-12	2745-2747	we	_
18-13	2748-2752	have	_
18-14	2753-2763	previously	_
18-15	2764-2769	found	_
18-16	2770-2782	correlations	_
18-17	2783-2790	between	_
18-18	2791-2795	SSRT	_
18-19	2796-2804	deficits	_
18-20	2805-2808	and	_
18-21	2809-2819	aggression	_
18-22	2819-2820	.	_

#Text=It is possible that response inhibition deficits are associated with a failure to “put the brakes on”, leading to a release of aggression that could otherwise be managed.
19-1	2821-2823	It	_
19-2	2824-2826	is	_
19-3	2827-2835	possible	_
19-4	2836-2840	that	_
19-5	2841-2849	response	_
19-6	2850-2860	inhibition	_
19-7	2861-2869	deficits	_
19-8	2870-2873	are	_
19-9	2874-2884	associated	_
19-10	2885-2889	with	_
19-11	2890-2891	a	_
19-12	2892-2899	failure	_
19-13	2900-2902	to	_
19-14	2903-2904	“	_
19-15	2904-2907	put	_
19-16	2908-2911	the	_
19-17	2912-2918	brakes	_
19-18	2919-2921	on	_
19-19	2921-2922	”	_
19-20	2922-2923	,	_
19-21	2924-2931	leading	_
19-22	2932-2934	to	_
19-23	2935-2936	a	_
19-24	2937-2944	release	_
19-25	2945-2947	of	_
19-26	2948-2958	aggression	_
19-27	2959-2963	that	_
19-28	2964-2969	could	_
19-29	2970-2979	otherwise	_
19-30	2980-2982	be	_
19-31	2983-2990	managed	_
19-32	2990-2991	.	_

#Text=Thus, patients with schizophrenia show an increase in impulsive aggression, and that impaired response inhibition contributes to this problem.
20-1	2992-2996	Thus	_
20-2	2996-2997	,	_
20-3	2998-3006	patients	_
20-4	3007-3011	with	_
20-5	3012-3025	schizophrenia	_
20-6	3026-3030	show	_
20-7	3031-3033	an	_
20-8	3034-3042	increase	_
20-9	3043-3045	in	_
20-10	3046-3055	impulsive	_
20-11	3056-3066	aggression	_
20-12	3066-3067	,	_
20-13	3068-3071	and	_
20-14	3072-3076	that	_
20-15	3077-3085	impaired	_
20-16	3086-3094	response	_
20-17	3095-3105	inhibition	_
20-18	3106-3117	contributes	_
20-19	3118-3120	to	_
20-20	3121-3125	this	_
20-21	3126-3133	problem	_
20-22	3133-3134	.	_

#Text=Similarly, schizophrenia is associated with increased suicidal ideation and behavior.
21-1	3135-3144	Similarly	_
21-2	3144-3145	,	_
21-3	3146-3159	schizophrenia	_
21-4	3160-3162	is	_
21-5	3163-3173	associated	_
21-6	3174-3178	with	_
21-7	3179-3188	increased	_
21-8	3189-3197	suicidal	_
21-9	3198-3206	ideation	_
21-10	3207-3210	and	_
21-11	3211-3219	behavior	_
21-12	3219-3220	.	_

#Text=Thus, impaired response inhibition may also contribute to the transition from suicidal ideation to action.
22-1	3221-3225	Thus	_
22-2	3225-3226	,	_
22-3	3227-3235	impaired	_
22-4	3236-3244	response	_
22-5	3245-3255	inhibition	_
22-6	3256-3259	may	_
22-7	3260-3264	also	_
22-8	3265-3275	contribute	_
22-9	3276-3278	to	_
22-10	3279-3282	the	_
22-11	3283-3293	transition	_
22-12	3294-3298	from	_
22-13	3299-3307	suicidal	_
22-14	3308-3316	ideation	_
22-15	3317-3319	to	_
22-16	3320-3326	action	_
22-17	3326-3327	.	_

#Text=Indeed, models of suicidal ideation and behavior include impulsivity as a general risk factor for both phenomena.
23-1	3328-3334	Indeed	_
23-2	3334-3335	,	_
23-3	3336-3342	models	_
23-4	3343-3345	of	_
23-5	3346-3354	suicidal	_
23-6	3355-3363	ideation	_
23-7	3364-3367	and	_
23-8	3368-3376	behavior	_
23-9	3377-3384	include	_
23-10	3385-3396	impulsivity	_
23-11	3397-3399	as	_
23-12	3400-3401	a	_
23-13	3402-3409	general	_
23-14	3410-3414	risk	_
23-15	3415-3421	factor	_
23-16	3422-3425	for	_
23-17	3426-3430	both	_
23-18	3431-3440	phenomena	_
23-19	3440-3441	.	_

#Text=Response inhibition in schizophrenia likely contributes to 1) poorer community outcomes and 2) behaviors that lead to complications in treatment, increased rates of hospitalization and prolonged hospital stays.
24-1	3442-3450	Response	_
24-2	3451-3461	inhibition	_
24-3	3462-3464	in	_
24-4	3465-3478	schizophrenia	_
24-5	3479-3485	likely	_
24-6	3486-3497	contributes	_
24-7	3498-3500	to	_
24-8	3501-3502	1	_
24-9	3502-3503	)	_
24-10	3504-3510	poorer	_
24-11	3511-3520	community	_
24-12	3521-3529	outcomes	_
24-13	3530-3533	and	_
24-14	3534-3535	2	_
24-15	3535-3536	)	_
24-16	3537-3546	behaviors	_
24-17	3547-3551	that	_
24-18	3552-3556	lead	_
24-19	3557-3559	to	_
24-20	3560-3573	complications	_
24-21	3574-3576	in	_
24-22	3577-3586	treatment	_
24-23	3586-3587	,	_
24-24	3588-3597	increased	_
24-25	3598-3603	rates	_
24-26	3604-3606	of	_
24-27	3607-3622	hospitalization	_
24-28	3623-3626	and	_
24-29	3627-3636	prolonged	_
24-30	3637-3645	hospital	_
24-31	3646-3651	stays	_
24-32	3651-3652	.	_

#Text=The present study directly addresses this gap in our understanding of networks underlying response inhibition deficits in Sz by using the stop signal task, which indexes response inhibition, and a combined neurophysiological and fMRI/resting state functional connectivity (RSFC) approach.
25-1	3653-3656	The	_
25-2	3657-3664	present	_
25-3	3665-3670	study	_
25-4	3671-3679	directly	_
25-5	3680-3689	addresses	_
25-6	3690-3694	this	_
25-7	3695-3698	gap	_
25-8	3699-3701	in	_
25-9	3702-3705	our	_
25-10	3706-3719	understanding	_
25-11	3720-3722	of	_
25-12	3723-3731	networks	_
25-13	3732-3742	underlying	_
25-14	3743-3751	response	_
25-15	3752-3762	inhibition	_
25-16	3763-3771	deficits	_
25-17	3772-3774	in	_
25-18	3775-3777	Sz	_
25-19	3778-3780	by	_
25-20	3781-3786	using	_
25-21	3787-3790	the	_
25-22	3791-3795	stop	_
25-23	3796-3802	signal	_
25-24	3803-3807	task	_
25-25	3807-3808	,	_
25-26	3809-3814	which	_
25-27	3815-3822	indexes	_
25-28	3823-3831	response	_
25-29	3832-3842	inhibition	_
25-30	3842-3843	,	_
25-31	3844-3847	and	_
25-32	3848-3849	a	_
25-33	3850-3858	combined	_
25-34	3859-3877	neurophysiological	_
25-35	3878-3881	and	_
25-36	3882-3886	fMRI	_
25-37	3886-3887	/	_
25-38	3887-3894	resting	_
25-39	3895-3900	state	_
25-40	3901-3911	functional	_
25-41	3912-3924	connectivity	_
25-42	3925-3926	(	_
25-43	3926-3930	RSFC	_
25-44	3930-3931	)	_
25-45	3932-3940	approach	_
25-46	3940-3941	.	_

#Text=RSFC was first described >20 years ago, and has been increasingly used to evaluate network-level contributions to impaired cognitive performance across neuropsychiatric disorders.
26-1	3942-3946	RSFC	_
26-2	3947-3950	was	_
26-3	3951-3956	first	_
26-4	3957-3966	described	_
26-5	3967-3968	>	_
26-6	3968-3970	20	_
26-7	3970-3971	 	_
26-8	3971-3976	years	_
26-9	3977-3980	ago	_
26-10	3980-3981	,	_
26-11	3982-3985	and	_
26-12	3986-3989	has	_
26-13	3990-3994	been	_
26-14	3995-4007	increasingly	_
26-15	4008-4012	used	_
26-16	4013-4015	to	_
26-17	4016-4024	evaluate	_
26-18	4025-4038	network-level	_
26-19	4039-4052	contributions	_
26-20	4053-4055	to	_
26-21	4056-4064	impaired	_
26-22	4065-4074	cognitive	_
26-23	4075-4086	performance	_
26-24	4087-4093	across	_
26-25	4094-4110	neuropsychiatric	_
26-26	4111-4120	disorders	_
26-27	4120-4121	.	_

#Text=Moreover, RSFC has been shown to be useful for investigating brain network abnormalities in Sz, and has the benefit of not being dependent on task performance confounds.
27-1	4122-4130	Moreover	_
27-2	4130-4131	,	_
27-3	4132-4136	RSFC	_
27-4	4137-4140	has	_
27-5	4141-4145	been	_
27-6	4146-4151	shown	_
27-7	4152-4154	to	_
27-8	4155-4157	be	_
27-9	4158-4164	useful	_
27-10	4165-4168	for	_
27-11	4169-4182	investigating	_
27-12	4183-4188	brain	_
27-13	4189-4196	network	_
27-14	4197-4210	abnormalities	_
27-15	4211-4213	in	_
27-16	4214-4216	Sz	_
27-17	4216-4217	,	_
27-18	4218-4221	and	_
27-19	4222-4225	has	_
27-20	4226-4229	the	_
27-21	4230-4237	benefit	_
27-22	4238-4240	of	_
27-23	4241-4244	not	_
27-24	4245-4250	being	_
27-25	4251-4260	dependent	_
27-26	4261-4263	on	_
27-27	4264-4268	task	_
27-28	4269-4280	performance	_
27-29	4281-4290	confounds	_
27-30	4290-4291	.	_

#Text=In the RSFC approach, complex brain operations are thought to reflect the interplay of multiple, interacting brain networks, including the visual sensory and frontoparietal task control networks that may be specifically relevant to attention-dependent visual task performance.
28-1	4292-4294	In	_
28-2	4295-4298	the	_
28-3	4299-4303	RSFC	_
28-4	4304-4312	approach	_
28-5	4312-4313	,	_
28-6	4314-4321	complex	_
28-7	4322-4327	brain	_
28-8	4328-4338	operations	_
28-9	4339-4342	are	_
28-10	4343-4350	thought	_
28-11	4351-4353	to	_
28-12	4354-4361	reflect	_
28-13	4362-4365	the	_
28-14	4366-4375	interplay	_
28-15	4376-4378	of	_
28-16	4379-4387	multiple	_
28-17	4387-4388	,	_
28-18	4389-4400	interacting	_
28-19	4401-4406	brain	_
28-20	4407-4415	networks	_
28-21	4415-4416	,	_
28-22	4417-4426	including	_
28-23	4427-4430	the	_
28-24	4431-4437	visual	_
28-25	4438-4445	sensory	_
28-26	4446-4449	and	_
28-27	4450-4464	frontoparietal	_
28-28	4465-4469	task	_
28-29	4470-4477	control	_
28-30	4478-4486	networks	_
28-31	4487-4491	that	_
28-32	4492-4495	may	_
28-33	4496-4498	be	_
28-34	4499-4511	specifically	_
28-35	4512-4520	relevant	_
28-36	4521-4523	to	_
28-37	4524-4543	attention-dependent	_
28-38	4544-4550	visual	_
28-39	4551-4555	task	_
28-40	4556-4567	performance	_
28-41	4567-4568	.	_

#Text=In general, two aspects of RSFC may be considered, within-network connectivity, also termed network homogeneity and between-network connectivity.
29-1	4569-4571	In	_
29-2	4572-4579	general	_
29-3	4579-4580	,	_
29-4	4581-4584	two	_
29-5	4585-4592	aspects	_
29-6	4593-4595	of	_
29-7	4596-4600	RSFC	_
29-8	4601-4604	may	_
29-9	4605-4607	be	_
29-10	4608-4618	considered	_
29-11	4618-4619	,	_
29-12	4620-4634	within-network	_
29-13	4635-4647	connectivity	_
29-14	4647-4648	,	_
29-15	4649-4653	also	_
29-16	4654-4660	termed	_
29-17	4661-4668	network	_
29-18	4669-4680	homogeneity	_
29-19	4681-4684	and	_
29-20	4685-4700	between-network	_
29-21	4701-4713	connectivity	_
29-22	4713-4714	.	_

#Text=Here, we evaluated both aspects of RSFC relative to stop signal task performance.
30-1	4715-4719	Here	_
30-2	4719-4720	,	_
30-3	4721-4723	we	_
30-4	4724-4733	evaluated	_
30-5	4734-4738	both	_
30-6	4739-4746	aspects	_
30-7	4747-4749	of	_
30-8	4750-4754	RSFC	_
30-9	4755-4763	relative	_
30-10	4764-4766	to	_
30-11	4767-4771	stop	_
30-12	4772-4778	signal	_
30-13	4779-4783	task	_
30-14	4784-4795	performance	_
30-15	4795-4796	.	_

#Text=The stop signal task is a dual-task paradigm.
31-1	4797-4800	The	_
31-2	4801-4805	stop	_
31-3	4806-4812	signal	_
31-4	4813-4817	task	_
31-5	4818-4820	is	_
31-6	4821-4822	a	_
31-7	4823-4832	dual-task	_
31-8	4833-4841	paradigm	_
31-9	4841-4842	.	_

#Text=The “Go” task requires participants to rapidly press a button following each go signal (75% of trials).
32-1	4843-4846	The	_
32-2	4847-4848	“	_
32-3	4848-4850	Go	_
32-4	4850-4851	”	_
32-5	4852-4856	task	_
32-6	4857-4865	requires	_
32-7	4866-4878	participants	_
32-8	4879-4881	to	_
32-9	4882-4889	rapidly	_
32-10	4890-4895	press	_
32-11	4896-4897	a	_
32-12	4898-4904	button	_
32-13	4905-4914	following	_
32-14	4915-4919	each	_
32-15	4920-4922	go	_
32-16	4923-4929	signal	_
32-17	4930-4931	(	_
32-18	4931-4934	75%	_
32-19	4935-4937	of	_
32-20	4938-4944	trials	_
32-21	4944-4945	)	_
32-22	4945-4946	.	_

#Text=The secondary “Stop” task requires participants to withhold a motor response when a stop signal is presented after the go signal (~25% of trials).
33-1	4947-4950	The	_
33-2	4951-4960	secondary	_
33-3	4961-4962	“	_
33-4	4962-4966	Stop	_
33-5	4966-4967	”	_
33-6	4968-4972	task	_
33-7	4973-4981	requires	_
33-8	4982-4994	participants	_
33-9	4995-4997	to	_
33-10	4998-5006	withhold	_
33-11	5007-5008	a	_
33-12	5009-5014	motor	_
33-13	5015-5023	response	_
33-14	5024-5028	when	_
33-15	5029-5030	a	_
33-16	5031-5035	stop	_
33-17	5036-5042	signal	_
33-18	5043-5045	is	_
33-19	5046-5055	presented	_
33-20	5056-5061	after	_
33-21	5062-5065	the	_
33-22	5066-5068	go	_
33-23	5069-5075	signal	_
33-24	5076-5077	(	_
33-25	5077-5078	~	_
33-26	5078-5081	25%	_
33-27	5082-5084	of	_
33-28	5085-5091	trials	_
33-29	5091-5092	)	_
33-30	5092-5093	.	_

#Text=The time between go- and stop-signal onset (stop signal delay (SSD)), is typically titrated to yield correct inhibition on ~50% of stop trials.
34-1	5094-5097	The	_
34-2	5098-5102	time	_
34-3	5103-5110	between	_
34-4	5111-5113	go	_
34-5	5113-5114	-	_
34-6	5115-5118	and	_
34-7	5119-5130	stop-signal	_
34-8	5131-5136	onset	_
34-9	5137-5138	(	_
34-10	5138-5142	stop	_
34-11	5143-5149	signal	_
34-12	5150-5155	delay	_
34-13	5156-5157	(	_
34-14	5157-5160	SSD	_
34-15	5160-5161	)	_
34-16	5161-5162	)	_
34-17	5162-5163	,	_
34-18	5164-5166	is	_
34-19	5167-5176	typically	_
34-20	5177-5185	titrated	_
34-21	5186-5188	to	_
34-22	5189-5194	yield	_
34-23	5195-5202	correct	_
34-24	5203-5213	inhibition	_
34-25	5214-5216	on	_
34-26	5217-5218	~	_
34-27	5218-5221	50%	_
34-28	5222-5224	of	_
34-29	5225-5229	stop	_
34-30	5230-5236	trials	_
34-31	5236-5237	.	_

#Text=SSD variability allows estimation of the stop signal reaction time (SSRT), which indexes inhibitory processing speed.
35-1	5238-5241	SSD	_
35-2	5242-5253	variability	_
35-3	5254-5260	allows	_
35-4	5261-5271	estimation	_
35-5	5272-5274	of	_
35-6	5275-5278	the	_
35-7	5279-5283	stop	_
35-8	5284-5290	signal	_
35-9	5291-5299	reaction	_
35-10	5300-5304	time	_
35-11	5305-5306	(	_
35-12	5306-5310	SSRT	_
35-13	5310-5311	)	_
35-14	5311-5312	,	_
35-15	5313-5318	which	_
35-16	5319-5326	indexes	_
35-17	5327-5337	inhibitory	_
35-18	5338-5348	processing	_
35-19	5349-5354	speed	_
35-20	5354-5355	.	_

#Text=Stop signal task performance has been conceptualized as a “horserace” model.
36-1	5356-5360	Stop	_
36-2	5361-5367	signal	_
36-3	5368-5372	task	_
36-4	5373-5384	performance	_
36-5	5385-5388	has	_
36-6	5389-5393	been	_
36-7	5394-5408	conceptualized	_
36-8	5409-5411	as	_
36-9	5412-5413	a	_
36-10	5414-5415	“	_
36-11	5415-5424	horserace	_
36-12	5424-5425	”	_
36-13	5426-5431	model	_
36-14	5431-5432	.	_

#Text=In this model, go versus stop processes are thought to engage 2 distinct networks.
37-1	5433-5435	In	_
37-2	5436-5440	this	_
37-3	5441-5446	model	_
37-4	5446-5447	,	_
37-5	5448-5450	go	_
37-6	5451-5457	versus	_
37-7	5458-5462	stop	_
37-8	5463-5472	processes	_
37-9	5473-5476	are	_
37-10	5477-5484	thought	_
37-11	5485-5487	to	_
37-12	5488-5494	engage	_
37-13	5495-5496	2	_
37-14	5497-5505	distinct	_
37-15	5506-5514	networks	_
37-16	5514-5515	.	_

#Text=The go network precipitates the rapid behavioral response and the stop network is involved response inhibition.
38-1	5516-5519	The	_
38-2	5520-5522	go	_
38-3	5523-5530	network	_
38-4	5531-5543	precipitates	_
38-5	5544-5547	the	_
38-6	5548-5553	rapid	_
38-7	5554-5564	behavioral	_
38-8	5565-5573	response	_
38-9	5574-5577	and	_
38-10	5578-5581	the	_
38-11	5582-5586	stop	_
38-12	5587-5594	network	_
38-13	5595-5597	is	_
38-14	5598-5606	involved	_
38-15	5607-5615	response	_
38-16	5616-5626	inhibition	_
38-17	5626-5627	.	_

#Text=On stop trials, both networks are engaged.
39-1	5628-5630	On	_
39-2	5631-5635	stop	_
39-3	5636-5642	trials	_
39-4	5642-5643	,	_
39-5	5644-5648	both	_
39-6	5649-5657	networks	_
39-7	5658-5661	are	_
39-8	5662-5669	engaged	_
39-9	5669-5670	.	_

#Text=The performance of the participant on stop trials depends on the speed of information transfer within each distinct network.
40-1	5671-5674	The	_
40-2	5675-5686	performance	_
40-3	5687-5689	of	_
40-4	5690-5693	the	_
40-5	5694-5705	participant	_
40-6	5706-5708	on	_
40-7	5709-5713	stop	_
40-8	5714-5720	trials	_
40-9	5721-5728	depends	_
40-10	5729-5731	on	_
40-11	5732-5735	the	_
40-12	5736-5741	speed	_
40-13	5742-5744	of	_
40-14	5745-5756	information	_
40-15	5757-5765	transfer	_
40-16	5766-5772	within	_
40-17	5773-5777	each	_
40-18	5778-5786	distinct	_
40-19	5787-5794	network	_
40-20	5794-5795	.	_

#Text=When the go process takes longer than the SSRT, the participant successfully inhibits the motor response.
41-1	5796-5800	When	_
41-2	5801-5804	the	_
41-3	5805-5807	go	_
41-4	5808-5815	process	_
41-5	5816-5821	takes	_
41-6	5822-5828	longer	_
41-7	5829-5833	than	_
41-8	5834-5837	the	_
41-9	5838-5842	SSRT	_
41-10	5842-5843	,	_
41-11	5844-5847	the	_
41-12	5848-5859	participant	_
41-13	5860-5872	successfully	_
41-14	5873-5881	inhibits	_
41-15	5882-5885	the	_
41-16	5886-5891	motor	_
41-17	5892-5900	response	_
41-18	5900-5901	.	_

#Text=Brain networks supporting response inhibition in healthy controls have been previously investigated in event-related potential (ERP) and fMRI studies, providing a strong context within which to interpret the findings of this study.
42-1	5902-5907	Brain	_
42-2	5908-5916	networks	_
42-3	5917-5927	supporting	_
42-4	5928-5936	response	_
42-5	5937-5947	inhibition	_
42-6	5948-5950	in	_
42-7	5951-5958	healthy	_
42-8	5959-5967	controls	_
42-9	5968-5972	have	_
42-10	5973-5977	been	_
42-11	5978-5988	previously	_
42-12	5989-6001	investigated	_
42-13	6002-6004	in	_
42-14	6005-6018	event-related	_
42-15	6019-6028	potential	_
42-16	6029-6030	(	_
42-17	6030-6033	ERP	_
42-18	6033-6034	)	_
42-19	6035-6038	and	_
42-20	6039-6043	fMRI	_
42-21	6044-6051	studies	_
42-22	6051-6052	,	_
42-23	6053-6062	providing	_
42-24	6063-6064	a	_
42-25	6065-6071	strong	_
42-26	6072-6079	context	_
42-27	6080-6086	within	_
42-28	6087-6092	which	_
42-29	6093-6095	to	_
42-30	6096-6105	interpret	_
42-31	6106-6109	the	_
42-32	6110-6118	findings	_
42-33	6119-6121	of	_
42-34	6122-6126	this	_
42-35	6127-6132	study	_
42-36	6132-6133	.	_

#Text=In ERP, a characteristic sequence of components is observed including N1, N2 and P3 peaksThe N1 (~170 ms) ERP component peak over occipital regions and reflects initial activation of extrastriate visual centers by stimuli within the dorsal stream “vision for action” system (;).
43-1	6134-6136	In	_
43-2	6137-6140	ERP	_
43-3	6140-6141	,	_
43-4	6142-6143	a	_
43-5	6144-6158	characteristic	_
43-6	6159-6167	sequence	_
43-7	6168-6170	of	_
43-8	6171-6181	components	_
43-9	6182-6184	is	_
43-10	6185-6193	observed	_
43-11	6194-6203	including	_
43-12	6204-6206	N1	_
43-13	6206-6207	,	_
43-14	6208-6210	N2	_
43-15	6211-6214	and	_
43-16	6215-6217	P3	_
43-17	6218-6226	peaksThe	_
43-18	6227-6229	N1	_
43-19	6230-6231	(	_
43-20	6231-6232	~	_
43-21	6232-6235	170	_
43-22	6235-6236	 	_
43-23	6236-6238	ms	_
43-24	6238-6239	)	_
43-25	6240-6243	ERP	_
43-26	6244-6253	component	_
43-27	6254-6258	peak	_
43-28	6259-6263	over	_
43-29	6264-6273	occipital	_
43-30	6274-6281	regions	_
43-31	6282-6285	and	_
43-32	6286-6294	reflects	_
43-33	6295-6302	initial	_
43-34	6303-6313	activation	_
43-35	6314-6316	of	_
43-36	6317-6329	extrastriate	_
43-37	6330-6336	visual	_
43-38	6337-6344	centers	_
43-39	6345-6347	by	_
43-40	6348-6355	stimuli	_
43-41	6356-6362	within	_
43-42	6363-6366	the	_
43-43	6367-6373	dorsal	_
43-44	6374-6380	stream	_
43-45	6381-6382	“	_
43-46	6382-6388	vision	_
43-47	6389-6392	for	_
43-48	6393-6399	action	_
43-49	6399-6400	”	_
43-50	6401-6407	system	_
43-51	6408-6409	(	_
43-52	6409-6410	;	_
43-53	6410-6411	)	_
43-54	6411-6412	.	_

#Text=The N1 is considered a “pre-decision” component and may be followed by an N2 (~220 ms) over frontal sites.
44-1	6413-6416	The	_
44-2	6417-6419	N1	_
44-3	6420-6422	is	_
44-4	6423-6433	considered	_
44-5	6434-6435	a	_
44-6	6436-6437	“	_
44-7	6437-6449	pre-decision	_
44-8	6449-6450	”	_
44-9	6451-6460	component	_
44-10	6461-6464	and	_
44-11	6465-6468	may	_
44-12	6469-6471	be	_
44-13	6472-6480	followed	_
44-14	6481-6483	by	_
44-15	6484-6486	an	_
44-16	6487-6489	N2	_
44-17	6490-6491	(	_
44-18	6491-6492	~	_
44-19	6492-6495	220	_
44-20	6495-6496	 	_
44-21	6496-6498	ms	_
44-22	6498-6499	)	_
44-23	6500-6504	over	_
44-24	6505-6512	frontal	_
44-25	6513-6518	sites	_
44-26	6518-6519	.	_

#Text=The N2 peak is observed in the same time-frame as the SSRT, and is similar to error-related negativity, which has been studied in Sz primarily using go/no-go tasks because it appears to reflect conflict and/or error monitoring processes.
45-1	6520-6523	The	_
45-2	6524-6526	N2	_
45-3	6527-6531	peak	_
45-4	6532-6534	is	_
45-5	6535-6543	observed	_
45-6	6544-6546	in	_
45-7	6547-6550	the	_
45-8	6551-6555	same	_
45-9	6556-6566	time-frame	_
45-10	6567-6569	as	_
45-11	6570-6573	the	_
45-12	6574-6578	SSRT	_
45-13	6578-6579	,	_
45-14	6580-6583	and	_
45-15	6584-6586	is	_
45-16	6587-6594	similar	_
45-17	6595-6597	to	_
45-18	6598-6611	error-related	_
45-19	6612-6622	negativity	_
45-20	6622-6623	,	_
45-21	6624-6629	which	_
45-22	6630-6633	has	_
45-23	6634-6638	been	_
45-24	6639-6646	studied	_
45-25	6647-6649	in	_
45-26	6650-6652	Sz	_
45-27	6653-6662	primarily	_
45-28	6663-6668	using	_
45-29	6669-6671	go	_
45-30	6671-6672	/	_
45-31	6672-6677	no-go	_
45-32	6678-6683	tasks	_
45-33	6684-6691	because	_
45-34	6692-6694	it	_
45-35	6695-6702	appears	_
45-36	6703-6705	to	_
45-37	6706-6713	reflect	_
45-38	6714-6722	conflict	_
45-39	6723-6726	and	_
45-40	6726-6727	/	_
45-41	6727-6729	or	_
45-42	6730-6735	error	_
45-43	6736-6746	monitoring	_
45-44	6747-6756	processes	_
45-45	6756-6757	.	_

#Text=A P3 is observed over centroparietal sites ~315 ms post-stimulus.
46-1	6758-6759	A	_
46-2	6760-6762	P3	_
46-3	6763-6765	is	_
46-4	6766-6774	observed	_
46-5	6775-6779	over	_
46-6	6780-6794	centroparietal	_
46-7	6795-6800	sites	_
46-8	6801-6802	~	_
46-9	6802-6805	315	_
46-10	6805-6806	 	_
46-11	6806-6808	ms	_
46-12	6809-6822	post-stimulus	_
46-13	6822-6823	.	_

#Text=The P3 is considered a “post-decision” component.
47-1	6824-6827	The	_
47-2	6828-6830	P3	_
47-3	6831-6833	is	_
47-4	6834-6844	considered	_
47-5	6845-6846	a	_
47-6	6847-6848	“	_
47-7	6848-6861	post-decision	_
47-8	6861-6862	”	_
47-9	6863-6872	component	_
47-10	6872-6873	.	_

#Text=Other combined ERP + fMRI studies have shown brain activation deficits during the stop signal task in Sz. showed that patients had longer SSRTs, reduced N1 and P3 amplitudes to go and stop signals, and reduced inferior frontal gyrus activation compared to controls. fMRI and lesion studies have demonstrated that response inhibition is supported by the right inferior frontal gyrus (rIFG), presupplementary area (pSMA), subthalamic nucleus, globus pallidus, and thalamus (;;;;).
48-1	6874-6879	Other	_
48-2	6880-6888	combined	_
48-3	6889-6892	ERP	_
48-4	6892-6893	 	_
48-5	6893-6894	+	_
48-6	6894-6895	 	_
48-7	6895-6899	fMRI	_
48-8	6900-6907	studies	_
48-9	6908-6912	have	_
48-10	6913-6918	shown	_
48-11	6919-6924	brain	_
48-12	6925-6935	activation	_
48-13	6936-6944	deficits	_
48-14	6945-6951	during	_
48-15	6952-6955	the	_
48-16	6956-6960	stop	_
48-17	6961-6967	signal	_
48-18	6968-6972	task	_
48-19	6973-6975	in	_
48-20	6976-6978	Sz	_
48-21	6978-6979	.	_
48-22	6980-6986	showed	_
48-23	6987-6991	that	_
48-24	6992-7000	patients	_
48-25	7001-7004	had	_
48-26	7005-7011	longer	_
48-27	7012-7017	SSRTs	_
48-28	7017-7018	,	_
48-29	7019-7026	reduced	_
48-30	7027-7029	N1	_
48-31	7030-7033	and	_
48-32	7034-7036	P3	_
48-33	7037-7047	amplitudes	_
48-34	7048-7050	to	_
48-35	7051-7053	go	_
48-36	7054-7057	and	_
48-37	7058-7062	stop	_
48-38	7063-7070	signals	_
48-39	7070-7071	,	_
48-40	7072-7075	and	_
48-41	7076-7083	reduced	_
48-42	7084-7092	inferior	_
48-43	7093-7100	frontal	_
48-44	7101-7106	gyrus	_
48-45	7107-7117	activation	_
48-46	7118-7126	compared	_
48-47	7127-7129	to	_
48-48	7130-7138	controls	_
48-49	7138-7139	.	_
48-50	7140-7144	fMRI	_
48-51	7145-7148	and	_
48-52	7149-7155	lesion	_
48-53	7156-7163	studies	_
48-54	7164-7168	have	_
48-55	7169-7181	demonstrated	_
48-56	7182-7186	that	_
48-57	7187-7195	response	_
48-58	7196-7206	inhibition	_
48-59	7207-7209	is	_
48-60	7210-7219	supported	_
48-61	7220-7222	by	_
48-62	7223-7226	the	_
48-63	7227-7232	right	_
48-64	7233-7241	inferior	_
48-65	7242-7249	frontal	_
48-66	7250-7255	gyrus	_
48-67	7256-7257	(	_
48-68	7257-7261	rIFG	_
48-69	7261-7262	)	_
48-70	7262-7263	,	_
48-71	7264-7280	presupplementary	_
48-72	7281-7285	area	_
48-73	7286-7287	(	_
48-74	7287-7291	pSMA	_
48-75	7291-7292	)	_
48-76	7292-7293	,	_
48-77	7294-7305	subthalamic	_
48-78	7306-7313	nucleus	_
48-79	7313-7314	,	_
48-80	7315-7321	globus	_
48-81	7322-7330	pallidus	_
48-82	7330-7331	,	_
48-83	7332-7335	and	_
48-84	7336-7344	thalamus	_
48-85	7345-7346	(	_
48-86	7346-7347	;	_
48-87	7347-7348	;	_
48-88	7348-7349	;	_
48-89	7349-7350	;	_
48-90	7350-7351	)	_
48-91	7351-7352	.	_

#Text=The role of frontoparietal brain networks, which additionally involve inferior parietal lobule activation, have also been emphasized in a number of fMRI studies (;;).
49-1	7353-7356	The	_
49-2	7357-7361	role	_
49-3	7362-7364	of	_
49-4	7365-7379	frontoparietal	_
49-5	7380-7385	brain	_
49-6	7386-7394	networks	_
49-7	7394-7395	,	_
49-8	7396-7401	which	_
49-9	7402-7414	additionally	_
49-10	7415-7422	involve	_
49-11	7423-7431	inferior	_
49-12	7432-7440	parietal	_
49-13	7441-7447	lobule	_
49-14	7448-7458	activation	_
49-15	7458-7459	,	_
49-16	7460-7464	have	_
49-17	7465-7469	also	_
49-18	7470-7474	been	_
49-19	7475-7485	emphasized	_
49-20	7486-7488	in	_
49-21	7489-7490	a	_
49-22	7491-7497	number	_
49-23	7498-7500	of	_
49-24	7501-7505	fMRI	_
49-25	7506-7513	studies	_
49-26	7514-7515	(	_
49-27	7515-7516	;	_
49-28	7516-7517	;	_
49-29	7517-7518	)	_
49-30	7518-7519	.	_

#Text=RSFC abnormalities may contribute to cognitive and behavioral impairment in Sz.
50-1	7520-7524	RSFC	_
50-2	7525-7538	abnormalities	_
50-3	7539-7542	may	_
50-4	7543-7553	contribute	_
50-5	7554-7556	to	_
50-6	7557-7566	cognitive	_
50-7	7567-7570	and	_
50-8	7571-7581	behavioral	_
50-9	7582-7592	impairment	_
50-10	7593-7595	in	_
50-11	7596-7598	Sz	_
50-12	7598-7599	.	_

#Text=For example, we recently observed that emotionally based impulsivity (urgency) in Sz is associated with lower RSFC between ventral prefrontal and both limbic and executive regions.
51-1	7600-7603	For	_
51-2	7604-7611	example	_
51-3	7611-7612	,	_
51-4	7613-7615	we	_
51-5	7616-7624	recently	_
51-6	7625-7633	observed	_
51-7	7634-7638	that	_
51-8	7639-7650	emotionally	_
51-9	7651-7656	based	_
51-10	7657-7668	impulsivity	_
51-11	7669-7670	(	_
51-12	7670-7677	urgency	_
51-13	7677-7678	)	_
51-14	7679-7681	in	_
51-15	7682-7684	Sz	_
51-16	7685-7687	is	_
51-17	7688-7698	associated	_
51-18	7699-7703	with	_
51-19	7704-7709	lower	_
51-20	7710-7714	RSFC	_
51-21	7715-7722	between	_
51-22	7723-7730	ventral	_
51-23	7731-7741	prefrontal	_
51-24	7742-7745	and	_
51-25	7746-7750	both	_
51-26	7751-7757	limbic	_
51-27	7758-7761	and	_
51-28	7762-7771	executive	_
51-29	7772-7779	regions	_
51-30	7779-7780	.	_

#Text=Similarly, impaired mismatch negativity to emotional tones correlated with lower RSFC between auditory cortex and insula.
52-1	7781-7790	Similarly	_
52-2	7790-7791	,	_
52-3	7792-7800	impaired	_
52-4	7801-7809	mismatch	_
52-5	7810-7820	negativity	_
52-6	7821-7823	to	_
52-7	7824-7833	emotional	_
52-8	7834-7839	tones	_
52-9	7840-7850	correlated	_
52-10	7851-7855	with	_
52-11	7856-7861	lower	_
52-12	7862-7866	RSFC	_
52-13	7867-7874	between	_
52-14	7875-7883	auditory	_
52-15	7884-7890	cortex	_
52-16	7891-7894	and	_
52-17	7895-7901	insula	_
52-18	7901-7902	.	_

#Text=Further, increased attention has also focused on the study of canonical brain networks, including visual networks related to sensory input, and frontoparietal networks that incorporate the rIFG.
53-1	7903-7910	Further	_
53-2	7910-7911	,	_
53-3	7912-7921	increased	_
53-4	7922-7931	attention	_
53-5	7932-7935	has	_
53-6	7936-7940	also	_
53-7	7941-7948	focused	_
53-8	7949-7951	on	_
53-9	7952-7955	the	_
53-10	7956-7961	study	_
53-11	7962-7964	of	_
53-12	7965-7974	canonical	_
53-13	7975-7980	brain	_
53-14	7981-7989	networks	_
53-15	7989-7990	,	_
53-16	7991-8000	including	_
53-17	8001-8007	visual	_
53-18	8008-8016	networks	_
53-19	8017-8024	related	_
53-20	8025-8027	to	_
53-21	8028-8035	sensory	_
53-22	8036-8041	input	_
53-23	8041-8042	,	_
53-24	8043-8046	and	_
53-25	8047-8061	frontoparietal	_
53-26	8062-8070	networks	_
53-27	8071-8075	that	_
53-28	8076-8087	incorporate	_
53-29	8088-8091	the	_
53-30	8092-8096	rIFG	_
53-31	8096-8097	.	_

#Text=Deficits in Sz on higher-order tasks such as the stop signal task have been previously shown to involve both impaired sensory responses to presented stimuli, and aberrant information processing within and between relevant cortical networks.
54-1	8098-8106	Deficits	_
54-2	8107-8109	in	_
54-3	8110-8112	Sz	_
54-4	8113-8115	on	_
54-5	8116-8128	higher-order	_
54-6	8129-8134	tasks	_
54-7	8135-8139	such	_
54-8	8140-8142	as	_
54-9	8143-8146	the	_
54-10	8147-8151	stop	_
54-11	8152-8158	signal	_
54-12	8159-8163	task	_
54-13	8164-8168	have	_
54-14	8169-8173	been	_
54-15	8174-8184	previously	_
54-16	8185-8190	shown	_
54-17	8191-8193	to	_
54-18	8194-8201	involve	_
54-19	8202-8206	both	_
54-20	8207-8215	impaired	_
54-21	8216-8223	sensory	_
54-22	8224-8233	responses	_
54-23	8234-8236	to	_
54-24	8237-8246	presented	_
54-25	8247-8254	stimuli	_
54-26	8254-8255	,	_
54-27	8256-8259	and	_
54-28	8260-8268	aberrant	_
54-29	8269-8280	information	_
54-30	8281-8291	processing	_
54-31	8292-8298	within	_
54-32	8299-8302	and	_
54-33	8303-8310	between	_
54-34	8311-8319	relevant	_
54-35	8320-8328	cortical	_
54-36	8329-8337	networks	_
54-37	8337-8338	.	_

#Text=Although sensory dysfunction has been demonstrated for the stop signal task, network-level interactions, revealed by RSFC, have not yet been examined in combination with neurophysiological assessments.
55-1	8339-8347	Although	_
55-2	8348-8355	sensory	_
55-3	8356-8367	dysfunction	_
55-4	8368-8371	has	_
55-5	8372-8376	been	_
55-6	8377-8389	demonstrated	_
55-7	8390-8393	for	_
55-8	8394-8397	the	_
55-9	8398-8402	stop	_
55-10	8403-8409	signal	_
55-11	8410-8414	task	_
55-12	8414-8415	,	_
55-13	8416-8429	network-level	_
55-14	8430-8442	interactions	_
55-15	8442-8443	,	_
55-16	8444-8452	revealed	_
55-17	8453-8455	by	_
55-18	8456-8460	RSFC	_
55-19	8460-8461	,	_
55-20	8462-8466	have	_
55-21	8467-8470	not	_
55-22	8471-8474	yet	_
55-23	8475-8479	been	_
55-24	8480-8488	examined	_
55-25	8489-8491	in	_
55-26	8492-8503	combination	_
55-27	8504-8508	with	_
55-28	8509-8527	neurophysiological	_
55-29	8528-8539	assessments	_
55-30	8539-8540	.	_

#Text=Here, we investigated stop signal task performance in Sz, examining behavior, ERPs, as well as relationships among SSRT, ERPs, and RSFC.
56-1	8541-8545	Here	_
56-2	8545-8546	,	_
56-3	8547-8549	we	_
56-4	8550-8562	investigated	_
56-5	8563-8567	stop	_
56-6	8568-8574	signal	_
56-7	8575-8579	task	_
56-8	8580-8591	performance	_
56-9	8592-8594	in	_
56-10	8595-8597	Sz	_
56-11	8597-8598	,	_
56-12	8599-8608	examining	_
56-13	8609-8617	behavior	_
56-14	8617-8618	,	_
56-15	8619-8623	ERPs	_
56-16	8623-8624	,	_
56-17	8625-8627	as	_
56-18	8628-8632	well	_
56-19	8633-8635	as	_
56-20	8636-8649	relationships	_
56-21	8650-8655	among	_
56-22	8656-8660	SSRT	_
56-23	8660-8661	,	_
56-24	8662-8666	ERPs	_
56-25	8666-8667	,	_
56-26	8668-8671	and	_
56-27	8672-8676	RSFC	_
56-28	8676-8677	.	_

#Text=For RSFC, we examined canonical brain networks and their interactions using Human Connectome Project (HCP) approaches.
57-1	8678-8681	For	_
57-2	8682-8686	RSFC	_
57-3	8686-8687	,	_
57-4	8688-8690	we	_
57-5	8691-8699	examined	_
57-6	8700-8709	canonical	_
57-7	8710-8715	brain	_
57-8	8716-8724	networks	_
57-9	8725-8728	and	_
57-10	8729-8734	their	_
57-11	8735-8747	interactions	_
57-12	8748-8753	using	_
57-13	8754-8759	Human	_
57-14	8760-8770	Connectome	_
57-15	8771-8778	Project	_
57-16	8779-8780	(	_
57-17	8780-8783	HCP	_
57-18	8783-8784	)	_
57-19	8785-8795	approaches	_
57-20	8795-8796	.	_

#Text=We hypothesized that response inhibition deficits in Sz are mediated by deficits in both sensory function, as reflected in sensory ERP (e.g., N1), and sensory/frontal interaction, as reflected in RSFC analyses.
58-1	8797-8799	We	_
58-2	8800-8812	hypothesized	_
58-3	8813-8817	that	_
58-4	8818-8826	response	_
58-5	8827-8837	inhibition	_
58-6	8838-8846	deficits	_
58-7	8847-8849	in	_
58-8	8850-8852	Sz	_
58-9	8853-8856	are	_
58-10	8857-8865	mediated	_
58-11	8866-8868	by	_
58-12	8869-8877	deficits	_
58-13	8878-8880	in	_
58-14	8881-8885	both	_
58-15	8886-8893	sensory	_
58-16	8894-8902	function	_
58-17	8902-8903	,	_
58-18	8904-8906	as	_
58-19	8907-8916	reflected	_
58-20	8917-8919	in	_
58-21	8920-8927	sensory	_
58-22	8928-8931	ERP	_
58-23	8932-8933	(	_
58-24	8933-8936	e.g	_
58-25	8936-8937	.	_
58-26	8937-8938	,	_
58-27	8939-8941	N1	_
58-28	8941-8942	)	_
58-29	8942-8943	,	_
58-30	8944-8947	and	_
58-31	8948-8955	sensory	_
58-32	8955-8956	/	_
58-33	8956-8963	frontal	_
58-34	8964-8975	interaction	_
58-35	8975-8976	,	_
58-36	8977-8979	as	_
58-37	8980-8989	reflected	_
58-38	8990-8992	in	_
58-39	8993-8997	RSFC	_
58-40	8998-9006	analyses	_
58-41	9006-9007	.	_

#Text=Materials and methods
#Text=Participants
#Text=Data were analyzed from 42 participants (21 patients).
59-1	9008-9017	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]
59-2	9018-9021	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]
59-3	9022-9029	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]
59-4	9030-9042	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-5	9043-9047	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-6	9048-9052	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-7	9053-9061	analyzed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-8	9062-9066	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-9	9067-9069	42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-10	9070-9082	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-11	9083-9084	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-12	9084-9086	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-13	9087-9095	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-14	9095-9096	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]
59-15	9096-9097	.	_

#Text=Of these, 31 (17 patients) had resting state fMRI data.
60-1	9098-9100	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-2	9101-9106	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-3	9106-9107	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-4	9108-9110	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-5	9111-9112	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-6	9112-9114	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-7	9115-9123	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-8	9123-9124	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-9	9125-9128	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-10	9129-9136	resting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
60-11	9137-9142	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
60-12	9143-9147	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
60-13	9148-9152	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
60-14	9152-9153	.	_

#Text=Patients were diagnosed with schizophrenia or schizoaffective disorder, confirmed by the Structured Clinical Interview for DSM-IV-TR.
61-1	9154-9162	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-2	9163-9167	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-3	9168-9177	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-4	9178-9182	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-5	9183-9196	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
61-6	9197-9199	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-7	9200-9215	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]
61-8	9216-9224	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]
61-9	9224-9225	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-10	9226-9235	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-11	9236-9238	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-12	9239-9242	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
61-13	9243-9253	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
61-14	9254-9262	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
61-15	9263-9272	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
61-16	9273-9276	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
61-17	9277-9286	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[9]
61-18	9286-9287	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Controls had no major Axis I diagnoses.
62-1	9288-9296	Controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-2	9297-9300	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-3	9301-9303	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-4	9304-9309	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-5	9310-9314	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-6	9315-9316	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-7	9317-9326	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
62-8	9326-9327	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=Participants had no substance use disorders for ≥3 months preceding enrollment.
63-1	9328-9340	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-2	9341-9344	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-3	9345-9347	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-4	9348-9357	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-5	9358-9361	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-6	9362-9371	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-7	9372-9375	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-8	9376-9377	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-9	9377-9378	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-10	9378-9379	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-11	9379-9385	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-12	9386-9395	preceding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-13	9396-9406	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
63-14	9406-9407	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=We administered the Positive and Negative Syndrome Scale (PANSS) to rate psychopathology in patients, with scores analyzed using a five factor model.
64-1	9408-9410	We	_
64-2	9411-9423	administered	_
64-3	9424-9427	the	_
64-4	9428-9436	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-5	9437-9440	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-6	9441-9449	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-7	9450-9458	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-8	9459-9464	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-9	9465-9466	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-10	9466-9471	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-11	9471-9472	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]
64-12	9473-9475	to	_
64-13	9476-9480	rate	_
64-14	9481-9496	psychopathology	_
64-15	9497-9499	in	_
64-16	9500-9508	patients	_
64-17	9508-9509	,	_
64-18	9510-9514	with	_
64-19	9515-9521	scores	_
64-20	9522-9530	analyzed	_
64-21	9531-9536	using	_
64-22	9537-9538	a	_
64-23	9539-9543	five	_
64-24	9544-9550	factor	_
64-25	9551-9556	model	_
64-26	9556-9557	.	_

#Text=Antipsychotic dosages were converted to chlorpromazine equivalents.
65-1	9558-9571	Antipsychotic	_
65-2	9572-9579	dosages	_
65-3	9580-9584	were	_
65-4	9585-9594	converted	_
65-5	9595-9597	to	_
65-6	9598-9612	chlorpromazine	_
65-7	9613-9624	equivalents	_
65-8	9624-9625	.	_

#Text=For ERP, an additional 9 controls and 5 patients were excluded for noisy EEG data, and 1 control and 4 patients did not meet performance criteria adapted from.
66-1	9626-9629	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-2	9630-9633	ERP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-3	9633-9634	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-4	9635-9637	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-5	9638-9648	additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-6	9649-9650	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-7	9651-9659	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-8	9660-9663	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-9	9664-9665	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-10	9666-9674	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-11	9675-9679	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-12	9680-9688	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-13	9689-9692	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-14	9693-9698	noisy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-15	9699-9702	EEG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-16	9703-9707	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-17	9707-9708	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-18	9709-9712	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-19	9713-9714	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-20	9715-9722	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-21	9723-9726	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-22	9727-9728	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-23	9729-9737	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-24	9738-9741	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-25	9742-9745	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-26	9746-9750	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-27	9751-9762	performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-28	9763-9771	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-29	9772-9779	adapted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-30	9780-9784	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
66-31	9784-9785	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=Included and excluded participants did not differ on demographic variables.
67-1	9786-9794	Included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-2	9795-9798	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-3	9799-9807	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-4	9808-9820	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-5	9821-9824	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-6	9825-9828	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-7	9829-9835	differ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-8	9836-9838	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-9	9839-9850	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-10	9851-9860	variables	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
67-11	9860-9861	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]

#Text=After all exclusions (see MRI processing section, below), the final sample was 21 patients and 21 controls for ERP and 16 patients and 14 controls for resting state fMRI.
68-1	9862-9867	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-2	9868-9871	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-3	9872-9882	exclusions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-4	9883-9884	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-5	9884-9887	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-6	9888-9891	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-7	9892-9902	processing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-8	9903-9910	section	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-9	9910-9911	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-10	9912-9917	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-11	9917-9918	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-12	9918-9919	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-13	9920-9923	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-14	9924-9929	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-15	9930-9936	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-16	9937-9940	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-17	9941-9943	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-18	9944-9952	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-19	9953-9956	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-20	9957-9959	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-21	9960-9968	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-22	9969-9972	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-23	9973-9976	ERP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-24	9977-9980	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-25	9981-9983	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-26	9984-9992	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-27	9993-9996	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-28	9997-9999	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-29	10000-10008	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-30	10009-10012	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
68-31	10013-10020	resting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[16]
68-32	10021-10026	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[16]
68-33	10027-10031	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[16]
68-34	10031-10032	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=The local institutional review board approved all procedures, which were in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).
69-1	10033-10036	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-2	10037-10042	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-3	10043-10056	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-4	10057-10063	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-5	10064-10069	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-6	10070-10078	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-7	10079-10082	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-8	10083-10093	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-9	10093-10094	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-10	10095-10100	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-11	10101-10105	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-12	10106-10108	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-13	10109-10119	compliance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-14	10120-10124	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-15	10125-10128	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-16	10129-10133	Code	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-17	10134-10136	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-18	10137-10143	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-19	10144-10146	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-20	10147-10150	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-21	10151-10156	World	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-22	10157-10164	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-23	10165-10176	Association	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-24	10177-10178	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-25	10178-10189	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-26	10190-10192	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-27	10193-10201	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-28	10201-10202	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-29	10202-10203	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=Informed consent was obtained from all individual participants included in the study.
70-1	10204-10212	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-2	10213-10220	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-3	10221-10224	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-4	10225-10233	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-5	10234-10238	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-6	10239-10242	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-7	10243-10253	individual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-8	10254-10266	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-9	10267-10275	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-10	10276-10278	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-11	10279-10282	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-12	10283-10288	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-13	10288-10289	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=Procedures
#Text=ERP
#Text=A 64-channel electrode cap was used to acquire continuous EEG arranged using the Advanced NeuroTechnology recording system (Entschede, The Netherlands), referenced to the nose.
71-1	10290-10300	Procedures	_
71-2	10301-10304	ERP	_
71-3	10305-10306	A	_
71-4	10307-10309	64	_
71-5	10309-10310	-	_
71-6	10310-10317	channel	_
71-7	10318-10327	electrode	_
71-8	10328-10331	cap	_
71-9	10332-10335	was	_
71-10	10336-10340	used	_
71-11	10341-10343	to	_
71-12	10344-10351	acquire	_
71-13	10352-10362	continuous	_
71-14	10363-10366	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
71-15	10367-10375	arranged	_
71-16	10376-10381	using	_
71-17	10382-10385	the	_
71-18	10386-10394	Advanced	_
71-19	10395-10410	NeuroTechnology	_
71-20	10411-10420	recording	_
71-21	10421-10427	system	_
71-22	10428-10429	(	_
71-23	10429-10438	Entschede	_
71-24	10438-10439	,	_
71-25	10440-10443	The	_
71-26	10444-10455	Netherlands	_
71-27	10455-10456	)	_
71-28	10456-10457	,	_
71-29	10458-10468	referenced	_
71-30	10469-10471	to	_
71-31	10472-10475	the	_
71-32	10476-10480	nose	_
71-33	10480-10481	.	_

#Text=Impedances were maintained below 5kΩ throughout the testing session.
72-1	10482-10492	Impedances	_
72-2	10493-10497	were	_
72-3	10498-10508	maintained	_
72-4	10509-10514	below	_
72-5	10515-10518	5kΩ	_
72-6	10519-10529	throughout	_
72-7	10530-10533	the	_
72-8	10534-10541	testing	_
72-9	10542-10549	session	_
72-10	10549-10550	.	_

#Text=Data were digitized at 512 Hz.
73-1	10551-10555	Data	_
73-2	10556-10560	were	_
73-3	10561-10570	digitized	_
73-4	10571-10573	at	_
73-5	10574-10577	512	_
73-6	10577-10578	 	_
73-7	10578-10580	Hz	_
73-8	10580-10581	.	_

#Text=Preprocessing was done using Brain Electrical Source Analysis software (BESA; Gräfelfing, Germany).
74-1	10582-10595	Preprocessing	_
74-2	10596-10599	was	_
74-3	10600-10604	done	_
74-4	10605-10610	using	_
74-5	10611-10616	Brain	_
74-6	10617-10627	Electrical	_
74-7	10628-10634	Source	_
74-8	10635-10643	Analysis	_
74-9	10644-10652	software	_
74-10	10653-10654	(	_
74-11	10654-10658	BESA	_
74-12	10658-10659	;	_
74-13	10660-10670	Gräfelfing	_
74-14	10670-10671	,	_
74-15	10672-10679	Germany	_
74-16	10679-10680	)	_
74-17	10680-10681	.	_

#Text=Bad channels were interpolated if possible or eliminated and were limited to ≤9 per subject.
75-1	10682-10685	Bad	_
75-2	10686-10694	channels	_
75-3	10695-10699	were	_
75-4	10700-10712	interpolated	_
75-5	10713-10715	if	_
75-6	10716-10724	possible	_
75-7	10725-10727	or	_
75-8	10728-10738	eliminated	_
75-9	10739-10742	and	_
75-10	10743-10747	were	_
75-11	10748-10755	limited	_
75-12	10756-10758	to	_
75-13	10759-10760	≤	_
75-14	10760-10761	9	_
75-15	10762-10765	per	_
75-16	10766-10773	subject	_
75-17	10773-10774	.	_

#Text=The number of interpolated channels did not differ between groups (mean = 4.4 ± 2.6, p = 0.86).
76-1	10775-10778	The	_
76-2	10779-10785	number	_
76-3	10786-10788	of	_
76-4	10789-10801	interpolated	_
76-5	10802-10810	channels	_
76-6	10811-10814	did	_
76-7	10815-10818	not	_
76-8	10819-10825	differ	_
76-9	10826-10833	between	_
76-10	10834-10840	groups	_
76-11	10841-10842	(	_
76-12	10842-10846	mean	_
76-13	10846-10847	 	_
76-14	10847-10848	=	_
76-15	10848-10849	 	_
76-16	10849-10852	4.4	_
76-17	10852-10853	 	_
76-18	10853-10854	±	_
76-19	10854-10855	 	_
76-20	10855-10858	2.6	_
76-21	10858-10859	,	_
76-22	10860-10861	p	_
76-23	10861-10862	 	_
76-24	10862-10863	=	_
76-25	10863-10864	 	_
76-26	10864-10868	0.86	_
76-27	10868-10869	)	_
76-28	10869-10870	.	_

#Text=Data were imported into EEGLAB and subjected to independent components analysis (ICA) to remove eye-blink and saccade-related components (≤2 per subject).
77-1	10871-10875	Data	_
77-2	10876-10880	were	_
77-3	10881-10889	imported	_
77-4	10890-10894	into	_
77-5	10895-10901	EEGLAB	_
77-6	10902-10905	and	_
77-7	10906-10915	subjected	_
77-8	10916-10918	to	_
77-9	10919-10930	independent	_
77-10	10931-10941	components	_
77-11	10942-10950	analysis	_
77-12	10951-10952	(	_
77-13	10952-10955	ICA	_
77-14	10955-10956	)	_
77-15	10957-10959	to	_
77-16	10960-10966	remove	_
77-17	10967-10976	eye-blink	_
77-18	10977-10980	and	_
77-19	10981-10996	saccade-related	_
77-20	10997-11007	components	_
77-21	11008-11009	(	_
77-22	11009-11010	≤	_
77-23	11010-11011	2	_
77-24	11012-11015	per	_
77-25	11016-11023	subject	_
77-26	11023-11024	)	_
77-27	11024-11025	.	_

#Text=Cleaned data were then re-imported into BESA and rereferenced to common ears.
78-1	11026-11033	Cleaned	_
78-2	11034-11038	data	_
78-3	11039-11043	were	_
78-4	11044-11048	then	_
78-5	11049-11060	re-imported	_
78-6	11061-11065	into	_
78-7	11066-11070	BESA	_
78-8	11071-11074	and	_
78-9	11075-11087	rereferenced	_
78-10	11088-11090	to	_
78-11	11091-11097	common	_
78-12	11098-11102	ears	_
78-13	11102-11103	.	_

#Text=Extracted epochs ranged from 100 ms pre-stimulus to 700 ms post-stimulus.
79-1	11104-11113	Extracted	_
79-2	11114-11120	epochs	_
79-3	11121-11127	ranged	_
79-4	11128-11132	from	_
79-5	11133-11136	100	_
79-6	11136-11137	 	_
79-7	11137-11139	ms	_
79-8	11140-11152	pre-stimulus	_
79-9	11153-11155	to	_
79-10	11156-11159	700	_
79-11	11159-11160	 	_
79-12	11160-11162	ms	_
79-13	11163-11176	post-stimulus	_
79-14	11176-11177	.	_

#Text=Epochs were baseline-corrected (baseline: -100 ms to stimulus onset).
80-1	11178-11184	Epochs	_
80-2	11185-11189	were	_
80-3	11190-11208	baseline-corrected	_
80-4	11209-11210	(	_
80-5	11210-11218	baseline	_
80-6	11218-11219	:	_
80-7	11220-11221	-	_
80-8	11221-11224	100	_
80-9	11224-11225	 	_
80-10	11225-11227	ms	_
80-11	11228-11230	to	_
80-12	11231-11239	stimulus	_
80-13	11240-11245	onset	_
80-14	11245-11246	)	_
80-15	11246-11247	.	_

#Text=The ICA is especially effective for removal of blink artifacts, which occur frequently during the tracings.
81-1	11248-11251	The	_
81-2	11252-11255	ICA	_
81-3	11256-11258	is	_
81-4	11259-11269	especially	_
81-5	11270-11279	effective	_
81-6	11280-11283	for	_
81-7	11284-11291	removal	_
81-8	11292-11294	of	_
81-9	11295-11300	blink	_
81-10	11301-11310	artifacts	_
81-11	11310-11311	,	_
81-12	11312-11317	which	_
81-13	11318-11323	occur	_
81-14	11324-11334	frequently	_
81-15	11335-11341	during	_
81-16	11342-11345	the	_
81-17	11346-11354	tracings	_
81-18	11354-11355	.	_

#Text=However, they are less effective in removing more infrequency artifacts (e.g. random movements).
82-1	11356-11363	However	_
82-2	11363-11364	,	_
82-3	11365-11369	they	_
82-4	11370-11373	are	_
82-5	11374-11378	less	_
82-6	11379-11388	effective	_
82-7	11389-11391	in	_
82-8	11392-11400	removing	_
82-9	11401-11405	more	_
82-10	11406-11417	infrequency	_
82-11	11418-11427	artifacts	_
82-12	11428-11429	(	_
82-13	11429-11432	e.g	_
82-14	11432-11433	.	_
82-15	11434-11440	random	_
82-16	11441-11450	movements	_
82-17	11450-11451	)	_
82-18	11451-11452	.	_

#Text=Such artifacts as well as potential residual blinks must be removed by threshold-based artifact rejection.
83-1	11453-11457	Such	_
83-2	11458-11467	artifacts	_
83-3	11468-11470	as	_
83-4	11471-11475	well	_
83-5	11476-11478	as	_
83-6	11479-11488	potential	_
83-7	11489-11497	residual	_
83-8	11498-11504	blinks	_
83-9	11505-11509	must	_
83-10	11510-11512	be	_
83-11	11513-11520	removed	_
83-12	11521-11523	by	_
83-13	11524-11539	threshold-based	_
83-14	11540-11548	artifact	_
83-15	11549-11558	rejection	_
83-16	11558-11559	.	_

#Text=The result was that BESA removed <15% of trials after the ICA step.
84-1	11560-11563	The	_
84-2	11564-11570	result	_
84-3	11571-11574	was	_
84-4	11575-11579	that	_
84-5	11580-11584	BESA	_
84-6	11585-11592	removed	_
84-7	11593-11594	<	_
84-8	11594-11597	15%	_
84-9	11598-11600	of	_
84-10	11601-11607	trials	_
84-11	11608-11613	after	_
84-12	11614-11617	the	_
84-13	11618-11621	ICA	_
84-14	11622-11626	step	_
84-15	11626-11627	.	_

#Text=Normally, rejection rates are much higher.
85-1	11628-11636	Normally	_
85-2	11636-11637	,	_
85-3	11638-11647	rejection	_
85-4	11648-11653	rates	_
85-5	11654-11657	are	_
85-6	11658-11662	much	_
85-7	11663-11669	higher	_
85-8	11669-11670	.	_

#Text=Thus, by using ICA first, we were able to increase the number of trials in our analyses.
86-1	11671-11675	Thus	_
86-2	11675-11676	,	_
86-3	11677-11679	by	_
86-4	11680-11685	using	_
86-5	11686-11689	ICA	_
86-6	11690-11695	first	_
86-7	11695-11696	,	_
86-8	11697-11699	we	_
86-9	11700-11704	were	_
86-10	11705-11709	able	_
86-11	11710-11712	to	_
86-12	11713-11721	increase	_
86-13	11722-11725	the	_
86-14	11726-11732	number	_
86-15	11733-11735	of	_
86-16	11736-11742	trials	_
86-17	11743-11745	in	_
86-18	11746-11749	our	_
86-19	11750-11758	analyses	_
86-20	11758-11759	.	_

#Text=Data were then filtered with a high-pass filter (0.5 Hz, 6db/octave), a low-pass filter (40 Hz, 48db/octave), and a notch filter (60 Hz).
87-1	11760-11764	Data	_
87-2	11765-11769	were	_
87-3	11770-11774	then	_
87-4	11775-11783	filtered	_
87-5	11784-11788	with	_
87-6	11789-11790	a	_
87-7	11791-11800	high-pass	_
87-8	11801-11807	filter	_
87-9	11808-11809	(	_
87-10	11809-11812	0.5	_
87-11	11812-11813	 	_
87-12	11813-11815	Hz	_
87-13	11815-11816	,	_
87-14	11817-11820	6db	_
87-15	11820-11821	/	_
87-16	11821-11827	octave	_
87-17	11827-11828	)	_
87-18	11828-11829	,	_
87-19	11830-11831	a	_
87-20	11832-11840	low-pass	_
87-21	11841-11847	filter	_
87-22	11848-11849	(	_
87-23	11849-11851	40	_
87-24	11851-11852	 	_
87-25	11852-11854	Hz	_
87-26	11854-11855	,	_
87-27	11856-11860	48db	_
87-28	11860-11861	/	_
87-29	11861-11867	octave	_
87-30	11867-11868	)	_
87-31	11868-11869	,	_
87-32	11870-11873	and	_
87-33	11874-11875	a	_
87-34	11876-11881	notch	_
87-35	11882-11888	filter	_
87-36	11889-11890	(	_
87-37	11890-11892	60	_
87-38	11892-11893	 	_
87-39	11893-11895	Hz	_
87-40	11895-11896	)	_
87-41	11896-11897	.	_

#Text=Based on the scalp topography in healthy controls, ROIs were created for N1 s (P3,P4,P7,P8,O1,O2,Oz), N2 s (Fz,Cz) and P3s (C3,C4,P3,P4,Cz,Pz).
88-1	11898-11903	Based	_
88-2	11904-11906	on	_
88-3	11907-11910	the	_
88-4	11911-11916	scalp	_
88-5	11917-11927	topography	_
88-6	11928-11930	in	_
88-7	11931-11938	healthy	_
88-8	11939-11947	controls	_
88-9	11947-11948	,	_
88-10	11949-11953	ROIs	_
88-11	11954-11958	were	_
88-12	11959-11966	created	_
88-13	11967-11970	for	_
88-14	11971-11973	N1	_
88-15	11973-11974	 	_
88-16	11974-11975	s	_
88-17	11976-11977	(	_
88-18	11977-11979	P3	_
88-19	11979-11980	,	_
88-20	11980-11982	P4	_
88-21	11982-11983	,	_
88-22	11983-11985	P7	_
88-23	11985-11986	,	_
88-24	11986-11988	P8	_
88-25	11988-11989	,	_
88-26	11989-11991	O1	_
88-27	11991-11992	,	_
88-28	11992-11994	O2	_
88-29	11994-11995	,	_
88-30	11995-11997	Oz	_
88-31	11997-11998	)	_
88-32	11998-11999	,	_
88-33	12000-12002	N2	_
88-34	12002-12003	 	_
88-35	12003-12004	s	_
88-36	12005-12006	(	_
88-37	12006-12008	Fz	_
88-38	12008-12009	,	_
88-39	12009-12011	Cz	_
88-40	12011-12012	)	_
88-41	12013-12016	and	_
88-42	12017-12020	P3s	_
88-43	12021-12022	(	_
88-44	12022-12024	C3	_
88-45	12024-12025	,	_
88-46	12025-12027	C4	_
88-47	12027-12028	,	_
88-48	12028-12030	P3	_
88-49	12030-12031	,	_
88-50	12031-12033	P4	_
88-51	12033-12034	,	_
88-52	12034-12036	Cz	_
88-53	12036-12037	,	_
88-54	12037-12039	Pz	_
88-55	12039-12040	)	_
88-56	12040-12041	.	_

#Text=Voltages were averaged across sites for these ROIs.
89-1	12042-12050	Voltages	_
89-2	12051-12055	were	_
89-3	12056-12064	averaged	_
89-4	12065-12071	across	_
89-5	12072-12077	sites	_
89-6	12078-12081	for	_
89-7	12082-12087	these	_
89-8	12088-12092	ROIs	_
89-9	12092-12093	.	_

#Text=Participants completed four blocks of a visual stop signal task programmed using Presentation Software (Neurobehavioral Systems, Albany, CA).
90-1	12094-12106	Participants	_
90-2	12107-12116	completed	_
90-3	12117-12121	four	_
90-4	12122-12128	blocks	_
90-5	12129-12131	of	_
90-6	12132-12133	a	_
90-7	12134-12140	visual	_
90-8	12141-12145	stop	_
90-9	12146-12152	signal	_
90-10	12153-12157	task	_
90-11	12158-12168	programmed	_
90-12	12169-12174	using	_
90-13	12175-12187	Presentation	_
90-14	12188-12196	Software	_
90-15	12197-12198	(	_
90-16	12198-12213	Neurobehavioral	_
90-17	12214-12221	Systems	_
90-18	12221-12222	,	_
90-19	12223-12229	Albany	_
90-20	12229-12230	,	_
90-21	12231-12233	CA	_
90-22	12233-12234	)	_
90-23	12234-12235	.	_

#Text=There were 720 go and 238 stop trials.
91-1	12236-12241	There	_
91-2	12242-12246	were	_
91-3	12247-12250	720	_
91-4	12251-12253	go	_
91-5	12254-12257	and	_
91-6	12258-12261	238	_
91-7	12262-12266	stop	_
91-8	12267-12273	trials	_
91-9	12273-12274	.	_

#Text=On each trial, participants saw a fixation followed by an X or O for 1250 ms.
92-1	12275-12277	On	_
92-2	12278-12282	each	_
92-3	12283-12288	trial	_
92-4	12288-12289	,	_
92-5	12290-12302	participants	_
92-6	12303-12306	saw	_
92-7	12307-12308	a	_
92-8	12309-12317	fixation	_
92-9	12318-12326	followed	_
92-10	12327-12329	by	_
92-11	12330-12332	an	_
92-12	12333-12334	X	_
92-13	12335-12337	or	_
92-14	12338-12339	O	_
92-15	12340-12343	for	_
92-16	12344-12348	1250	_
92-17	12348-12349	 	_
92-18	12349-12351	ms	_
92-19	12351-12352	.	_

#Text=On go trials, participants responded with the left (X) or right (O) mouse button using their right hand.
93-1	12353-12355	On	_
93-2	12356-12358	go	_
93-3	12359-12365	trials	_
93-4	12365-12366	,	_
93-5	12367-12379	participants	_
93-6	12380-12389	responded	_
93-7	12390-12394	with	_
93-8	12395-12398	the	_
93-9	12399-12403	left	_
93-10	12404-12405	(	_
93-11	12405-12406	X	_
93-12	12406-12407	)	_
93-13	12408-12410	or	_
93-14	12411-12416	right	_
93-15	12417-12418	(	_
93-16	12418-12419	O	_
93-17	12419-12420	)	_
93-18	12421-12426	mouse	_
93-19	12427-12433	button	_
93-20	12434-12439	using	_
93-21	12440-12445	their	_
93-22	12446-12451	right	_
93-23	12452-12456	hand	_
93-24	12456-12457	.	_

#Text=On stop trials, a large red square was superimposed on the target for 267 ms.
94-1	12458-12460	On	_
94-2	12461-12465	stop	_
94-3	12466-12472	trials	_
94-4	12472-12473	,	_
94-5	12474-12475	a	_
94-6	12476-12481	large	_
94-7	12482-12485	red	_
94-8	12486-12492	square	_
94-9	12493-12496	was	_
94-10	12497-12509	superimposed	_
94-11	12510-12512	on	_
94-12	12513-12516	the	_
94-13	12517-12523	target	_
94-14	12524-12527	for	_
94-15	12528-12531	267	_
94-16	12531-12532	 	_
94-17	12532-12534	ms	_
94-18	12534-12535	.	_

#Text=The SSD was initially set at 267 ms and titrated in 50 ms steps to vary task difficulty (range 67–767 ms).
95-1	12536-12539	The	_
95-2	12540-12543	SSD	_
95-3	12544-12547	was	_
95-4	12548-12557	initially	_
95-5	12558-12561	set	_
95-6	12562-12564	at	_
95-7	12565-12568	267	_
95-8	12568-12569	 	_
95-9	12569-12571	ms	_
95-10	12572-12575	and	_
95-11	12576-12584	titrated	_
95-12	12585-12587	in	_
95-13	12588-12590	50	_
95-14	12590-12591	 	_
95-15	12591-12593	ms	_
95-16	12594-12599	steps	_
95-17	12600-12602	to	_
95-18	12603-12607	vary	_
95-19	12608-12612	task	_
95-20	12613-12623	difficulty	_
95-21	12624-12625	(	_
95-22	12625-12630	range	_
95-23	12631-12633	67	_
95-24	12633-12634	–	_
95-25	12634-12637	767	_
95-26	12637-12638	 	_
95-27	12638-12640	ms	_
95-28	12640-12641	)	_
95-29	12641-12642	.	_

#Text=SSRT was computed as the difference between median go reaction time (RT) and median SSD.
96-1	12643-12647	SSRT	_
96-2	12648-12651	was	_
96-3	12652-12660	computed	_
96-4	12661-12663	as	_
96-5	12664-12667	the	_
96-6	12668-12678	difference	_
96-7	12679-12686	between	_
96-8	12687-12693	median	_
96-9	12694-12696	go	_
96-10	12697-12705	reaction	_
96-11	12706-12710	time	_
96-12	12711-12712	(	_
96-13	12712-12714	RT	_
96-14	12714-12715	)	_
96-15	12716-12719	and	_
96-16	12720-12726	median	_
96-17	12727-12730	SSD	_
96-18	12730-12731	.	_

#Text=MRI
#Text=Scanning took place at NKI's Center for Biomedical Imaging and Neuromodulation.
97-1	12732-12735	MRI	_
97-2	12736-12744	Scanning	_
97-3	12745-12749	took	_
97-4	12750-12755	place	_
97-5	12756-12758	at	_
97-6	12759-12764	NKI's	_
97-7	12765-12771	Center	_
97-8	12772-12775	for	_
97-9	12776-12786	Biomedical	_
97-10	12787-12794	Imaging	_
97-11	12795-12798	and	_
97-12	12799-12814	Neuromodulation	_
97-13	12814-12815	.	_

#Text=We acquired an MPRAGE (TR = 2500 ms, TE = 3.5 ms, TI = 1200 ms, matrix = 256 × 256, FOV = 256 mm, 192 1 mm slices, no gap, acceleration factor = 1 or 2).
98-1	12816-12818	We	_
98-2	12819-12827	acquired	_
98-3	12828-12830	an	_
98-4	12831-12837	MPRAGE	_
98-5	12838-12839	(	_
98-6	12839-12841	TR	_
98-7	12841-12842	 	_
98-8	12842-12843	=	_
98-9	12843-12844	 	_
98-10	12844-12848	2500	_
98-11	12848-12849	 	_
98-12	12849-12851	ms	_
98-13	12851-12852	,	_
98-14	12853-12855	TE	_
98-15	12855-12856	 	_
98-16	12856-12857	=	_
98-17	12857-12858	 	_
98-18	12858-12861	3.5	_
98-19	12861-12862	 	_
98-20	12862-12864	ms	_
98-21	12864-12865	,	_
98-22	12866-12868	TI	_
98-23	12868-12869	 	_
98-24	12869-12870	=	_
98-25	12870-12871	 	_
98-26	12871-12875	1200	_
98-27	12875-12876	 	_
98-28	12876-12878	ms	_
98-29	12878-12879	,	_
98-30	12880-12886	matrix	_
98-31	12886-12887	 	_
98-32	12887-12888	=	_
98-33	12888-12889	 	_
98-34	12889-12892	256	_
98-35	12892-12893	 	_
98-36	12893-12894	×	_
98-37	12894-12895	 	_
98-38	12895-12898	256	_
98-39	12898-12899	,	_
98-40	12900-12903	FOV	_
98-41	12903-12904	 	_
98-42	12904-12905	=	_
98-43	12905-12906	 	_
98-44	12906-12909	256	_
98-45	12909-12910	 	_
98-46	12910-12912	mm	_
98-47	12912-12913	,	_
98-48	12914-12917	192	_
98-49	12918-12919	1	_
98-50	12919-12920	 	_
98-51	12920-12922	mm	_
98-52	12923-12929	slices	_
98-53	12929-12930	,	_
98-54	12931-12933	no	_
98-55	12934-12937	gap	_
98-56	12937-12938	,	_
98-57	12939-12951	acceleration	_
98-58	12952-12958	factor	_
98-59	12958-12959	 	_
98-60	12959-12960	=	_
98-61	12960-12961	 	_
98-62	12961-12962	1	_
98-63	12963-12965	or	_
98-64	12966-12967	2	_
98-65	12967-12968	)	_
98-66	12968-12969	.	_

#Text=Blood oxygenation level dependent (BOLD) data were acquired during resting state.
99-1	12970-12975	Blood	_
99-2	12976-12987	oxygenation	_
99-3	12988-12993	level	_
99-4	12994-13003	dependent	_
99-5	13004-13005	(	_
99-6	13005-13009	BOLD	_
99-7	13009-13010	)	_
99-8	13011-13015	data	_
99-9	13016-13020	were	_
99-10	13021-13029	acquired	_
99-11	13030-13036	during	_
99-12	13037-13044	resting	_
99-13	13045-13050	state	_
99-14	13050-13051	.	_

#Text=Resting state data were acquired in a scan with eyes closed (TR = 2000 ms, TE = 30 ms, matrix = 96 × 96, FOV = 240 mm, 34–36 2.8 mm slices, 0.7 mm gap, acceleration factor = 2).
100-1	13052-13059	Resting	_
100-2	13060-13065	state	_
100-3	13066-13070	data	_
100-4	13071-13075	were	_
100-5	13076-13084	acquired	_
100-6	13085-13087	in	_
100-7	13088-13089	a	_
100-8	13090-13094	scan	_
100-9	13095-13099	with	_
100-10	13100-13104	eyes	_
100-11	13105-13111	closed	_
100-12	13112-13113	(	_
100-13	13113-13115	TR	_
100-14	13115-13116	 	_
100-15	13116-13117	=	_
100-16	13117-13118	 	_
100-17	13118-13122	2000	_
100-18	13122-13123	 	_
100-19	13123-13125	ms	_
100-20	13125-13126	,	_
100-21	13127-13129	TE	_
100-22	13129-13130	 	_
100-23	13130-13131	=	_
100-24	13131-13132	 	_
100-25	13132-13134	30	_
100-26	13134-13135	 	_
100-27	13135-13137	ms	_
100-28	13137-13138	,	_
100-29	13139-13145	matrix	_
100-30	13145-13146	 	_
100-31	13146-13147	=	_
100-32	13147-13148	 	_
100-33	13148-13150	96	_
100-34	13150-13151	 	_
100-35	13151-13152	×	_
100-36	13152-13153	 	_
100-37	13153-13155	96	_
100-38	13155-13156	,	_
100-39	13157-13160	FOV	_
100-40	13160-13161	 	_
100-41	13161-13162	=	_
100-42	13162-13163	 	_
100-43	13163-13166	240	_
100-44	13166-13167	 	_
100-45	13167-13169	mm	_
100-46	13169-13170	,	_
100-47	13171-13173	34	_
100-48	13173-13174	–	_
100-49	13174-13176	36	_
100-50	13177-13180	2.8	_
100-51	13180-13181	 	_
100-52	13181-13183	mm	_
100-53	13184-13190	slices	_
100-54	13190-13191	,	_
100-55	13192-13195	0.7	_
100-56	13195-13196	 	_
100-57	13196-13198	mm	_
100-58	13199-13202	gap	_
100-59	13202-13203	,	_
100-60	13204-13216	acceleration	_
100-61	13217-13223	factor	_
100-62	13223-13224	 	_
100-63	13224-13225	=	_
100-64	13225-13226	 	_
100-65	13226-13227	2	_
100-66	13227-13228	)	_
100-67	13228-13229	.	_

#Text=Because of differences in the length of resting state scans, they were limited to the first 150 volumes.
101-1	13230-13237	Because	_
101-2	13238-13240	of	_
101-3	13241-13252	differences	_
101-4	13253-13255	in	_
101-5	13256-13259	the	_
101-6	13260-13266	length	_
101-7	13267-13269	of	_
101-8	13270-13277	resting	_
101-9	13278-13283	state	_
101-10	13284-13289	scans	_
101-11	13289-13290	,	_
101-12	13291-13295	they	_
101-13	13296-13300	were	_
101-14	13301-13308	limited	_
101-15	13309-13311	to	_
101-16	13312-13315	the	_
101-17	13316-13321	first	_
101-18	13322-13325	150	_
101-19	13326-13333	volumes	_
101-20	13333-13334	.	_

#Text=All participants verified wakefulness during the resting state scan.
102-1	13335-13338	All	_
102-2	13339-13351	participants	_
102-3	13352-13360	verified	_
102-4	13361-13372	wakefulness	_
102-5	13373-13379	during	_
102-6	13380-13383	the	_
102-7	13384-13391	resting	_
102-8	13392-13397	state	_
102-9	13398-13402	scan	_
102-10	13402-13403	.	_

#Text=It should be noted that the resting state scans were not collected on the same day as the stop signal task recordings.
103-1	13404-13406	It	_
103-2	13407-13413	should	_
103-3	13414-13416	be	_
103-4	13417-13422	noted	_
103-5	13423-13427	that	_
103-6	13428-13431	the	_
103-7	13432-13439	resting	_
103-8	13440-13445	state	_
103-9	13446-13451	scans	_
103-10	13452-13456	were	_
103-11	13457-13460	not	_
103-12	13461-13470	collected	_
103-13	13471-13473	on	_
103-14	13474-13477	the	_
103-15	13478-13482	same	_
103-16	13483-13486	day	_
103-17	13487-13489	as	_
103-18	13490-13493	the	_
103-19	13494-13498	stop	_
103-20	13499-13505	signal	_
103-21	13506-13510	task	_
103-22	13511-13521	recordings	_
103-23	13521-13522	.	_

#Text=On average, the MRI was done 43.1 ± 393.0 days prior to the ERP session.
104-1	13523-13525	On	_
104-2	13526-13533	average	_
104-3	13533-13534	,	_
104-4	13535-13538	the	_
104-5	13539-13542	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
104-6	13543-13546	was	_
104-7	13547-13551	done	_
104-8	13552-13556	43.1	_
104-9	13556-13557	 	_
104-10	13557-13558	±	_
104-11	13558-13559	 	_
104-12	13559-13564	393.0	_
104-13	13564-13565	 	_
104-14	13565-13569	days	_
104-15	13570-13575	prior	_
104-16	13576-13578	to	_
104-17	13579-13582	the	_
104-18	13583-13586	ERP	_
104-19	13587-13594	session	_
104-20	13594-13595	.	_

#Text=Time between MRI scans and ERP did not differ between groups (t = −0.34, p = 0.74).
105-1	13596-13600	Time	_
105-2	13601-13608	between	_
105-3	13609-13612	MRI	_
105-4	13613-13618	scans	_
105-5	13619-13622	and	_
105-6	13623-13626	ERP	_
105-7	13627-13630	did	_
105-8	13631-13634	not	_
105-9	13635-13641	differ	_
105-10	13642-13649	between	_
105-11	13650-13656	groups	_
105-12	13657-13658	(	_
105-13	13658-13659	t	_
105-14	13659-13660	 	_
105-15	13660-13661	=	_
105-16	13661-13662	 	_
105-17	13662-13663	−	_
105-18	13663-13667	0.34	_
105-19	13667-13668	,	_
105-20	13669-13670	p	_
105-21	13670-13671	 	_
105-22	13671-13672	=	_
105-23	13672-13673	 	_
105-24	13673-13677	0.74	_
105-25	13677-13678	)	_
105-26	13678-13679	.	_

#Text=Image processing
#Text=ERP
#Text=N1 was defined as the mean amplitude between 135 and 215 ms, N2 as the mean amplitude between 200 and 250 ms, and P3 as the mean positive amplitude between 220 and 450 ms.
106-1	13680-13685	Image	_
106-2	13686-13696	processing	_
106-3	13697-13700	ERP	_
106-4	13701-13703	N1	_
106-5	13704-13707	was	_
106-6	13708-13715	defined	_
106-7	13716-13718	as	_
106-8	13719-13722	the	_
106-9	13723-13727	mean	_
106-10	13728-13737	amplitude	_
106-11	13738-13745	between	_
106-12	13746-13749	135	_
106-13	13750-13753	and	_
106-14	13754-13757	215	_
106-15	13757-13758	 	_
106-16	13758-13760	ms	_
106-17	13760-13761	,	_
106-18	13762-13764	N2	_
106-19	13765-13767	as	_
106-20	13768-13771	the	_
106-21	13772-13776	mean	_
106-22	13777-13786	amplitude	_
106-23	13787-13794	between	_
106-24	13795-13798	200	_
106-25	13799-13802	and	_
106-26	13803-13806	250	_
106-27	13806-13807	 	_
106-28	13807-13809	ms	_
106-29	13809-13810	,	_
106-30	13811-13814	and	_
106-31	13815-13817	P3	_
106-32	13818-13820	as	_
106-33	13821-13824	the	_
106-34	13825-13829	mean	_
106-35	13830-13838	positive	_
106-36	13839-13848	amplitude	_
106-37	13849-13856	between	_
106-38	13857-13860	220	_
106-39	13861-13864	and	_
106-40	13865-13868	450	_
106-41	13868-13869	 	_
106-42	13869-13871	ms	_
106-43	13871-13872	.	_

#Text=Stop-related components were time-locked to stop-signal onset.
107-1	13873-13885	Stop-related	_
107-2	13886-13896	components	_
107-3	13897-13901	were	_
107-4	13902-13913	time-locked	_
107-5	13914-13916	to	_
107-6	13917-13928	stop-signal	_
107-7	13929-13934	onset	_
107-8	13934-13935	.	_

#Text=Mean latencies are shown in Supplementary Table 1.
108-1	13936-13940	Mean	_
108-2	13941-13950	latencies	_
108-3	13951-13954	are	_
108-4	13955-13960	shown	_
108-5	13961-13963	in	_
108-6	13964-13977	Supplementary	_
108-7	13978-13983	Table	_
108-8	13984-13985	1	_
108-9	13985-13986	.	_

#Text=MRI
#Text=Resting-state data were processed as in using Data Processing Assistant for Resting State fMRI – Advanced (DPARSFA, v4.0, available at http://www.rfmh.org/DPABI).
109-1	13987-13990	MRI	_
109-2	13991-14004	Resting-state	_
109-3	14005-14009	data	_
109-4	14010-14014	were	_
109-5	14015-14024	processed	_
109-6	14025-14027	as	_
109-7	14028-14030	in	_
109-8	14031-14036	using	_
109-9	14037-14041	Data	_
109-10	14042-14052	Processing	_
109-11	14053-14062	Assistant	_
109-12	14063-14066	for	_
109-13	14067-14074	Resting	_
109-14	14075-14080	State	_
109-15	14081-14085	fMRI	_
109-16	14086-14087	–	_
109-17	14088-14096	Advanced	_
109-18	14097-14098	(	_
109-19	14098-14105	DPARSFA	_
109-20	14105-14106	,	_
109-21	14107-14111	v4.0	_
109-22	14111-14112	,	_
109-23	14113-14122	available	_
109-24	14123-14125	at	_
109-25	14126-14130	http	_
109-26	14130-14131	:	_
109-27	14131-14132	/	_
109-28	14132-14133	/	_
109-29	14133-14145	www.rfmh.org	_
109-30	14145-14146	/	_
109-31	14146-14151	DPABI	_
109-32	14151-14152	)	_
109-33	14152-14153	.	_

#Text=The first 5 functional volumes were deleted, and the data were motion-corrected.
110-1	14154-14157	The	_
110-2	14158-14163	first	_
110-3	14164-14165	5	_
110-4	14166-14176	functional	_
110-5	14177-14184	volumes	_
110-6	14185-14189	were	_
110-7	14190-14197	deleted	_
110-8	14197-14198	,	_
110-9	14199-14202	and	_
110-10	14203-14206	the	_
110-11	14207-14211	data	_
110-12	14212-14216	were	_
110-13	14217-14233	motion-corrected	_
110-14	14233-14234	.	_

#Text=Next, a T1-weighted image was registered to the functional data, linear and quadratic trends were removed from the motion-corrected data, nuisance covariates were applied (24 motion parameters, CSF, and WM signals), data registered to 3 mm MNI standard space, and registered images were smoothed with a 6-mm FWHM kernel.
111-1	14235-14239	Next	_
111-2	14239-14240	,	_
111-3	14241-14242	a	_
111-4	14243-14245	T1	_
111-5	14245-14246	-	_
111-6	14246-14254	weighted	_
111-7	14255-14260	image	_
111-8	14261-14264	was	_
111-9	14265-14275	registered	_
111-10	14276-14278	to	_
111-11	14279-14282	the	_
111-12	14283-14293	functional	_
111-13	14294-14298	data	_
111-14	14298-14299	,	_
111-15	14300-14306	linear	_
111-16	14307-14310	and	_
111-17	14311-14320	quadratic	_
111-18	14321-14327	trends	_
111-19	14328-14332	were	_
111-20	14333-14340	removed	_
111-21	14341-14345	from	_
111-22	14346-14349	the	_
111-23	14350-14366	motion-corrected	_
111-24	14367-14371	data	_
111-25	14371-14372	,	_
111-26	14373-14381	nuisance	_
111-27	14382-14392	covariates	_
111-28	14393-14397	were	_
111-29	14398-14405	applied	_
111-30	14406-14407	(	_
111-31	14407-14409	24	_
111-32	14410-14416	motion	_
111-33	14417-14427	parameters	_
111-34	14427-14428	,	_
111-35	14429-14432	CSF	_
111-36	14432-14433	,	_
111-37	14434-14437	and	_
111-38	14438-14440	WM	_
111-39	14441-14448	signals	_
111-40	14448-14449	)	_
111-41	14449-14450	,	_
111-42	14451-14455	data	_
111-43	14456-14466	registered	_
111-44	14467-14469	to	_
111-45	14470-14471	3	_
111-46	14471-14472	 	_
111-47	14472-14474	mm	_
111-48	14475-14478	MNI	_
111-49	14479-14487	standard	_
111-50	14488-14493	space	_
111-51	14493-14494	,	_
111-52	14495-14498	and	_
111-53	14499-14509	registered	_
111-54	14510-14516	images	_
111-55	14517-14521	were	_
111-56	14522-14530	smoothed	_
111-57	14531-14535	with	_
111-58	14536-14537	a	_
111-59	14538-14539	6	_
111-60	14539-14540	-	_
111-61	14540-14542	mm	_
111-62	14543-14547	FWHM	_
111-63	14548-14554	kernel	_
111-64	14554-14555	.	_

#Text=Images were then filtered with a 0.01–0.1 Hz bandpass.
112-1	14556-14562	Images	_
112-2	14563-14567	were	_
112-3	14568-14572	then	_
112-4	14573-14581	filtered	_
112-5	14582-14586	with	_
112-6	14587-14588	a	_
112-7	14589-14593	0.01	_
112-8	14593-14594	–	_
112-9	14594-14597	0.1	_
112-10	14597-14598	 	_
112-11	14598-14600	Hz	_
112-12	14601-14609	bandpass	_
112-13	14609-14610	.	_

#Text=To examine RSFC, we used masks from.
113-1	14611-14613	To	_
113-2	14614-14621	examine	_
113-3	14622-14626	RSFC	_
113-4	14626-14627	,	_
113-5	14628-14630	we	_
113-6	14631-14635	used	_
113-7	14636-14641	masks	_
113-8	14642-14646	from	_
113-9	14646-14647	.	_

#Text=The liberal masks from this distribution were resampled into 3 mm MNI space using nearest neighbor interpolation.
114-1	14648-14651	The	_
114-2	14652-14659	liberal	_
114-3	14660-14665	masks	_
114-4	14666-14670	from	_
114-5	14671-14675	this	_
114-6	14676-14688	distribution	_
114-7	14689-14693	were	_
114-8	14694-14703	resampled	_
114-9	14704-14708	into	_
114-10	14709-14710	3	_
114-11	14710-14711	 	_
114-12	14711-14713	mm	_
114-13	14714-14717	MNI	_
114-14	14718-14723	space	_
114-15	14724-14729	using	_
114-16	14730-14737	nearest	_
114-17	14738-14746	neighbor	_
114-18	14747-14760	interpolation	_
114-19	14760-14761	.	_

#Text=Resting state fMRI
#Text=To address issues of “micromovements”, framewise displacement (FD; (;)) was a covariate in analyses involving these data.
115-1	14762-14769	Resting	_
115-2	14770-14775	state	_
115-3	14776-14780	fMRI	_
115-4	14781-14783	To	_
115-5	14784-14791	address	_
115-6	14792-14798	issues	_
115-7	14799-14801	of	_
115-8	14802-14803	“	_
115-9	14803-14817	micromovements	_
115-10	14817-14818	”	_
115-11	14818-14819	,	_
115-12	14820-14829	framewise	_
115-13	14830-14842	displacement	_
115-14	14843-14844	(	_
115-15	14844-14846	FD	_
115-16	14846-14847	;	_
115-17	14848-14849	(	_
115-18	14849-14850	;	_
115-19	14850-14851	)	_
115-20	14851-14852	)	_
115-21	14853-14856	was	_
115-22	14857-14858	a	_
115-23	14859-14868	covariate	_
115-24	14869-14871	in	_
115-25	14872-14880	analyses	_
115-26	14881-14890	involving	_
115-27	14891-14896	these	_
115-28	14897-14901	data	_
115-29	14901-14902	.	_

#Text=One patient who was >2 standard deviations from the mean FD was dropped; the final sample with ERP and RSFC data was 16 patients and 14 controls.
116-1	14903-14906	One	_
116-2	14907-14914	patient	_
116-3	14915-14918	who	_
116-4	14919-14922	was	_
116-5	14923-14924	>	_
116-6	14924-14925	2	_
116-7	14926-14934	standard	_
116-8	14935-14945	deviations	_
116-9	14946-14950	from	_
116-10	14951-14954	the	_
116-11	14955-14959	mean	_
116-12	14960-14962	FD	_
116-13	14963-14966	was	_
116-14	14967-14974	dropped	_
116-15	14974-14975	;	_
116-16	14976-14979	the	_
116-17	14980-14985	final	_
116-18	14986-14992	sample	_
116-19	14993-14997	with	_
116-20	14998-15001	ERP	_
116-21	15002-15005	and	_
116-22	15006-15010	RSFC	_
116-23	15011-15015	data	_
116-24	15016-15019	was	_
116-25	15020-15022	16	_
116-26	15023-15031	patients	_
116-27	15032-15035	and	_
116-28	15036-15038	14	_
116-29	15039-15047	controls	_
116-30	15047-15048	.	_

#Text=To examine absolute vs. relative relationships in RSFC, we analyzed with and without global signal as a nuisance covariate.
117-1	15049-15051	To	_
117-2	15052-15059	examine	_
117-3	15060-15068	absolute	_
117-4	15069-15071	vs	_
117-5	15071-15072	.	_
117-6	15073-15081	relative	_
117-7	15082-15095	relationships	_
117-8	15096-15098	in	_
117-9	15099-15103	RSFC	_
117-10	15103-15104	,	_
117-11	15105-15107	we	_
117-12	15108-15116	analyzed	_
117-13	15117-15121	with	_
117-14	15122-15125	and	_
117-15	15126-15133	without	_
117-16	15134-15140	global	_
117-17	15141-15147	signal	_
117-18	15148-15150	as	_
117-19	15151-15152	a	_
117-20	15153-15161	nuisance	_
117-21	15162-15171	covariate	_
117-22	15171-15172	.	_

#Text=Mean global signal did not differ between groups, t[28]= − 1.34, p = 0.19.
118-1	15173-15177	Mean	_
118-2	15178-15184	global	_
118-3	15185-15191	signal	_
118-4	15192-15195	did	_
118-5	15196-15199	not	_
118-6	15200-15206	differ	_
118-7	15207-15214	between	_
118-8	15215-15221	groups	_
118-9	15221-15222	,	_
118-10	15223-15224	t	_
118-11	15224-15225	[	_
118-12	15225-15227	28	_
118-13	15227-15228	]	_
118-14	15228-15229	=	_
118-15	15229-15230	 	_
118-16	15230-15231	−	_
118-17	15231-15232	 	_
118-18	15232-15236	1.34	_
118-19	15236-15237	,	_
118-20	15238-15239	p	_
118-21	15239-15240	 	_
118-22	15240-15241	=	_
118-23	15241-15242	 	_
118-24	15242-15246	0.19	_
118-25	15246-15247	.	_

#Text=Statistical analyses
#Text=Behavioral and ERP latency differences were evaluated using t-tests.
119-1	15248-15259	Statistical	_
119-2	15260-15268	analyses	_
119-3	15269-15279	Behavioral	_
119-4	15280-15283	and	_
119-5	15284-15287	ERP	_
119-6	15288-15295	latency	_
119-7	15296-15307	differences	_
119-8	15308-15312	were	_
119-9	15313-15322	evaluated	_
119-10	15323-15328	using	_
119-11	15329-15336	t-tests	_
119-12	15336-15337	.	_

#Text=Amplitudes were examined in a repeated-measures Analysis of Variance (ANOVA) with Group (Patient,Control) as a Between-subjects factor and Condition (successful Gos,successful Stops,unsuccessful Stops) as a Within-subjects factor.
120-1	15338-15348	Amplitudes	_
120-2	15349-15353	were	_
120-3	15354-15362	examined	_
120-4	15363-15365	in	_
120-5	15366-15367	a	_
120-6	15368-15385	repeated-measures	_
120-7	15386-15394	Analysis	_
120-8	15395-15397	of	_
120-9	15398-15406	Variance	_
120-10	15407-15408	(	_
120-11	15408-15413	ANOVA	_
120-12	15413-15414	)	_
120-13	15415-15419	with	_
120-14	15420-15425	Group	_
120-15	15426-15427	(	_
120-16	15427-15434	Patient	_
120-17	15434-15435	,	_
120-18	15435-15442	Control	_
120-19	15442-15443	)	_
120-20	15444-15446	as	_
120-21	15447-15448	a	_
120-22	15449-15465	Between-subjects	_
120-23	15466-15472	factor	_
120-24	15473-15476	and	_
120-25	15477-15486	Condition	_
120-26	15487-15488	(	_
120-27	15488-15498	successful	_
120-28	15499-15502	Gos	_
120-29	15502-15503	,	_
120-30	15503-15513	successful	_
120-31	15514-15519	Stops	_
120-32	15519-15520	,	_
120-33	15520-15532	unsuccessful	_
120-34	15533-15538	Stops	_
120-35	15538-15539	)	_
120-36	15540-15542	as	_
120-37	15543-15544	a	_
120-38	15545-15560	Within-subjects	_
120-39	15561-15567	factor	_
120-40	15567-15568	.	_

#Text=Between-variable relationships were examined using Pearson correlations.
121-1	15569-15585	Between-variable	_
121-2	15586-15599	relationships	_
121-3	15600-15604	were	_
121-4	15605-15613	examined	_
121-5	15614-15619	using	_
121-6	15620-15627	Pearson	_
121-7	15628-15640	correlations	_
121-8	15640-15641	.	_

#Text=To determine which network interactions were involved in response inhibition, we used the 7 resting state-based networks from (ftp://surfer.nmr.mgh.harvard.edu/pub/data/Yeo_JNeurophysiol11_MNI152.zip): visual, somatomotor, dorsal attention, ventral attention, limbic, frontoparietal, and DMN systems.
122-1	15642-15644	To	_
122-2	15645-15654	determine	_
122-3	15655-15660	which	_
122-4	15661-15668	network	_
122-5	15669-15681	interactions	_
122-6	15682-15686	were	_
122-7	15687-15695	involved	_
122-8	15696-15698	in	_
122-9	15699-15707	response	_
122-10	15708-15718	inhibition	_
122-11	15718-15719	,	_
122-12	15720-15722	we	_
122-13	15723-15727	used	_
122-14	15728-15731	the	_
122-15	15732-15733	7	_
122-16	15734-15741	resting	_
122-17	15742-15753	state-based	_
122-18	15754-15762	networks	_
122-19	15763-15767	from	_
122-20	15768-15769	(	_
122-21	15769-15772	ftp	_
122-22	15772-15773	:	_
122-23	15773-15774	/	_
122-24	15774-15775	/	_
122-25	15775-15801	surfer.nmr.mgh.harvard.edu	_
122-26	15801-15802	/	_
122-27	15802-15805	pub	_
122-28	15805-15806	/	_
122-29	15806-15810	data	_
122-30	15810-15811	/	_
122-31	15811-15830	Yeo_JNeurophysiol11	_
122-32	15830-15831	_	_
122-33	15831-15837	MNI152	_
122-34	15837-15838	.	_
122-35	15838-15841	zip	_
122-36	15841-15842	)	_
122-37	15842-15843	:	_
122-38	15844-15850	visual	_
122-39	15850-15851	,	_
122-40	15852-15863	somatomotor	_
122-41	15863-15864	,	_
122-42	15865-15871	dorsal	_
122-43	15872-15881	attention	_
122-44	15881-15882	,	_
122-45	15883-15890	ventral	_
122-46	15891-15900	attention	_
122-47	15900-15901	,	_
122-48	15902-15908	limbic	_
122-49	15908-15909	,	_
122-50	15910-15924	frontoparietal	_
122-51	15924-15925	,	_
122-52	15926-15929	and	_
122-53	15930-15933	DMN	_
122-54	15934-15941	systems	_
122-55	15941-15942	.	_

#Text=Network homogeneity
#Text=Within each network, we computed the arctangent–transformed restricted global brain connectivity (;) to measure network homogeneity, further masked by the cross-subject 90% voxel inclusion mask.
123-1	15943-15950	Network	_
123-2	15951-15962	homogeneity	_
123-3	15963-15969	Within	_
123-4	15970-15974	each	_
123-5	15975-15982	network	_
123-6	15982-15983	,	_
123-7	15984-15986	we	_
123-8	15987-15995	computed	_
123-9	15996-15999	the	_
123-10	16000-16022	arctangent–transformed	_
123-11	16023-16033	restricted	_
123-12	16034-16040	global	_
123-13	16041-16046	brain	_
123-14	16047-16059	connectivity	_
123-15	16060-16061	(	_
123-16	16061-16062	;	_
123-17	16062-16063	)	_
123-18	16064-16066	to	_
123-19	16067-16074	measure	_
123-20	16075-16082	network	_
123-21	16083-16094	homogeneity	_
123-22	16094-16095	,	_
123-23	16096-16103	further	_
123-24	16104-16110	masked	_
123-25	16111-16113	by	_
123-26	16114-16117	the	_
123-27	16118-16131	cross-subject	_
123-28	16132-16135	90%	_
123-29	16136-16141	voxel	_
123-30	16142-16151	inclusion	_
123-31	16152-16156	mask	_
123-32	16156-16157	.	_

#Text=Restricted network homogeneity refers to the average temporal correlation between each voxel and every other voxel within a given region of interest (network).
124-1	16158-16168	Restricted	_
124-2	16169-16176	network	_
124-3	16177-16188	homogeneity	_
124-4	16189-16195	refers	_
124-5	16196-16198	to	_
124-6	16199-16202	the	_
124-7	16203-16210	average	_
124-8	16211-16219	temporal	_
124-9	16220-16231	correlation	_
124-10	16232-16239	between	_
124-11	16240-16244	each	_
124-12	16245-16250	voxel	_
124-13	16251-16254	and	_
124-14	16255-16260	every	_
124-15	16261-16266	other	_
124-16	16267-16272	voxel	_
124-17	16273-16279	within	_
124-18	16280-16281	a	_
124-19	16282-16287	given	_
124-20	16288-16294	region	_
124-21	16295-16297	of	_
124-22	16298-16306	interest	_
124-23	16307-16308	(	_
124-24	16308-16315	network	_
124-25	16315-16316	)	_
124-26	16316-16317	.	_

#Text=Analyses were done without global signal-regression (GSR), because GSR may distort Network Homogeneity measures.
125-1	16318-16326	Analyses	_
125-2	16327-16331	were	_
125-3	16332-16336	done	_
125-4	16337-16344	without	_
125-5	16345-16351	global	_
125-6	16352-16369	signal-regression	_
125-7	16370-16371	(	_
125-8	16371-16374	GSR	_
125-9	16374-16375	)	_
125-10	16375-16376	,	_
125-11	16377-16384	because	_
125-12	16385-16388	GSR	_
125-13	16389-16392	may	_
125-14	16393-16400	distort	_
125-15	16401-16408	Network	_
125-16	16409-16420	Homogeneity	_
125-17	16421-16429	measures	_
125-18	16429-16430	.	_

#Text=Global Brain Connectivity was computed as the arc-tangent transformed correlation between each voxel and every other voxel in the 90% inclusion mask.
126-1	16431-16437	Global	_
126-2	16438-16443	Brain	_
126-3	16444-16456	Connectivity	_
126-4	16457-16460	was	_
126-5	16461-16469	computed	_
126-6	16470-16472	as	_
126-7	16473-16476	the	_
126-8	16477-16488	arc-tangent	_
126-9	16489-16500	transformed	_
126-10	16501-16512	correlation	_
126-11	16513-16520	between	_
126-12	16521-16525	each	_
126-13	16526-16531	voxel	_
126-14	16532-16535	and	_
126-15	16536-16541	every	_
126-16	16542-16547	other	_
126-17	16548-16553	voxel	_
126-18	16554-16556	in	_
126-19	16557-16560	the	_
126-20	16561-16564	90%	_
126-21	16565-16574	inclusion	_
126-22	16575-16579	mask	_
126-23	16579-16580	.	_

#Text=We computed a multivariate ANOVA with Group (Patient,Control) as the between-subject variable, Network as the Within-subject variable and FD as a covariate.
127-1	16581-16583	We	_
127-2	16584-16592	computed	_
127-3	16593-16594	a	_
127-4	16595-16607	multivariate	_
127-5	16608-16613	ANOVA	_
127-6	16614-16618	with	_
127-7	16619-16624	Group	_
127-8	16625-16626	(	_
127-9	16626-16633	Patient	_
127-10	16633-16634	,	_
127-11	16634-16641	Control	_
127-12	16641-16642	)	_
127-13	16643-16645	as	_
127-14	16646-16649	the	_
127-15	16650-16665	between-subject	_
127-16	16666-16674	variable	_
127-17	16674-16675	,	_
127-18	16676-16683	Network	_
127-19	16684-16686	as	_
127-20	16687-16690	the	_
127-21	16691-16705	Within-subject	_
127-22	16706-16714	variable	_
127-23	16715-16718	and	_
127-24	16719-16721	FD	_
127-25	16722-16724	as	_
127-26	16725-16726	a	_
127-27	16727-16736	covariate	_
127-28	16736-16737	.	_

#Text=RSFC analyses
#Text=The networks were seeds in an RSFC analysis.
128-1	16738-16742	RSFC	_
128-2	16743-16751	analyses	_
128-3	16752-16755	The	_
128-4	16756-16764	networks	_
128-5	16765-16769	were	_
128-6	16770-16775	seeds	_
128-7	16776-16778	in	_
128-8	16779-16781	an	_
128-9	16782-16786	RSFC	_
128-10	16787-16795	analysis	_
128-11	16795-16796	.	_

#Text=RSFC values were converted to Fisher Z-scores.
129-1	16797-16801	RSFC	_
129-2	16802-16808	values	_
129-3	16809-16813	were	_
129-4	16814-16823	converted	_
129-5	16824-16826	to	_
129-6	16827-16833	Fisher	_
129-7	16834-16842	Z-scores	_
129-8	16842-16843	.	_

#Text=To examine the contribution of RSFC network interactions beyond Group and N1 effects, we used multiple regression.
130-1	16844-16846	To	_
130-2	16847-16854	examine	_
130-3	16855-16858	the	_
130-4	16859-16871	contribution	_
130-5	16872-16874	of	_
130-6	16875-16879	RSFC	_
130-7	16880-16887	network	_
130-8	16888-16900	interactions	_
130-9	16901-16907	beyond	_
130-10	16908-16913	Group	_
130-11	16914-16917	and	_
130-12	16918-16920	N1	_
130-13	16921-16928	effects	_
130-14	16928-16929	,	_
130-15	16930-16932	we	_
130-16	16933-16937	used	_
130-17	16938-16946	multiple	_
130-18	16947-16957	regression	_
130-19	16957-16958	.	_

#Text=Neuropsychological data
#Text=Neuropsychological data from the WAIS-III, WMS-III, and the MATRICS Consensus Cognitive Battery (MCCB) were available for a subset of ERP participants (up to 17 patients, 20 controls).
131-1	16959-16977	Neuropsychological	_
131-2	16978-16982	data	_
131-3	16983-17001	Neuropsychological	_
131-4	17002-17006	data	_
131-5	17007-17011	from	_
131-6	17012-17015	the	_
131-7	17016-17024	WAIS-III	_
131-8	17024-17025	,	_
131-9	17026-17033	WMS-III	_
131-10	17033-17034	,	_
131-11	17035-17038	and	_
131-12	17039-17042	the	_
131-13	17043-17050	MATRICS	_
131-14	17051-17060	Consensus	_
131-15	17061-17070	Cognitive	_
131-16	17071-17078	Battery	_
131-17	17079-17080	(	_
131-18	17080-17084	MCCB	_
131-19	17084-17085	)	_
131-20	17086-17090	were	_
131-21	17091-17100	available	_
131-22	17101-17104	for	_
131-23	17105-17106	a	_
131-24	17107-17113	subset	_
131-25	17114-17116	of	_
131-26	17117-17120	ERP	_
131-27	17121-17133	participants	_
131-28	17134-17135	(	_
131-29	17135-17137	up	_
131-30	17138-17140	to	_
131-31	17141-17143	17	_
131-32	17144-17152	patients	_
131-33	17152-17153	,	_
131-34	17154-17156	20	_
131-35	17157-17165	controls	_
131-36	17165-17166	)	_
131-37	17166-17167	.	_

#Text=We investigated correlations between these tests and N1 amplitude and SSRT.
132-1	17168-17170	We	_
132-2	17171-17183	investigated	_
132-3	17184-17196	correlations	_
132-4	17197-17204	between	_
132-5	17205-17210	these	_
132-6	17211-17216	tests	_
132-7	17217-17220	and	_
132-8	17221-17223	N1	_
132-9	17224-17233	amplitude	_
132-10	17234-17237	and	_
132-11	17238-17242	SSRT	_
132-12	17242-17243	.	_

#Text=Results
#Text=Behavioral data
#Text=Demographics and behavioral data.
133-1	17244-17251	Results	_
133-2	17252-17262	Behavioral	_
133-3	17263-17267	data	_
133-4	17268-17280	Demographics	_
133-5	17281-17284	and	_
133-6	17285-17295	behavioral	_
133-7	17296-17300	data	_
133-8	17300-17301	.	_

#Text=Table 1\t \t
#Text=Variable\tPatients\tControls\t\t\t\t\t \tM\tSD\tM\tSD\tt/×2\tdf\tp\tda\t \tAge (years)\t39.8\t10.2\t33.6\t11.4\t1.84\t40\t0.07\t0.56\t \tParental SES\t35.8\t9.6\t43.0\t14.0\t−1.85\t40\t0.07\t−0.60\t \tGender (F/M)\t2/19\t–\t5/16\t–\t0.69\t1\t0.41\t–\t \tHandedness (R/L)\t20/1\t–\t16/5\t–\t1.75\t1\t0.19\t–\t \tMedication (mg)b\t787.7\t489.9\t–\t–\t–\t–\t–\t–\t \tGo Accuracy (%)c\t85.6\t12.2\t95.9\t6.0\t−3.46\t29.1\t0.002\t−1.06\t \tStop Accuracy (%)c\t54.3\t5.3\t53.7\t3.2\t0.46\t32.7\t0.65\t0.14\t \tSSD (ms)d\t447.3\t140.9\t464.2\t135.2\t−0.40\t40\t0.69\t0.12\t \tGo RT (ms)d\t733.6\t137.5\t671.7\t127.7\t1.51\t40\t0.14\t0.47\t \tSSRT (ms)c, e\t286.2\t93.8\t207.5\t51.5\t3.37\t31.1\t0.002\t1.04\t \tStop RT (ms)b\t637.0\t114.4\t600.2\t121.6\t1.01\t40\t0.32\t0.32\t \t
#Text=Note.
134-1	17302-17307	Table	_
134-2	17308-17309	1	_
134-3	17313-17321	Variable	_
134-4	17322-17330	Patients	_
134-5	17331-17339	Controls	_
134-6	17346-17347	M	_
134-7	17348-17350	SD	_
134-8	17351-17352	M	_
134-9	17353-17355	SD	_
134-10	17356-17357	t	_
134-11	17357-17358	/	_
134-12	17358-17359	×	_
134-13	17359-17360	2	_
134-14	17361-17363	df	_
134-15	17364-17365	p	_
134-16	17366-17368	da	_
134-17	17371-17374	Age	_
134-18	17375-17376	(	_
134-19	17376-17381	years	_
134-20	17381-17382	)	_
134-21	17383-17387	39.8	_
134-22	17388-17392	10.2	_
134-23	17393-17397	33.6	_
134-24	17398-17402	11.4	_
134-25	17403-17407	1.84	_
134-26	17408-17410	40	_
134-27	17411-17415	0.07	_
134-28	17416-17420	0.56	_
134-29	17423-17431	Parental	_
134-30	17432-17435	SES	_
134-31	17436-17440	35.8	_
134-32	17441-17444	9.6	_
134-33	17445-17449	43.0	_
134-34	17450-17454	14.0	_
134-35	17455-17456	−	_
134-36	17456-17460	1.85	_
134-37	17461-17463	40	_
134-38	17464-17468	0.07	_
134-39	17469-17470	−	_
134-40	17470-17474	0.60	_
134-41	17477-17483	Gender	_
134-42	17484-17485	(	_
134-43	17485-17486	F	_
134-44	17486-17487	/	_
134-45	17487-17488	M	_
134-46	17488-17489	)	_
134-47	17490-17491	2	_
134-48	17491-17492	/	_
134-49	17492-17494	19	_
134-50	17495-17496	–	_
134-51	17497-17498	5	_
134-52	17498-17499	/	_
134-53	17499-17501	16	_
134-54	17502-17503	–	_
134-55	17504-17508	0.69	_
134-56	17509-17510	1	_
134-57	17511-17515	0.41	_
134-58	17516-17517	–	_
134-59	17520-17530	Handedness	_
134-60	17531-17532	(	_
134-61	17532-17533	R	_
134-62	17533-17534	/	_
134-63	17534-17535	L	_
134-64	17535-17536	)	_
134-65	17537-17539	20	_
134-66	17539-17540	/	_
134-67	17540-17541	1	_
134-68	17542-17543	–	_
134-69	17544-17546	16	_
134-70	17546-17547	/	_
134-71	17547-17548	5	_
134-72	17549-17550	–	_
134-73	17551-17555	1.75	_
134-74	17556-17557	1	_
134-75	17558-17562	0.19	_
134-76	17563-17564	–	_
134-77	17567-17577	Medication	_
134-78	17578-17579	(	_
134-79	17579-17581	mg	_
134-80	17581-17582	)	_
134-81	17582-17583	b	_
134-82	17584-17589	787.7	_
134-83	17590-17595	489.9	_
134-84	17596-17597	–	_
134-85	17598-17599	–	_
134-86	17600-17601	–	_
134-87	17602-17603	–	_
134-88	17604-17605	–	_
134-89	17606-17607	–	_
134-90	17610-17612	Go	_
134-91	17613-17621	Accuracy	_
134-92	17622-17623	(	_
134-93	17623-17624	%	_
134-94	17624-17625	)	_
134-95	17625-17626	c	_
134-96	17627-17631	85.6	_
134-97	17632-17636	12.2	_
134-98	17637-17641	95.9	_
134-99	17642-17645	6.0	_
134-100	17646-17647	−	_
134-101	17647-17651	3.46	_
134-102	17652-17656	29.1	_
134-103	17657-17662	0.002	_
134-104	17663-17664	−	_
134-105	17664-17668	1.06	_
134-106	17671-17675	Stop	_
134-107	17676-17684	Accuracy	_
134-108	17685-17686	(	_
134-109	17686-17687	%	_
134-110	17687-17688	)	_
134-111	17688-17689	c	_
134-112	17690-17694	54.3	_
134-113	17695-17698	5.3	_
134-114	17699-17703	53.7	_
134-115	17704-17707	3.2	_
134-116	17708-17712	0.46	_
134-117	17713-17717	32.7	_
134-118	17718-17722	0.65	_
134-119	17723-17727	0.14	_
134-120	17730-17733	SSD	_
134-121	17734-17735	(	_
134-122	17735-17737	ms	_
134-123	17737-17738	)	_
134-124	17738-17739	d	_
134-125	17740-17745	447.3	_
134-126	17746-17751	140.9	_
134-127	17752-17757	464.2	_
134-128	17758-17763	135.2	_
134-129	17764-17765	−	_
134-130	17765-17769	0.40	_
134-131	17770-17772	40	_
134-132	17773-17777	0.69	_
134-133	17778-17782	0.12	_
134-134	17785-17787	Go	_
134-135	17788-17790	RT	_
134-136	17791-17792	(	_
134-137	17792-17794	ms	_
134-138	17794-17795	)	_
134-139	17795-17796	d	_
134-140	17797-17802	733.6	_
134-141	17803-17808	137.5	_
134-142	17809-17814	671.7	_
134-143	17815-17820	127.7	_
134-144	17821-17825	1.51	_
134-145	17826-17828	40	_
134-146	17829-17833	0.14	_
134-147	17834-17838	0.47	_
134-148	17841-17845	SSRT	_
134-149	17846-17847	(	_
134-150	17847-17849	ms	_
134-151	17849-17850	)	_
134-152	17850-17851	c	_
134-153	17851-17852	,	_
134-154	17853-17854	e	_
134-155	17855-17860	286.2	_
134-156	17861-17865	93.8	_
134-157	17866-17871	207.5	_
134-158	17872-17876	51.5	_
134-159	17877-17881	3.37	_
134-160	17882-17886	31.1	_
134-161	17887-17892	0.002	_
134-162	17893-17897	1.04	_
134-163	17900-17904	Stop	_
134-164	17905-17907	RT	_
134-165	17908-17909	(	_
134-166	17909-17911	ms	_
134-167	17911-17912	)	_
134-168	17912-17913	b	_
134-169	17914-17919	637.0	_
134-170	17920-17925	114.4	_
134-171	17926-17931	600.2	_
134-172	17932-17937	121.6	_
134-173	17938-17942	1.01	_
134-174	17943-17945	40	_
134-175	17946-17950	0.32	_
134-176	17951-17955	0.32	_
134-177	17959-17963	Note	_
134-178	17963-17964	.	_

#Text=Data presented are for 21 patients and 21 healthy controls.
#Text=d = Cohen's effect size.
135-1	17965-17969	Data	_
135-2	17970-17979	presented	_
135-3	17980-17983	are	_
135-4	17984-17987	for	_
135-5	17988-17990	21	_
135-6	17991-17999	patients	_
135-7	18000-18003	and	_
135-8	18004-18006	21	_
135-9	18007-18014	healthy	_
135-10	18015-18023	controls	_
135-11	18023-18024	.	_
135-12	18025-18026	d	_
135-13	18026-18027	 	_
135-14	18027-18028	=	_
135-15	18028-18029	 	_
135-16	18029-18036	Cohen's	_
135-17	18037-18043	effect	_
135-18	18044-18048	size	_
135-19	18048-18049	.	_

#Text=CPZ equivalents.
136-1	18050-18053	CPZ	_
136-2	18054-18065	equivalents	_
136-3	18065-18066	.	_

#Text=Unequal variances.
137-1	18067-18074	Unequal	_
137-2	18075-18084	variances	_
137-3	18084-18085	.	_

#Text=SSD = median stop signal delay.
138-1	18086-18089	SSD	_
138-2	18089-18090	 	_
138-3	18090-18091	=	_
138-4	18091-18092	 	_
138-5	18092-18098	median	_
138-6	18099-18103	stop	_
138-7	18104-18110	signal	_
138-8	18111-18116	delay	_
138-9	18116-18117	.	_

#Text=SSRT = median stop signal reaction time.
139-1	18118-18122	SSRT	_
139-2	18122-18123	 	_
139-3	18123-18124	=	_
139-4	18124-18125	 	_
139-5	18125-18131	median	_
139-6	18132-18136	stop	_
139-7	18137-18143	signal	_
139-8	18144-18152	reaction	_
139-9	18153-18157	time	_
139-10	18157-18158	.	_

#Text=By design, groups had similar stop accuracy, with both groups able to inhibit response correctly in ~50% of stop trials, demonstrating effectiveness of the active titration.
140-1	18159-18161	By	_
140-2	18162-18168	design	_
140-3	18168-18169	,	_
140-4	18170-18176	groups	_
140-5	18177-18180	had	_
140-6	18181-18188	similar	_
140-7	18189-18193	stop	_
140-8	18194-18202	accuracy	_
140-9	18202-18203	,	_
140-10	18204-18208	with	_
140-11	18209-18213	both	_
140-12	18214-18220	groups	_
140-13	18221-18225	able	_
140-14	18226-18228	to	_
140-15	18229-18236	inhibit	_
140-16	18237-18245	response	_
140-17	18246-18255	correctly	_
140-18	18256-18258	in	_
140-19	18259-18260	~	_
140-20	18260-18263	50%	_
140-21	18264-18266	of	_
140-22	18267-18271	stop	_
140-23	18272-18278	trials	_
140-24	18278-18279	,	_
140-25	18280-18293	demonstrating	_
140-26	18294-18307	effectiveness	_
140-27	18308-18310	of	_
140-28	18311-18314	the	_
140-29	18315-18321	active	_
140-30	18322-18331	titration	_
140-31	18331-18332	.	_

#Text=As expected, despite the similar stop accuracy, patients had lower go accuracy and longer SSRTs than controls (Table 1).
141-1	18333-18335	As	_
141-2	18336-18344	expected	_
141-3	18344-18345	,	_
141-4	18346-18353	despite	_
141-5	18354-18357	the	_
141-6	18358-18365	similar	_
141-7	18366-18370	stop	_
141-8	18371-18379	accuracy	_
141-9	18379-18380	,	_
141-10	18381-18389	patients	_
141-11	18390-18393	had	_
141-12	18394-18399	lower	_
141-13	18400-18402	go	_
141-14	18403-18411	accuracy	_
141-15	18412-18415	and	_
141-16	18416-18422	longer	_
141-17	18423-18428	SSRTs	_
141-18	18429-18433	than	_
141-19	18434-18442	controls	_
141-20	18443-18444	(	_
141-21	18444-18449	Table	_
141-22	18450-18451	1	_
141-23	18451-18452	)	_
141-24	18452-18453	.	_

#Text=Multiple regression analysis showed that the SSRT group effect remained significant after controlling for go accuracy (t39 = −2.45, p = 0.019, R2change = 0.12).
142-1	18454-18462	Multiple	_
142-2	18463-18473	regression	_
142-3	18474-18482	analysis	_
142-4	18483-18489	showed	_
142-5	18490-18494	that	_
142-6	18495-18498	the	_
142-7	18499-18503	SSRT	_
142-8	18504-18509	group	_
142-9	18510-18516	effect	_
142-10	18517-18525	remained	_
142-11	18526-18537	significant	_
142-12	18538-18543	after	_
142-13	18544-18555	controlling	_
142-14	18556-18559	for	_
142-15	18560-18562	go	_
142-16	18563-18571	accuracy	_
142-17	18572-18573	(	_
142-18	18573-18576	t39	_
142-19	18576-18577	 	_
142-20	18577-18578	=	_
142-21	18578-18579	 	_
142-22	18579-18580	−	_
142-23	18580-18584	2.45	_
142-24	18584-18585	,	_
142-25	18586-18587	p	_
142-26	18587-18588	 	_
142-27	18588-18589	=	_
142-28	18589-18590	 	_
142-29	18590-18595	0.019	_
142-30	18595-18596	,	_
142-31	18597-18605	R2change	_
142-32	18605-18606	 	_
142-33	18606-18607	=	_
142-34	18607-18608	 	_
142-35	18608-18612	0.12	_
142-36	18612-18613	)	_
142-37	18613-18614	.	_

#Text=Controlling for group membership, go accuracy did not correlate significantly with SSRT (partial r39 = −0.17, p = 0.29) but correlated negatively with go RT (partial r39 = −0.35, p = 0.024), suggesting a speed/accuracy trade-off.
143-1	18615-18626	Controlling	_
143-2	18627-18630	for	_
143-3	18631-18636	group	_
143-4	18637-18647	membership	_
143-5	18647-18648	,	_
143-6	18649-18651	go	_
143-7	18652-18660	accuracy	_
143-8	18661-18664	did	_
143-9	18665-18668	not	_
143-10	18669-18678	correlate	_
143-11	18679-18692	significantly	_
143-12	18693-18697	with	_
143-13	18698-18702	SSRT	_
143-14	18703-18704	(	_
143-15	18704-18711	partial	_
143-16	18712-18715	r39	_
143-17	18715-18716	 	_
143-18	18716-18717	=	_
143-19	18717-18718	 	_
143-20	18718-18719	−	_
143-21	18719-18723	0.17	_
143-22	18723-18724	,	_
143-23	18725-18726	p	_
143-24	18726-18727	 	_
143-25	18727-18728	=	_
143-26	18728-18729	 	_
143-27	18729-18733	0.29	_
143-28	18733-18734	)	_
143-29	18735-18738	but	_
143-30	18739-18749	correlated	_
143-31	18750-18760	negatively	_
143-32	18761-18765	with	_
143-33	18766-18768	go	_
143-34	18769-18771	RT	_
143-35	18772-18773	(	_
143-36	18773-18780	partial	_
143-37	18781-18784	r39	_
143-38	18784-18785	 	_
143-39	18785-18786	=	_
143-40	18786-18787	 	_
143-41	18787-18788	−	_
143-42	18788-18792	0.35	_
143-43	18792-18793	,	_
143-44	18794-18795	p	_
143-45	18795-18796	 	_
143-46	18796-18797	=	_
143-47	18797-18798	 	_
143-48	18798-18803	0.024	_
143-49	18803-18804	)	_
143-50	18804-18805	,	_
143-51	18806-18816	suggesting	_
143-52	18817-18818	a	_
143-53	18819-18824	speed	_
143-54	18824-18825	/	_
143-55	18825-18833	accuracy	_
143-56	18834-18843	trade-off	_
143-57	18843-18844	.	_

#Text=Go RT also significantly correlated with stop accuracy, controlling for group (partial r39 = 0.74, p < 0.001), suggesting that RTs were slowed to optimize stop performance.
144-1	18845-18847	Go	_
144-2	18848-18850	RT	_
144-3	18851-18855	also	_
144-4	18856-18869	significantly	_
144-5	18870-18880	correlated	_
144-6	18881-18885	with	_
144-7	18886-18890	stop	_
144-8	18891-18899	accuracy	_
144-9	18899-18900	,	_
144-10	18901-18912	controlling	_
144-11	18913-18916	for	_
144-12	18917-18922	group	_
144-13	18923-18924	(	_
144-14	18924-18931	partial	_
144-15	18932-18935	r39	_
144-16	18935-18936	 	_
144-17	18936-18937	=	_
144-18	18937-18938	 	_
144-19	18938-18942	0.74	_
144-20	18942-18943	,	_
144-21	18944-18945	p	_
144-22	18945-18946	 	_
144-23	18946-18947	<	_
144-24	18947-18948	 	_
144-25	18948-18953	0.001	_
144-26	18953-18954	)	_
144-27	18954-18955	,	_
144-28	18956-18966	suggesting	_
144-29	18967-18971	that	_
144-30	18972-18975	RTs	_
144-31	18976-18980	were	_
144-32	18981-18987	slowed	_
144-33	18988-18990	to	_
144-34	18991-18999	optimize	_
144-35	19000-19004	stop	_
144-36	19005-19016	performance	_
144-37	19016-19017	.	_

#Text=ERP results
#Text=A) Timeline relative to onset of stop signal.
145-1	19018-19021	ERP	_
145-2	19022-19029	results	_
145-3	19030-19031	A	_
145-4	19031-19032	)	_
145-5	19033-19041	Timeline	_
145-6	19042-19050	relative	_
145-7	19051-19053	to	_
145-8	19054-19059	onset	_
145-9	19060-19062	of	_
145-10	19063-19067	stop	_
145-11	19068-19074	signal	_
145-12	19074-19075	.	_

#Text=Onset of go and stop stimuli are shown.
146-1	19076-19081	Onset	_
146-2	19082-19084	of	_
146-3	19085-19087	go	_
146-4	19088-19091	and	_
146-5	19092-19096	stop	_
146-6	19097-19104	stimuli	_
146-7	19105-19108	are	_
146-8	19109-19114	shown	_
146-9	19114-19115	.	_

#Text=Left topographic maps shows N1 to successful gos for controls, right topographic maps shows N1 to successful stops for controls.
147-1	19116-19120	Left	_
147-2	19121-19132	topographic	_
147-3	19133-19137	maps	_
147-4	19138-19143	shows	_
147-5	19144-19146	N1	_
147-6	19147-19149	to	_
147-7	19150-19160	successful	_
147-8	19161-19164	gos	_
147-9	19165-19168	for	_
147-10	19169-19177	controls	_
147-11	19177-19178	,	_
147-12	19179-19184	right	_
147-13	19185-19196	topographic	_
147-14	19197-19201	maps	_
147-15	19202-19207	shows	_
147-16	19208-19210	N1	_
147-17	19211-19213	to	_
147-18	19214-19224	successful	_
147-19	19225-19230	stops	_
147-20	19231-19234	for	_
147-21	19235-19243	controls	_
147-22	19243-19244	.	_

#Text=B) ERP topography for controls (CN), patients (PT), and controls–patients (Cn-Pt) for N1 component for successful gos (left; 0.2 μV/step) and successful stops (right; 0.5 μV/step).
148-1	19245-19246	B	_
148-2	19246-19247	)	_
148-3	19248-19251	ERP	_
148-4	19252-19262	topography	_
148-5	19263-19266	for	_
148-6	19267-19275	controls	_
148-7	19276-19277	(	_
148-8	19277-19279	CN	_
148-9	19279-19280	)	_
148-10	19280-19281	,	_
148-11	19282-19290	patients	_
148-12	19291-19292	(	_
148-13	19292-19294	PT	_
148-14	19294-19295	)	_
148-15	19295-19296	,	_
148-16	19297-19300	and	_
148-17	19301-19318	controls–patients	_
148-18	19319-19320	(	_
148-19	19320-19325	Cn-Pt	_
148-20	19325-19326	)	_
148-21	19327-19330	for	_
148-22	19331-19333	N1	_
148-23	19334-19343	component	_
148-24	19344-19347	for	_
148-25	19348-19358	successful	_
148-26	19359-19362	gos	_
148-27	19363-19364	(	_
148-28	19364-19368	left	_
148-29	19368-19369	;	_
148-30	19370-19373	0.2	_
148-31	19373-19374	 	_
148-32	19374-19376	μV	_
148-33	19376-19377	/	_
148-34	19377-19381	step	_
148-35	19381-19382	)	_
148-36	19383-19386	and	_
148-37	19387-19397	successful	_
148-38	19398-19403	stops	_
148-39	19404-19405	(	_
148-40	19405-19410	right	_
148-41	19410-19411	;	_
148-42	19412-19415	0.5	_
148-43	19415-19416	 	_
148-44	19416-19418	μV	_
148-45	19418-19419	/	_
148-46	19419-19423	step	_
148-47	19423-19424	)	_
148-48	19424-19425	.	_

#Text=Critical electrodes are shown in green.
149-1	19426-19434	Critical	_
149-2	19435-19445	electrodes	_
149-3	19446-19449	are	_
149-4	19450-19455	shown	_
149-5	19456-19458	in	_
149-6	19459-19464	green	_
149-7	19464-19465	.	_

#Text=C) Grand average for successful go N1 component (left) and successful stop N1 component (middle).
150-1	19466-19467	C	_
150-2	19467-19468	)	_
150-3	19469-19474	Grand	_
150-4	19475-19482	average	_
150-5	19483-19486	for	_
150-6	19487-19497	successful	_
150-7	19498-19500	go	_
150-8	19501-19503	N1	_
150-9	19504-19513	component	_
150-10	19514-19515	(	_
150-11	19515-19519	left	_
150-12	19519-19520	)	_
150-13	19521-19524	and	_
150-14	19525-19535	successful	_
150-15	19536-19540	stop	_
150-16	19541-19543	N1	_
150-17	19544-19553	component	_
150-18	19554-19555	(	_
150-19	19555-19561	middle	_
150-20	19561-19562	)	_
150-21	19562-19563	.	_

#Text=Time windows are shown in gray.
151-1	19564-19568	Time	_
151-2	19569-19576	windows	_
151-3	19577-19580	are	_
151-4	19581-19586	shown	_
151-5	19587-19589	in	_
151-6	19590-19594	gray	_
151-7	19594-19595	.	_

#Text=Right panel shows correlation between N1 amplitude (successful stops) vs.
152-1	19596-19601	Right	_
152-2	19602-19607	panel	_
152-3	19608-19613	shows	_
152-4	19614-19625	correlation	_
152-5	19626-19633	between	_
152-6	19634-19636	N1	_
152-7	19637-19646	amplitude	_
152-8	19647-19648	(	_
152-9	19648-19658	successful	_
152-10	19659-19664	stops	_
152-11	19664-19665	)	_
152-12	19666-19668	vs	_
152-13	19668-19669	.	_

#Text=SSRT.
153-1	19670-19674	SSRT	_
153-2	19674-19675	.	_

#Text=Fig. 1
#Text=A) Timeline as in Fig. 1A.
154-1	19676-19679	Fig	_
154-2	19679-19680	.	_
154-3	19681-19682	1	_
154-4	19683-19684	A	_
154-5	19684-19685	)	_
154-6	19686-19694	Timeline	_
154-7	19695-19697	as	_
154-8	19698-19700	in	_
154-9	19701-19704	Fig	_
154-10	19704-19705	.	_
154-11	19706-19708	1A	_
154-12	19708-19709	.	_

#Text=Left topographic maps shows N2 to unsuccessful stops for controls, right topographic map shows P3 to successful stops for controls.
155-1	19710-19714	Left	_
155-2	19715-19726	topographic	_
155-3	19727-19731	maps	_
155-4	19732-19737	shows	_
155-5	19738-19740	N2	_
155-6	19741-19743	to	_
155-7	19744-19756	unsuccessful	_
155-8	19757-19762	stops	_
155-9	19763-19766	for	_
155-10	19767-19775	controls	_
155-11	19775-19776	,	_
155-12	19777-19782	right	_
155-13	19783-19794	topographic	_
155-14	19795-19798	map	_
155-15	19799-19804	shows	_
155-16	19805-19807	P3	_
155-17	19808-19810	to	_
155-18	19811-19821	successful	_
155-19	19822-19827	stops	_
155-20	19828-19831	for	_
155-21	19832-19840	controls	_
155-22	19840-19841	.	_

#Text=B) ERP topography for unsuccessful stop N2 component (left) and successful P3 component (right).
156-1	19842-19843	B	_
156-2	19843-19844	)	_
156-3	19845-19848	ERP	_
156-4	19849-19859	topography	_
156-5	19860-19863	for	_
156-6	19864-19876	unsuccessful	_
156-7	19877-19881	stop	_
156-8	19882-19884	N2	_
156-9	19885-19894	component	_
156-10	19895-19896	(	_
156-11	19896-19900	left	_
156-12	19900-19901	)	_
156-13	19902-19905	and	_
156-14	19906-19916	successful	_
156-15	19917-19919	P3	_
156-16	19920-19929	component	_
156-17	19930-19931	(	_
156-18	19931-19936	right	_
156-19	19936-19937	)	_
156-20	19937-19938	.	_

#Text=C) Grand average maps for N2 to unsuccessful stops (left), P3 to successful stops (middle), Right: Correlation between SSRT and P3 to successful stops.
157-1	19939-19940	C	_
157-2	19940-19941	)	_
157-3	19942-19947	Grand	_
157-4	19948-19955	average	_
157-5	19956-19960	maps	_
157-6	19961-19964	for	_
157-7	19965-19967	N2	_
157-8	19968-19970	to	_
157-9	19971-19983	unsuccessful	_
157-10	19984-19989	stops	_
157-11	19990-19991	(	_
157-12	19991-19995	left	_
157-13	19995-19996	)	_
157-14	19996-19997	,	_
157-15	19998-20000	P3	_
157-16	20001-20003	to	_
157-17	20004-20014	successful	_
157-18	20015-20020	stops	_
157-19	20021-20022	(	_
157-20	20022-20028	middle	_
157-21	20028-20029	)	_
157-22	20029-20030	,	_
157-23	20031-20036	Right	_
157-24	20036-20037	:	_
157-25	20038-20049	Correlation	_
157-26	20050-20057	between	_
157-27	20058-20062	SSRT	_
157-28	20063-20066	and	_
157-29	20067-20069	P3	_
157-30	20070-20072	to	_
157-31	20073-20083	successful	_
157-32	20084-20089	stops	_
157-33	20089-20090	.	_

#Text=We used a late window for the N2 component to avoid overlap with the N1 potential.
158-1	20091-20093	We	_
158-2	20094-20098	used	_
158-3	20099-20100	a	_
158-4	20101-20105	late	_
158-5	20106-20112	window	_
158-6	20113-20116	for	_
158-7	20117-20120	the	_
158-8	20121-20123	N2	_
158-9	20124-20133	component	_
158-10	20134-20136	to	_
158-11	20137-20142	avoid	_
158-12	20143-20150	overlap	_
158-13	20151-20155	with	_
158-14	20156-20159	the	_
158-15	20160-20162	N1	_
158-16	20163-20172	potential	_
158-17	20172-20173	.	_

#Text=Fig. 2
#Text=Mean amplitudes (μV) of ERP measures.
159-1	20174-20177	Fig	_
159-2	20177-20178	.	_
159-3	20179-20180	2	_
159-4	20181-20185	Mean	_
159-5	20186-20196	amplitudes	_
159-6	20197-20198	(	_
159-7	20198-20200	μV	_
159-8	20200-20201	)	_
159-9	20202-20204	of	_
159-10	20205-20208	ERP	_
159-11	20209-20217	measures	_
159-12	20217-20218	.	_

#Text=Table 2\t \t
#Text=Variable\tPatients\tControls\t\t\t\t\t \tM\tSD\tM\tSD\tt/×2\tdf\tp\td\t \tGo trials\t \tN1 (μV)\t0.40\t1.29\t−0.62\t1.33\t2.54\t40\t0.015\t0.78\t \tP3 (μV)\t2.30\t1.64\t1.04\t2.14\t2.15\t40\t0.038\t0.66\t \t  \t \tSuccessful stop trials\t \tN1 (μV)\t−1.95\t2.14\t−4.51\t3.21\t3.04\t40\t0.004\t0.94\t \tP3 (μV)\t3.41\t2.55\t6.74\t3.94\t−3.26\t34.2\t0.003\t−1.00\t \t  \t \tUnsuccessful stop trials\t \tN1 (μV)\t−1.75\t1.81\t−4.28\t3.53\t2.90\t28.0\t0.006\t0.90\t \tN2 (μV)\t−0.51\t3.25\t−3.29\t4.44\t2.30\t40\t0.027\t0.71\t \tP3 (μV)\t1.92\t2.51\t4.25\t3.49\t−2.49\t40\t0.017\t−0.77\t \t
#Text=Note.
160-1	20219-20224	Table	_
160-2	20225-20226	2	_
160-3	20230-20238	Variable	_
160-4	20239-20247	Patients	_
160-5	20248-20256	Controls	_
160-6	20263-20264	M	_
160-7	20265-20267	SD	_
160-8	20268-20269	M	_
160-9	20270-20272	SD	_
160-10	20273-20274	t	_
160-11	20274-20275	/	_
160-12	20275-20276	×	_
160-13	20276-20277	2	_
160-14	20278-20280	df	_
160-15	20281-20282	p	_
160-16	20283-20284	d	_
160-17	20287-20289	Go	_
160-18	20290-20296	trials	_
160-19	20299-20301	N1	_
160-20	20302-20303	(	_
160-21	20303-20305	μV	_
160-22	20305-20306	)	_
160-23	20307-20311	0.40	_
160-24	20312-20316	1.29	_
160-25	20317-20318	−	_
160-26	20318-20322	0.62	_
160-27	20323-20327	1.33	_
160-28	20328-20332	2.54	_
160-29	20333-20335	40	_
160-30	20336-20341	0.015	_
160-31	20342-20346	0.78	_
160-32	20349-20351	P3	_
160-33	20352-20353	(	_
160-34	20353-20355	μV	_
160-35	20355-20356	)	_
160-36	20357-20361	2.30	_
160-37	20362-20366	1.64	_
160-38	20367-20371	1.04	_
160-39	20372-20376	2.14	_
160-40	20377-20381	2.15	_
160-41	20382-20384	40	_
160-42	20385-20390	0.038	_
160-43	20391-20395	0.66	_
160-44	20403-20413	Successful	_
160-45	20414-20418	stop	_
160-46	20419-20425	trials	_
160-47	20428-20430	N1	_
160-48	20431-20432	(	_
160-49	20432-20434	μV	_
160-50	20434-20435	)	_
160-51	20436-20437	−	_
160-52	20437-20441	1.95	_
160-53	20442-20446	2.14	_
160-54	20447-20448	−	_
160-55	20448-20452	4.51	_
160-56	20453-20457	3.21	_
160-57	20458-20462	3.04	_
160-58	20463-20465	40	_
160-59	20466-20471	0.004	_
160-60	20472-20476	0.94	_
160-61	20479-20481	P3	_
160-62	20482-20483	(	_
160-63	20483-20485	μV	_
160-64	20485-20486	)	_
160-65	20487-20491	3.41	_
160-66	20492-20496	2.55	_
160-67	20497-20501	6.74	_
160-68	20502-20506	3.94	_
160-69	20507-20508	−	_
160-70	20508-20512	3.26	_
160-71	20513-20517	34.2	_
160-72	20518-20523	0.003	_
160-73	20524-20525	−	_
160-74	20525-20529	1.00	_
160-75	20537-20549	Unsuccessful	_
160-76	20550-20554	stop	_
160-77	20555-20561	trials	_
160-78	20564-20566	N1	_
160-79	20567-20568	(	_
160-80	20568-20570	μV	_
160-81	20570-20571	)	_
160-82	20572-20573	−	_
160-83	20573-20577	1.75	_
160-84	20578-20582	1.81	_
160-85	20583-20584	−	_
160-86	20584-20588	4.28	_
160-87	20589-20593	3.53	_
160-88	20594-20598	2.90	_
160-89	20599-20603	28.0	_
160-90	20604-20609	0.006	_
160-91	20610-20614	0.90	_
160-92	20617-20619	N2	_
160-93	20620-20621	(	_
160-94	20621-20623	μV	_
160-95	20623-20624	)	_
160-96	20625-20626	−	_
160-97	20626-20630	0.51	_
160-98	20631-20635	3.25	_
160-99	20636-20637	−	_
160-100	20637-20641	3.29	_
160-101	20642-20646	4.44	_
160-102	20647-20651	2.30	_
160-103	20652-20654	40	_
160-104	20655-20660	0.027	_
160-105	20661-20665	0.71	_
160-106	20668-20670	P3	_
160-107	20671-20672	(	_
160-108	20672-20674	μV	_
160-109	20674-20675	)	_
160-110	20676-20680	1.92	_
160-111	20681-20685	2.51	_
160-112	20686-20690	4.25	_
160-113	20691-20695	3.49	_
160-114	20696-20697	−	_
160-115	20697-20701	2.49	_
160-116	20702-20704	40	_
160-117	20705-20710	0.017	_
160-118	20711-20712	−	_
160-119	20712-20716	0.77	_
160-120	20720-20724	Note	_
160-121	20724-20725	.	_

#Text=M=mean, SD = standard deviation.
161-1	20726-20727	M	_
161-2	20727-20728	=	_
161-3	20728-20732	mean	_
161-4	20732-20733	,	_
161-5	20734-20736	SD	_
161-6	20736-20737	 	_
161-7	20737-20738	=	_
161-8	20738-20739	 	_
161-9	20739-20747	standard	_
161-10	20748-20757	deviation	_
161-11	20757-20758	.	_

#Text=Scalp topography and grand average waveforms are shown in Fig. 1B/C for pre-decision and Fig. 2B/C for post-decision componentry.
162-1	20759-20764	Scalp	_
162-2	20765-20775	topography	_
162-3	20776-20779	and	_
162-4	20780-20785	grand	_
162-5	20786-20793	average	_
162-6	20794-20803	waveforms	_
162-7	20804-20807	are	_
162-8	20808-20813	shown	_
162-9	20814-20816	in	_
162-10	20817-20820	Fig	_
162-11	20820-20821	.	_
162-12	20822-20824	1B	_
162-13	20824-20825	/	_
162-14	20825-20826	C	_
162-15	20827-20830	for	_
162-16	20831-20843	pre-decision	_
162-17	20844-20847	and	_
162-18	20848-20851	Fig	_
162-19	20851-20852	.	_
162-20	20853-20855	2B	_
162-21	20855-20856	/	_
162-22	20856-20857	C	_
162-23	20858-20861	for	_
162-24	20862-20875	post-decision	_
162-25	20876-20887	componentry	_
162-26	20887-20888	.	_

#Text=Mean amplitudes are presented in Table 2.
163-1	20889-20893	Mean	_
163-2	20894-20904	amplitudes	_
163-3	20905-20908	are	_
163-4	20909-20918	presented	_
163-5	20919-20921	in	_
163-6	20922-20927	Table	_
163-7	20928-20929	2	_
163-8	20929-20930	.	_

#Text=Peak latencies (Supplementary Table 1) did not differ by Group for any component.
164-1	20931-20935	Peak	_
164-2	20936-20945	latencies	_
164-3	20946-20947	(	_
164-4	20947-20960	Supplementary	_
164-5	20961-20966	Table	_
164-6	20967-20968	1	_
164-7	20968-20969	)	_
164-8	20970-20973	did	_
164-9	20974-20977	not	_
164-10	20978-20984	differ	_
164-11	20985-20987	by	_
164-12	20988-20993	Group	_
164-13	20994-20997	for	_
164-14	20998-21001	any	_
164-15	21002-21011	component	_
164-16	21011-21012	.	_

#Text=N1
#Text=Patients had lower mean N1 amplitudes across conditions (main effect of Group, F2,39 = 10.20, p = 0.003).
165-1	21013-21015	N1	_
165-2	21016-21024	Patients	_
165-3	21025-21028	had	_
165-4	21029-21034	lower	_
165-5	21035-21039	mean	_
165-6	21040-21042	N1	_
165-7	21043-21053	amplitudes	_
165-8	21054-21060	across	_
165-9	21061-21071	conditions	_
165-10	21072-21073	(	_
165-11	21073-21077	main	_
165-12	21078-21084	effect	_
165-13	21085-21087	of	_
165-14	21088-21093	Group	_
165-15	21093-21094	,	_
165-16	21095-21100	F2,39	_
165-17	21100-21101	 	_
165-18	21101-21102	=	_
165-19	21102-21103	 	_
165-20	21103-21108	10.20	_
165-21	21108-21109	,	_
165-22	21110-21111	p	_
165-23	21111-21112	 	_
165-24	21112-21113	=	_
165-25	21113-21114	 	_
165-26	21114-21119	0.003	_
165-27	21119-21120	)	_
165-28	21120-21121	.	_

#Text=Furthermore, N1 s were larger for both successful and unsuccessful stops than gos (main effect of Condition, F1.45,56.70 = 56.44, p < 0.001), an effect that was larger in controls than patients (Group x Condition interaction, F1.45,56.70 = 3.88, p = 0.039, Greenhouse-Geisser correction for sphericity).
166-1	21122-21133	Furthermore	_
166-2	21133-21134	,	_
166-3	21135-21137	N1	_
166-4	21137-21138	 	_
166-5	21138-21139	s	_
166-6	21140-21144	were	_
166-7	21145-21151	larger	_
166-8	21152-21155	for	_
166-9	21156-21160	both	_
166-10	21161-21171	successful	_
166-11	21172-21175	and	_
166-12	21176-21188	unsuccessful	_
166-13	21189-21194	stops	_
166-14	21195-21199	than	_
166-15	21200-21203	gos	_
166-16	21204-21205	(	_
166-17	21205-21209	main	_
166-18	21210-21216	effect	_
166-19	21217-21219	of	_
166-20	21220-21229	Condition	_
166-21	21229-21230	,	_
166-22	21231-21242	F1.45,56.70	_
166-23	21242-21243	 	_
166-24	21243-21244	=	_
166-25	21244-21245	 	_
166-26	21245-21250	56.44	_
166-27	21250-21251	,	_
166-28	21252-21253	p	_
166-29	21253-21254	 	_
166-30	21254-21255	<	_
166-31	21255-21256	 	_
166-32	21256-21261	0.001	_
166-33	21261-21262	)	_
166-34	21262-21263	,	_
166-35	21264-21266	an	_
166-36	21267-21273	effect	_
166-37	21274-21278	that	_
166-38	21279-21282	was	_
166-39	21283-21289	larger	_
166-40	21290-21292	in	_
166-41	21293-21301	controls	_
166-42	21302-21306	than	_
166-43	21307-21315	patients	_
166-44	21316-21317	(	_
166-45	21317-21322	Group	_
166-46	21323-21324	x	_
166-47	21325-21334	Condition	_
166-48	21335-21346	interaction	_
166-49	21346-21347	,	_
166-50	21348-21359	F1.45,56.70	_
166-51	21359-21360	 	_
166-52	21360-21361	=	_
166-53	21361-21362	 	_
166-54	21362-21366	3.88	_
166-55	21366-21367	,	_
166-56	21368-21369	p	_
166-57	21369-21370	 	_
166-58	21370-21371	=	_
166-59	21371-21372	 	_
166-60	21372-21377	0.039	_
166-61	21377-21378	,	_
166-62	21379-21397	Greenhouse-Geisser	_
166-63	21398-21408	correction	_
166-64	21409-21412	for	_
166-65	21413-21423	sphericity	_
166-66	21423-21424	)	_
166-67	21424-21425	.	_

#Text=N1 s for gos and successful stops are shown in Fig. 1B/C.
167-1	21426-21428	N1	_
167-2	21428-21429	 	_
167-3	21429-21430	s	_
167-4	21431-21434	for	_
167-5	21435-21438	gos	_
167-6	21439-21442	and	_
167-7	21443-21453	successful	_
167-8	21454-21459	stops	_
167-9	21460-21463	are	_
167-10	21464-21469	shown	_
167-11	21470-21472	in	_
167-12	21473-21476	Fig	_
167-13	21476-21477	.	_
167-14	21478-21480	1B	_
167-15	21480-21481	/	_
167-16	21481-21482	C	_
167-17	21482-21483	.	_

#Text=Controlling for group, SSRTs positively correlated with N1 s for both successful (Fig. 1C, right) (partial r39 = 0.39, p = 0.01, raw r = 0.52, p < 0.001) and unsuccessful stops (partial r39 = 0.34, p < 0.03, raw r = 0.48, p = 0.001).
168-1	21484-21495	Controlling	_
168-2	21496-21499	for	_
168-3	21500-21505	group	_
168-4	21505-21506	,	_
168-5	21507-21512	SSRTs	_
168-6	21513-21523	positively	_
168-7	21524-21534	correlated	_
168-8	21535-21539	with	_
168-9	21540-21542	N1	_
168-10	21542-21543	 	_
168-11	21543-21544	s	_
168-12	21545-21548	for	_
168-13	21549-21553	both	_
168-14	21554-21564	successful	_
168-15	21565-21566	(	_
168-16	21566-21569	Fig	_
168-17	21569-21570	.	_
168-18	21571-21573	1C	_
168-19	21573-21574	,	_
168-20	21575-21580	right	_
168-21	21580-21581	)	_
168-22	21582-21583	(	_
168-23	21583-21590	partial	_
168-24	21591-21594	r39	_
168-25	21594-21595	 	_
168-26	21595-21596	=	_
168-27	21596-21597	 	_
168-28	21597-21601	0.39	_
168-29	21601-21602	,	_
168-30	21603-21604	p	_
168-31	21604-21605	 	_
168-32	21605-21606	=	_
168-33	21606-21607	 	_
168-34	21607-21611	0.01	_
168-35	21611-21612	,	_
168-36	21613-21616	raw	_
168-37	21617-21618	r	_
168-38	21618-21619	 	_
168-39	21619-21620	=	_
168-40	21620-21621	 	_
168-41	21621-21625	0.52	_
168-42	21625-21626	,	_
168-43	21627-21628	p	_
168-44	21628-21629	 	_
168-45	21629-21630	<	_
168-46	21630-21631	 	_
168-47	21631-21636	0.001	_
168-48	21636-21637	)	_
168-49	21638-21641	and	_
168-50	21642-21654	unsuccessful	_
168-51	21655-21660	stops	_
168-52	21661-21662	(	_
168-53	21662-21669	partial	_
168-54	21670-21673	r39	_
168-55	21673-21674	 	_
168-56	21674-21675	=	_
168-57	21675-21676	 	_
168-58	21676-21680	0.34	_
168-59	21680-21681	,	_
168-60	21682-21683	p	_
168-61	21683-21684	 	_
168-62	21684-21685	<	_
168-63	21685-21686	 	_
168-64	21686-21690	0.03	_
168-65	21690-21691	,	_
168-66	21692-21695	raw	_
168-67	21696-21697	r	_
168-68	21697-21698	 	_
168-69	21698-21699	=	_
168-70	21699-21700	 	_
168-71	21700-21704	0.48	_
168-72	21704-21705	,	_
168-73	21706-21707	p	_
168-74	21707-21708	 	_
168-75	21708-21709	=	_
168-76	21709-21710	 	_
168-77	21710-21715	0.001	_
168-78	21715-21716	)	_
168-79	21716-21717	.	_

#Text=N2
#Text=N2 peaks were only observed to unsuccessful stops (USTs) (Fig. 2C, left), and amplitudes were larger in controls than patients (t40 = 2.30, p = 0.027).
169-1	21718-21720	N2	_
169-2	21721-21723	N2	_
169-3	21724-21729	peaks	_
169-4	21730-21734	were	_
169-5	21735-21739	only	_
169-6	21740-21748	observed	_
169-7	21749-21751	to	_
169-8	21752-21764	unsuccessful	_
169-9	21765-21770	stops	_
169-10	21771-21772	(	_
169-11	21772-21776	USTs	_
169-12	21776-21777	)	_
169-13	21778-21779	(	_
169-14	21779-21782	Fig	_
169-15	21782-21783	.	_
169-16	21784-21786	2C	_
169-17	21786-21787	,	_
169-18	21788-21792	left	_
169-19	21792-21793	)	_
169-20	21793-21794	,	_
169-21	21795-21798	and	_
169-22	21799-21809	amplitudes	_
169-23	21810-21814	were	_
169-24	21815-21821	larger	_
169-25	21822-21824	in	_
169-26	21825-21833	controls	_
169-27	21834-21838	than	_
169-28	21839-21847	patients	_
169-29	21848-21849	(	_
169-30	21849-21852	t40	_
169-31	21852-21853	 	_
169-32	21853-21854	=	_
169-33	21854-21855	 	_
169-34	21855-21859	2.30	_
169-35	21859-21860	,	_
169-36	21861-21862	p	_
169-37	21862-21863	 	_
169-38	21863-21864	=	_
169-39	21864-21865	 	_
169-40	21865-21870	0.027	_
169-41	21870-21871	)	_
169-42	21871-21872	.	_

#Text=However, the amplitude did not correlate with SSRT or any of the other stop signal task measures.
170-1	21873-21880	However	_
170-2	21880-21881	,	_
170-3	21882-21885	the	_
170-4	21886-21895	amplitude	_
170-5	21896-21899	did	_
170-6	21900-21903	not	_
170-7	21904-21913	correlate	_
170-8	21914-21918	with	_
170-9	21919-21923	SSRT	_
170-10	21924-21926	or	_
170-11	21927-21930	any	_
170-12	21931-21933	of	_
170-13	21934-21937	the	_
170-14	21938-21943	other	_
170-15	21944-21948	stop	_
170-16	21949-21955	signal	_
170-17	21956-21960	task	_
170-18	21961-21969	measures	_
170-19	21969-21970	.	_

#Text=The N2 did not occurred approximately at the SSRT latency but after the presumed decision to respond given corticospinal transmission time (~20 ms).
171-1	21971-21974	The	_
171-2	21975-21977	N2	_
171-3	21978-21981	did	_
171-4	21982-21985	not	_
171-5	21986-21994	occurred	_
171-6	21995-22008	approximately	_
171-7	22009-22011	at	_
171-8	22012-22015	the	_
171-9	22016-22020	SSRT	_
171-10	22021-22028	latency	_
171-11	22029-22032	but	_
171-12	22033-22038	after	_
171-13	22039-22042	the	_
171-14	22043-22051	presumed	_
171-15	22052-22060	decision	_
171-16	22061-22063	to	_
171-17	22064-22071	respond	_
171-18	22072-22077	given	_
171-19	22078-22091	corticospinal	_
171-20	22092-22104	transmission	_
171-21	22105-22109	time	_
171-22	22110-22111	(	_
171-23	22111-22112	~	_
171-24	22112-22114	20	_
171-25	22114-22115	 	_
171-26	22115-22117	ms	_
171-27	22117-22118	)	_
171-28	22118-22119	.	_

#Text=We suggest that the N2 marks a transition in processes from stop preparation to detection of stop failure.
172-1	22120-22122	We	_
172-2	22123-22130	suggest	_
172-3	22131-22135	that	_
172-4	22136-22139	the	_
172-5	22140-22142	N2	_
172-6	22143-22148	marks	_
172-7	22149-22150	a	_
172-8	22151-22161	transition	_
172-9	22162-22164	in	_
172-10	22165-22174	processes	_
172-11	22175-22179	from	_
172-12	22180-22184	stop	_
172-13	22185-22196	preparation	_
172-14	22197-22199	to	_
172-15	22200-22209	detection	_
172-16	22210-22212	of	_
172-17	22213-22217	stop	_
172-18	22218-22225	failure	_
172-19	22225-22226	.	_

#Text=P3
#Text=There was a trend toward a significant main effect of Group (F2,40=3.83, p = 0.057) and a main effect of Condition (F1.38,54.99 = 39.74, p < 0.001) on P3, as well as a significant Group x Condition interaction (F1.38,54.99 = 19.90, p < 0.001).
173-1	22227-22229	P3	_
173-2	22230-22235	There	_
173-3	22236-22239	was	_
173-4	22240-22241	a	_
173-5	22242-22247	trend	_
173-6	22248-22254	toward	_
173-7	22255-22256	a	_
173-8	22257-22268	significant	_
173-9	22269-22273	main	_
173-10	22274-22280	effect	_
173-11	22281-22283	of	_
173-12	22284-22289	Group	_
173-13	22290-22291	(	_
173-14	22291-22296	F2,40	_
173-15	22296-22297	=	_
173-16	22297-22301	3.83	_
173-17	22301-22302	,	_
173-18	22303-22304	p	_
173-19	22304-22305	 	_
173-20	22305-22306	=	_
173-21	22306-22307	 	_
173-22	22307-22312	0.057	_
173-23	22312-22313	)	_
173-24	22314-22317	and	_
173-25	22318-22319	a	_
173-26	22320-22324	main	_
173-27	22325-22331	effect	_
173-28	22332-22334	of	_
173-29	22335-22344	Condition	_
173-30	22345-22346	(	_
173-31	22346-22357	F1.38,54.99	_
173-32	22357-22358	 	_
173-33	22358-22359	=	_
173-34	22359-22360	 	_
173-35	22360-22365	39.74	_
173-36	22365-22366	,	_
173-37	22367-22368	p	_
173-38	22368-22369	 	_
173-39	22369-22370	<	_
173-40	22370-22371	 	_
173-41	22371-22376	0.001	_
173-42	22376-22377	)	_
173-43	22378-22380	on	_
173-44	22381-22383	P3	_
173-45	22383-22384	,	_
173-46	22385-22387	as	_
173-47	22388-22392	well	_
173-48	22393-22395	as	_
173-49	22396-22397	a	_
173-50	22398-22409	significant	_
173-51	22410-22415	Group	_
173-52	22416-22417	x	_
173-53	22418-22427	Condition	_
173-54	22428-22439	interaction	_
173-55	22440-22441	(	_
173-56	22441-22452	F1.38,54.99	_
173-57	22452-22453	 	_
173-58	22453-22454	=	_
173-59	22454-22455	 	_
173-60	22455-22460	19.90	_
173-61	22460-22461	,	_
173-62	22462-22463	p	_
173-63	22463-22464	 	_
173-64	22464-22465	<	_
173-65	22465-22466	 	_
173-66	22466-22471	0.001	_
173-67	22471-22472	)	_
173-68	22472-22473	.	_

#Text=Patients had smaller P3s than controls on unsuccessful, and especially successful, stop trials.
174-1	22474-22482	Patients	_
174-2	22483-22486	had	_
174-3	22487-22494	smaller	_
174-4	22495-22498	P3s	_
174-5	22499-22503	than	_
174-6	22504-22512	controls	_
174-7	22513-22515	on	_
174-8	22516-22528	unsuccessful	_
174-9	22528-22529	,	_
174-10	22530-22533	and	_
174-11	22534-22544	especially	_
174-12	22545-22555	successful	_
174-13	22555-22556	,	_
174-14	22557-22561	stop	_
174-15	22562-22568	trials	_
174-16	22568-22569	.	_

#Text=Successful stop P3s are shown in Fig. 2C, middle.
175-1	22570-22580	Successful	_
175-2	22581-22585	stop	_
175-3	22586-22589	P3s	_
175-4	22590-22593	are	_
175-5	22594-22599	shown	_
175-6	22600-22602	in	_
175-7	22603-22606	Fig	_
175-8	22606-22607	.	_
175-9	22608-22610	2C	_
175-10	22610-22611	,	_
175-11	22612-22618	middle	_
175-12	22618-22619	.	_

#Text=P3 amplitudes were larger for successful than unsuccessful stops (patients: t20 = 4.84, p < 0.001, controls: t20 = 7.33, p < 0.001).
176-1	22620-22622	P3	_
176-2	22623-22633	amplitudes	_
176-3	22634-22638	were	_
176-4	22639-22645	larger	_
176-5	22646-22649	for	_
176-6	22650-22660	successful	_
176-7	22661-22665	than	_
176-8	22666-22678	unsuccessful	_
176-9	22679-22684	stops	_
176-10	22685-22686	(	_
176-11	22686-22694	patients	_
176-12	22694-22695	:	_
176-13	22696-22699	t20	_
176-14	22699-22700	 	_
176-15	22700-22701	=	_
176-16	22701-22702	 	_
176-17	22702-22706	4.84	_
176-18	22706-22707	,	_
176-19	22708-22709	p	_
176-20	22709-22710	 	_
176-21	22710-22711	<	_
176-22	22711-22712	 	_
176-23	22712-22717	0.001	_
176-24	22717-22718	,	_
176-25	22719-22727	controls	_
176-26	22727-22728	:	_
176-27	22729-22732	t20	_
176-28	22732-22733	 	_
176-29	22733-22734	=	_
176-30	22734-22735	 	_
176-31	22735-22739	7.33	_
176-32	22739-22740	,	_
176-33	22741-22742	p	_
176-34	22742-22743	 	_
176-35	22743-22744	<	_
176-36	22744-22745	 	_
176-37	22745-22750	0.001	_
176-38	22750-22751	)	_
176-39	22751-22752	.	_

#Text=Controlling for Group, SSRTs negatively correlated with P3 amplitude for successful stop trials (partial r39 = −0.41, p = 0.008, raw r40 = −0.54, p < 0.001, Fig. 2C, right).
177-1	22753-22764	Controlling	_
177-2	22765-22768	for	_
177-3	22769-22774	Group	_
177-4	22774-22775	,	_
177-5	22776-22781	SSRTs	_
177-6	22782-22792	negatively	_
177-7	22793-22803	correlated	_
177-8	22804-22808	with	_
177-9	22809-22811	P3	_
177-10	22812-22821	amplitude	_
177-11	22822-22825	for	_
177-12	22826-22836	successful	_
177-13	22837-22841	stop	_
177-14	22842-22848	trials	_
177-15	22849-22850	(	_
177-16	22850-22857	partial	_
177-17	22858-22861	r39	_
177-18	22861-22862	 	_
177-19	22862-22863	=	_
177-20	22863-22864	 	_
177-21	22864-22865	−	_
177-22	22865-22869	0.41	_
177-23	22869-22870	,	_
177-24	22871-22872	p	_
177-25	22872-22873	 	_
177-26	22873-22874	=	_
177-27	22874-22875	 	_
177-28	22875-22880	0.008	_
177-29	22880-22881	,	_
177-30	22882-22885	raw	_
177-31	22886-22889	r40	_
177-32	22889-22890	 	_
177-33	22890-22891	=	_
177-34	22891-22892	 	_
177-35	22892-22893	−	_
177-36	22893-22897	0.54	_
177-37	22897-22898	,	_
177-38	22899-22900	p	_
177-39	22900-22901	 	_
177-40	22901-22902	<	_
177-41	22902-22903	 	_
177-42	22903-22908	0.001	_
177-43	22908-22909	,	_
177-44	22910-22913	Fig	_
177-45	22913-22914	.	_
177-46	22915-22917	2C	_
177-47	22917-22918	,	_
177-48	22919-22924	right	_
177-49	22924-22925	)	_
177-50	22925-22926	.	_

#Text=P3 peak successful stop trial latencies were significantly longer than the SSRT (t41 = 6.07, p < 0.001).
178-1	22927-22929	P3	_
178-2	22930-22934	peak	_
178-3	22935-22945	successful	_
178-4	22946-22950	stop	_
178-5	22951-22956	trial	_
178-6	22957-22966	latencies	_
178-7	22967-22971	were	_
178-8	22972-22985	significantly	_
178-9	22986-22992	longer	_
178-10	22993-22997	than	_
178-11	22998-23001	the	_
178-12	23002-23006	SSRT	_
178-13	23007-23008	(	_
178-14	23008-23011	t41	_
178-15	23011-23012	 	_
178-16	23012-23013	=	_
178-17	23013-23014	 	_
178-18	23014-23018	6.07	_
178-19	23018-23019	,	_
178-20	23020-23021	p	_
178-21	23021-23022	 	_
178-22	23022-23023	<	_
178-23	23023-23024	 	_
178-24	23024-23029	0.001	_
178-25	23029-23030	)	_
178-26	23030-23031	.	_

#Text=The delay in P3 relative to the SSRT suggests that it reflects response monitoring, rather than pre-response evaluative processes.
179-1	23032-23035	The	_
179-2	23036-23041	delay	_
179-3	23042-23044	in	_
179-4	23045-23047	P3	_
179-5	23048-23056	relative	_
179-6	23057-23059	to	_
179-7	23060-23063	the	_
179-8	23064-23068	SSRT	_
179-9	23069-23077	suggests	_
179-10	23078-23082	that	_
179-11	23083-23085	it	_
179-12	23086-23094	reflects	_
179-13	23095-23103	response	_
179-14	23104-23114	monitoring	_
179-15	23114-23115	,	_
179-16	23116-23122	rather	_
179-17	23123-23127	than	_
179-18	23128-23140	pre-response	_
179-19	23141-23151	evaluative	_
179-20	23152-23161	processes	_
179-21	23161-23162	.	_

#Text=RSFC correlates
#Text=Relationships across behavioral, ERP, and RSFC levels
#Text=A) Left: Network maps and right: group differences in network homogeneity for networks from, Vis = visual (purple), Somat = Somatomotor (blue), DA = dorsal attention (green), VA = ventral attention (violet), Limbic (cream), FP = frontoparietal (orange), and DMN = default mode network (salmon), B) Group differences for network homogeneity for each network, C) Correlation between SSRT and Visual/FP networks, Inset: Visual (purple) and frontoparietal (orange) networks, D) Correlation between raw SSRT and Predicted SSRT, accounting for N1, and Visual/FP RSFC.
180-1	23163-23167	RSFC	_
180-2	23168-23178	correlates	_
180-3	23179-23192	Relationships	_
180-4	23193-23199	across	_
180-5	23200-23210	behavioral	_
180-6	23210-23211	,	_
180-7	23212-23215	ERP	_
180-8	23215-23216	,	_
180-9	23217-23220	and	_
180-10	23221-23225	RSFC	_
180-11	23226-23232	levels	_
180-12	23233-23234	A	_
180-13	23234-23235	)	_
180-14	23236-23240	Left	_
180-15	23240-23241	:	_
180-16	23242-23249	Network	_
180-17	23250-23254	maps	_
180-18	23255-23258	and	_
180-19	23259-23264	right	_
180-20	23264-23265	:	_
180-21	23266-23271	group	_
180-22	23272-23283	differences	_
180-23	23284-23286	in	_
180-24	23287-23294	network	_
180-25	23295-23306	homogeneity	_
180-26	23307-23310	for	_
180-27	23311-23319	networks	_
180-28	23320-23324	from	_
180-29	23324-23325	,	_
180-30	23326-23329	Vis	_
180-31	23329-23330	 	_
180-32	23330-23331	=	_
180-33	23331-23332	 	_
180-34	23332-23338	visual	_
180-35	23339-23340	(	_
180-36	23340-23346	purple	_
180-37	23346-23347	)	_
180-38	23347-23348	,	_
180-39	23349-23354	Somat	_
180-40	23354-23355	 	_
180-41	23355-23356	=	_
180-42	23356-23357	 	_
180-43	23357-23368	Somatomotor	_
180-44	23369-23370	(	_
180-45	23370-23374	blue	_
180-46	23374-23375	)	_
180-47	23375-23376	,	_
180-48	23377-23379	DA	_
180-49	23379-23380	 	_
180-50	23380-23381	=	_
180-51	23381-23382	 	_
180-52	23382-23388	dorsal	_
180-53	23389-23398	attention	_
180-54	23399-23400	(	_
180-55	23400-23405	green	_
180-56	23405-23406	)	_
180-57	23406-23407	,	_
180-58	23408-23410	VA	_
180-59	23410-23411	 	_
180-60	23411-23412	=	_
180-61	23412-23413	 	_
180-62	23413-23420	ventral	_
180-63	23421-23430	attention	_
180-64	23431-23432	(	_
180-65	23432-23438	violet	_
180-66	23438-23439	)	_
180-67	23439-23440	,	_
180-68	23441-23447	Limbic	_
180-69	23448-23449	(	_
180-70	23449-23454	cream	_
180-71	23454-23455	)	_
180-72	23455-23456	,	_
180-73	23457-23459	FP	_
180-74	23459-23460	 	_
180-75	23460-23461	=	_
180-76	23461-23462	 	_
180-77	23462-23476	frontoparietal	_
180-78	23477-23478	(	_
180-79	23478-23484	orange	_
180-80	23484-23485	)	_
180-81	23485-23486	,	_
180-82	23487-23490	and	_
180-83	23491-23494	DMN	_
180-84	23494-23495	 	_
180-85	23495-23496	=	_
180-86	23496-23497	 	_
180-87	23497-23504	default	_
180-88	23505-23509	mode	_
180-89	23510-23517	network	_
180-90	23518-23519	(	_
180-91	23519-23525	salmon	_
180-92	23525-23526	)	_
180-93	23526-23527	,	_
180-94	23528-23529	B	_
180-95	23529-23530	)	_
180-96	23531-23536	Group	_
180-97	23537-23548	differences	_
180-98	23549-23552	for	_
180-99	23553-23560	network	_
180-100	23561-23572	homogeneity	_
180-101	23573-23576	for	_
180-102	23577-23581	each	_
180-103	23582-23589	network	_
180-104	23589-23590	,	_
180-105	23591-23592	C	_
180-106	23592-23593	)	_
180-107	23594-23605	Correlation	_
180-108	23606-23613	between	_
180-109	23614-23618	SSRT	_
180-110	23619-23622	and	_
180-111	23623-23629	Visual	_
180-112	23629-23630	/	_
180-113	23630-23632	FP	_
180-114	23633-23641	networks	_
180-115	23641-23642	,	_
180-116	23643-23648	Inset	_
180-117	23648-23649	:	_
180-118	23650-23656	Visual	_
180-119	23657-23658	(	_
180-120	23658-23664	purple	_
180-121	23664-23665	)	_
180-122	23666-23669	and	_
180-123	23670-23684	frontoparietal	_
180-124	23685-23686	(	_
180-125	23686-23692	orange	_
180-126	23692-23693	)	_
180-127	23694-23702	networks	_
180-128	23702-23703	,	_
180-129	23704-23705	D	_
180-130	23705-23706	)	_
180-131	23707-23718	Correlation	_
180-132	23719-23726	between	_
180-133	23727-23730	raw	_
180-134	23731-23735	SSRT	_
180-135	23736-23739	and	_
180-136	23740-23749	Predicted	_
180-137	23750-23754	SSRT	_
180-138	23754-23755	,	_
180-139	23756-23766	accounting	_
180-140	23767-23770	for	_
180-141	23771-23773	N1	_
180-142	23773-23774	,	_
180-143	23775-23778	and	_
180-144	23779-23785	Visual	_
180-145	23785-23786	/	_
180-146	23786-23788	FP	_
180-147	23789-23793	RSFC	_
180-148	23793-23794	.	_

#Text=Fig. 3
#Text=The canonical Yeo et al. networks are shown in Fig. 3A.
181-1	23795-23798	Fig	_
181-2	23798-23799	.	_
181-3	23800-23801	3	_
181-4	23802-23805	The	_
181-5	23806-23815	canonical	_
181-6	23816-23819	Yeo	_
181-7	23820-23822	et	_
181-8	23823-23825	al	_
181-9	23825-23826	.	_
181-10	23827-23835	networks	_
181-11	23836-23839	are	_
181-12	23840-23845	shown	_
181-13	23846-23848	in	_
181-14	23849-23852	Fig	_
181-15	23852-23853	.	_
181-16	23854-23856	3A	_
181-17	23856-23857	.	_

#Text=Network interaction results (with GSR) are shown in Supplementary Table 2.
182-1	23858-23865	Network	_
182-2	23866-23877	interaction	_
182-3	23878-23885	results	_
182-4	23886-23887	(	_
182-5	23887-23891	with	_
182-6	23892-23895	GSR	_
182-7	23895-23896	)	_
182-8	23897-23900	are	_
182-9	23901-23906	shown	_
182-10	23907-23909	in	_
182-11	23910-23923	Supplementary	_
182-12	23924-23929	Table	_
182-13	23930-23931	2	_
182-14	23931-23932	.	_

#Text=We evaluated network interaction contribution to SSRT using multiple regression, with group and FD in a first step, all pairwise between-network RSFCs added in a second step using stepwise entry, and N1 added in a third step.
183-1	23933-23935	We	_
183-2	23936-23945	evaluated	_
183-3	23946-23953	network	_
183-4	23954-23965	interaction	_
183-5	23966-23978	contribution	_
183-6	23979-23981	to	_
183-7	23982-23986	SSRT	_
183-8	23987-23992	using	_
183-9	23993-24001	multiple	_
183-10	24002-24012	regression	_
183-11	24012-24013	,	_
183-12	24014-24018	with	_
183-13	24019-24024	group	_
183-14	24025-24028	and	_
183-15	24029-24031	FD	_
183-16	24032-24034	in	_
183-17	24035-24036	a	_
183-18	24037-24042	first	_
183-19	24043-24047	step	_
183-20	24047-24048	,	_
183-21	24049-24052	all	_
183-22	24053-24061	pairwise	_
183-23	24062-24077	between-network	_
183-24	24078-24083	RSFCs	_
183-25	24084-24089	added	_
183-26	24090-24092	in	_
183-27	24093-24094	a	_
183-28	24095-24101	second	_
183-29	24102-24106	step	_
183-30	24107-24112	using	_
183-31	24113-24121	stepwise	_
183-32	24122-24127	entry	_
183-33	24127-24128	,	_
183-34	24129-24132	and	_
183-35	24133-24135	N1	_
183-36	24136-24141	added	_
183-37	24142-24144	in	_
183-38	24145-24146	a	_
183-39	24147-24152	third	_
183-40	24153-24157	step	_
183-41	24157-24158	.	_

#Text=We chose the N1 component because it occurred prior to the SSRT and therefore may reflect the development of the inhibitory process rather than error processing.
184-1	24159-24161	We	_
184-2	24162-24167	chose	_
184-3	24168-24171	the	_
184-4	24172-24174	N1	_
184-5	24175-24184	component	_
184-6	24185-24192	because	_
184-7	24193-24195	it	_
184-8	24196-24204	occurred	_
184-9	24205-24210	prior	_
184-10	24211-24213	to	_
184-11	24214-24217	the	_
184-12	24218-24222	SSRT	_
184-13	24223-24226	and	_
184-14	24227-24236	therefore	_
184-15	24237-24240	may	_
184-16	24241-24248	reflect	_
184-17	24249-24252	the	_
184-18	24253-24264	development	_
184-19	24265-24267	of	_
184-20	24268-24271	the	_
184-21	24272-24282	inhibitory	_
184-22	24283-24290	process	_
184-23	24291-24297	rather	_
184-24	24298-24302	than	_
184-25	24303-24308	error	_
184-26	24309-24319	processing	_
184-27	24319-24320	.	_

#Text=Stepwise multiple regression model predicting SSRT from Group, N1 to successful stops, and canonical resting state network interactions.
185-1	24321-24329	Stepwise	_
185-2	24330-24338	multiple	_
185-3	24339-24349	regression	_
185-4	24350-24355	model	_
185-5	24356-24366	predicting	_
185-6	24367-24371	SSRT	_
185-7	24372-24376	from	_
185-8	24377-24382	Group	_
185-9	24382-24383	,	_
185-10	24384-24386	N1	_
185-11	24387-24389	to	_
185-12	24390-24400	successful	_
185-13	24401-24406	stops	_
185-14	24406-24407	,	_
185-15	24408-24411	and	_
185-16	24412-24421	canonical	_
185-17	24422-24429	resting	_
185-18	24430-24435	state	_
185-19	24436-24443	network	_
185-20	24444-24456	interactions	_
185-21	24456-24457	.	_

#Text=Table 3\t \t
#Text=Variable\tR2\tp\tR2change\tp\tt\tp\tPart r\t \tModel 1\t0.26\t0.016\t–\t\t\t\t\t \tGroup\t\t\t\t\t−2.97\t0.006\t−0.49\t \tModel 2\t0.40\t0.006\t0.13\t0.024\t\t\t\t \tGroup\t\t\t\t\t−1.79\t0.085\t−0.27\t \tN1 amplitude\t\t\t\t\t2.39\t0.024\t0.36\t \tModel 3\t0.41\t0.003\t0.14\t0.020\t\t\t\t \tGroup\t\t\t\t\t−2.79\t0.01\t−0.42\t \tVisual/Frontoparietal interaction\t\t\t\t\t2.49\t0.02\t0.38\t \tModel 4\t0.52\t0.001\t0.11\t0.024\t\t\t\t \tGroup\t\t\t\t\t−1.67\t0.11\t−0.23\t \tN1 amplitude\t\t\t\t\t2.41\t0.024\t0.33\t \tVisual/Frontoparietal interaction\t\t\t\t\t2.50\t0.019\t0.35\t \t
#Text=Note.
186-1	24458-24463	Table	_
186-2	24464-24465	3	_
186-3	24469-24477	Variable	_
186-4	24478-24480	R2	_
186-5	24481-24482	p	_
186-6	24483-24491	R2change	_
186-7	24492-24493	p	_
186-8	24494-24495	t	_
186-9	24496-24497	p	_
186-10	24498-24502	Part	_
186-11	24503-24504	r	_
186-12	24507-24512	Model	_
186-13	24513-24514	1	_
186-14	24515-24519	0.26	_
186-15	24520-24525	0.016	_
186-16	24526-24527	–	_
186-17	24534-24539	Group	_
186-18	24544-24545	−	_
186-19	24545-24549	2.97	_
186-20	24550-24555	0.006	_
186-21	24556-24557	−	_
186-22	24557-24561	0.49	_
186-23	24564-24569	Model	_
186-24	24570-24571	2	_
186-25	24572-24576	0.40	_
186-26	24577-24582	0.006	_
186-27	24583-24587	0.13	_
186-28	24588-24593	0.024	_
186-29	24599-24604	Group	_
186-30	24609-24610	−	_
186-31	24610-24614	1.79	_
186-32	24615-24620	0.085	_
186-33	24621-24622	−	_
186-34	24622-24626	0.27	_
186-35	24629-24631	N1	_
186-36	24632-24641	amplitude	_
186-37	24646-24650	2.39	_
186-38	24651-24656	0.024	_
186-39	24657-24661	0.36	_
186-40	24664-24669	Model	_
186-41	24670-24671	3	_
186-42	24672-24676	0.41	_
186-43	24677-24682	0.003	_
186-44	24683-24687	0.14	_
186-45	24688-24693	0.020	_
186-46	24699-24704	Group	_
186-47	24709-24710	−	_
186-48	24710-24714	2.79	_
186-49	24715-24719	0.01	_
186-50	24720-24721	−	_
186-51	24721-24725	0.42	_
186-52	24728-24734	Visual	_
186-53	24734-24735	/	_
186-54	24735-24749	Frontoparietal	_
186-55	24750-24761	interaction	_
186-56	24766-24770	2.49	_
186-57	24771-24775	0.02	_
186-58	24776-24780	0.38	_
186-59	24783-24788	Model	_
186-60	24789-24790	4	_
186-61	24791-24795	0.52	_
186-62	24796-24801	0.001	_
186-63	24802-24806	0.11	_
186-64	24807-24812	0.024	_
186-65	24818-24823	Group	_
186-66	24828-24829	−	_
186-67	24829-24833	1.67	_
186-68	24834-24838	0.11	_
186-69	24839-24840	−	_
186-70	24840-24844	0.23	_
186-71	24847-24849	N1	_
186-72	24850-24859	amplitude	_
186-73	24864-24868	2.41	_
186-74	24869-24874	0.024	_
186-75	24875-24879	0.33	_
186-76	24882-24888	Visual	_
186-77	24888-24889	/	_
186-78	24889-24903	Frontoparietal	_
186-79	24904-24915	interaction	_
186-80	24920-24924	2.50	_
186-81	24925-24930	0.019	_
186-82	24931-24935	0.35	_
186-83	24939-24943	Note	_
186-84	24943-24944	.	_

#Text=Analysis was conducted on 16 patients and 14 controls.
187-1	24945-24953	Analysis	_
187-2	24954-24957	was	_
187-3	24958-24967	conducted	_
187-4	24968-24970	on	_
187-5	24971-24973	16	_
187-6	24974-24982	patients	_
187-7	24983-24986	and	_
187-8	24987-24989	14	_
187-9	24990-24998	controls	_
187-10	24998-24999	.	_

#Text=In Models 2–4, pairwise functional connectivity of the visual with other networks was entered stepwise.
188-1	25000-25002	In	_
188-2	25003-25009	Models	_
188-3	25010-25011	2	_
188-4	25011-25012	–	_
188-5	25012-25013	4	_
188-6	25013-25014	,	_
188-7	25015-25023	pairwise	_
188-8	25024-25034	functional	_
188-9	25035-25047	connectivity	_
188-10	25048-25050	of	_
188-11	25051-25054	the	_
188-12	25055-25061	visual	_
188-13	25062-25066	with	_
188-14	25067-25072	other	_
188-15	25073-25081	networks	_
188-16	25082-25085	was	_
188-17	25086-25093	entered	_
188-18	25094-25102	stepwise	_
188-19	25102-25103	.	_

#Text=Statistically significant values are shown in bold.
189-1	25104-25117	Statistically	_
189-2	25118-25129	significant	_
189-3	25130-25136	values	_
189-4	25137-25140	are	_
189-5	25141-25146	shown	_
189-6	25147-25149	in	_
189-7	25150-25154	bold	_
189-8	25154-25155	.	_

#Text=R2change for Model 4 is relative to Model 3.
190-1	25156-25164	R2change	_
190-2	25165-25168	for	_
190-3	25169-25174	Model	_
190-4	25175-25176	4	_
190-5	25177-25179	is	_
190-6	25180-25188	relative	_
190-7	25189-25191	to	_
190-8	25192-25197	Model	_
190-9	25198-25199	3	_
190-10	25199-25200	.	_

#Text=Corresponding value relative to Model 2 is R2change = 0.12, p = 0.019.
191-1	25201-25214	Corresponding	_
191-2	25215-25220	value	_
191-3	25221-25229	relative	_
191-4	25230-25232	to	_
191-5	25233-25238	Model	_
191-6	25239-25240	2	_
191-7	25241-25243	is	_
191-8	25244-25252	R2change	_
191-9	25252-25253	 	_
191-10	25253-25254	=	_
191-11	25254-25255	 	_
191-12	25255-25259	0.12	_
191-13	25259-25260	,	_
191-14	25261-25262	p	_
191-15	25262-25263	 	_
191-16	25263-25264	=	_
191-17	25264-25265	 	_
191-18	25265-25270	0.019	_
191-19	25270-25271	.	_

#Text=FD (covariate) statistics were part r = −0.06, p = 0.74, for the Model 1, part r = −0.15, p = 0.34 for Model 2, part r = −0.12, p = 0.45 for Model 3, and part r = −0.20, p = 0.17 for Model 4.
192-1	25272-25274	FD	_
192-2	25275-25276	(	_
192-3	25276-25285	covariate	_
192-4	25285-25286	)	_
192-5	25287-25297	statistics	_
192-6	25298-25302	were	_
192-7	25303-25307	part	_
192-8	25308-25309	r	_
192-9	25309-25310	 	_
192-10	25310-25311	=	_
192-11	25311-25312	 	_
192-12	25312-25313	−	_
192-13	25313-25317	0.06	_
192-14	25317-25318	,	_
192-15	25319-25320	p	_
192-16	25320-25321	 	_
192-17	25321-25322	=	_
192-18	25322-25323	 	_
192-19	25323-25327	0.74	_
192-20	25327-25328	,	_
192-21	25329-25332	for	_
192-22	25333-25336	the	_
192-23	25337-25342	Model	_
192-24	25343-25344	1	_
192-25	25344-25345	,	_
192-26	25346-25350	part	_
192-27	25351-25352	r	_
192-28	25352-25353	 	_
192-29	25353-25354	=	_
192-30	25354-25355	 	_
192-31	25355-25356	−	_
192-32	25356-25360	0.15	_
192-33	25360-25361	,	_
192-34	25362-25363	p	_
192-35	25363-25364	 	_
192-36	25364-25365	=	_
192-37	25365-25366	 	_
192-38	25366-25370	0.34	_
192-39	25371-25374	for	_
192-40	25375-25380	Model	_
192-41	25381-25382	2	_
192-42	25382-25383	,	_
192-43	25384-25388	part	_
192-44	25389-25390	r	_
192-45	25390-25391	 	_
192-46	25391-25392	=	_
192-47	25392-25393	 	_
192-48	25393-25394	−	_
192-49	25394-25398	0.12	_
192-50	25398-25399	,	_
192-51	25400-25401	p	_
192-52	25401-25402	 	_
192-53	25402-25403	=	_
192-54	25403-25404	 	_
192-55	25404-25408	0.45	_
192-56	25409-25412	for	_
192-57	25413-25418	Model	_
192-58	25419-25420	3	_
192-59	25420-25421	,	_
192-60	25422-25425	and	_
192-61	25426-25430	part	_
192-62	25431-25432	r	_
192-63	25432-25433	 	_
192-64	25433-25434	=	_
192-65	25434-25435	 	_
192-66	25435-25436	−	_
192-67	25436-25440	0.20	_
192-68	25440-25441	,	_
192-69	25442-25443	p	_
192-70	25443-25444	 	_
192-71	25444-25445	=	_
192-72	25445-25446	 	_
192-73	25446-25450	0.17	_
192-74	25451-25454	for	_
192-75	25455-25460	Model	_
192-76	25461-25462	4	_
192-77	25462-25463	.	_

#Text=Results are shown in Table 3.
193-1	25464-25471	Results	_
193-2	25472-25475	are	_
193-3	25476-25481	shown	_
193-4	25482-25484	in	_
193-5	25485-25490	Table	_
193-6	25491-25492	3	_
193-7	25492-25493	.	_

#Text=In this analysis, patient status, larger N1 s, and more negative RSFC between visual and frontoparietal (FP) networks (see Fig. 3C and D) independently predicted shorter SSRT.
194-1	25494-25496	In	_
194-2	25497-25501	this	_
194-3	25502-25510	analysis	_
194-4	25510-25511	,	_
194-5	25512-25519	patient	_
194-6	25520-25526	status	_
194-7	25526-25527	,	_
194-8	25528-25534	larger	_
194-9	25535-25537	N1	_
194-10	25537-25538	 	_
194-11	25538-25539	s	_
194-12	25539-25540	,	_
194-13	25541-25544	and	_
194-14	25545-25549	more	_
194-15	25550-25558	negative	_
194-16	25559-25563	RSFC	_
194-17	25564-25571	between	_
194-18	25572-25578	visual	_
194-19	25579-25582	and	_
194-20	25583-25597	frontoparietal	_
194-21	25598-25599	(	_
194-22	25599-25601	FP	_
194-23	25601-25602	)	_
194-24	25603-25611	networks	_
194-25	25612-25613	(	_
194-26	25613-25616	see	_
194-27	25617-25620	Fig	_
194-28	25620-25621	.	_
194-29	25622-25624	3C	_
194-30	25625-25628	and	_
194-31	25629-25630	D	_
194-32	25630-25631	)	_
194-33	25632-25645	independently	_
194-34	25646-25655	predicted	_
194-35	25656-25663	shorter	_
194-36	25664-25668	SSRT	_
194-37	25668-25669	.	_

#Text=The other network pairs did not contribute to SSRT variance.
195-1	25670-25673	The	_
195-2	25674-25679	other	_
195-3	25680-25687	network	_
195-4	25688-25693	pairs	_
195-5	25694-25697	did	_
195-6	25698-25701	not	_
195-7	25702-25712	contribute	_
195-8	25713-25715	to	_
195-9	25716-25720	SSRT	_
195-10	25721-25729	variance	_
195-11	25729-25730	.	_

#Text=The combined model explained 52% of SSRT variance.
196-1	25731-25734	The	_
196-2	25735-25743	combined	_
196-3	25744-25749	model	_
196-4	25750-25759	explained	_
196-5	25760-25763	52%	_
196-6	25764-25766	of	_
196-7	25767-25771	SSRT	_
196-8	25772-25780	variance	_
196-9	25780-25781	.	_

#Text=As a control analysis, we evaluated the potential correlation of SSRT with other between-network connectivities (Supplementary Table 2).
197-1	25782-25784	As	_
197-2	25785-25786	a	_
197-3	25787-25794	control	_
197-4	25795-25803	analysis	_
197-5	25803-25804	,	_
197-6	25805-25807	we	_
197-7	25808-25817	evaluated	_
197-8	25818-25821	the	_
197-9	25822-25831	potential	_
197-10	25832-25843	correlation	_
197-11	25844-25846	of	_
197-12	25847-25851	SSRT	_
197-13	25852-25856	with	_
197-14	25857-25862	other	_
197-15	25863-25878	between-network	_
197-16	25879-25893	connectivities	_
197-17	25894-25895	(	_
197-18	25895-25908	Supplementary	_
197-19	25909-25914	Table	_
197-20	25915-25916	2	_
197-21	25916-25917	)	_
197-22	25917-25918	.	_

#Text=Moreover, although significant alterations in RSFC were observed in some network pairs (e.g. dorsal attention network/DMN), no significant correlations with behavior were found.
198-1	25919-25927	Moreover	_
198-2	25927-25928	,	_
198-3	25929-25937	although	_
198-4	25938-25949	significant	_
198-5	25950-25961	alterations	_
198-6	25962-25964	in	_
198-7	25965-25969	RSFC	_
198-8	25970-25974	were	_
198-9	25975-25983	observed	_
198-10	25984-25986	in	_
198-11	25987-25991	some	_
198-12	25992-25999	network	_
198-13	26000-26005	pairs	_
198-14	26006-26007	(	_
198-15	26007-26010	e.g	_
198-16	26010-26011	.	_
198-17	26012-26018	dorsal	_
198-18	26019-26028	attention	_
198-19	26029-26036	network	_
198-20	26036-26037	/	_
198-21	26037-26040	DMN	_
198-22	26040-26041	)	_
198-23	26041-26042	,	_
198-24	26043-26045	no	_
198-25	26046-26057	significant	_
198-26	26058-26070	correlations	_
198-27	26071-26075	with	_
198-28	26076-26084	behavior	_
198-29	26085-26089	were	_
198-30	26090-26095	found	_
198-31	26095-26096	.	_

#Text=It is possible that the regression model reflects an interation between sensory processing and resting state functional connectivity.
199-1	26097-26099	It	_
199-2	26100-26102	is	_
199-3	26103-26111	possible	_
199-4	26112-26116	that	_
199-5	26117-26120	the	_
199-6	26121-26131	regression	_
199-7	26132-26137	model	_
199-8	26138-26146	reflects	_
199-9	26147-26149	an	_
199-10	26150-26160	interation	_
199-11	26161-26168	between	_
199-12	26169-26176	sensory	_
199-13	26177-26187	processing	_
199-14	26188-26191	and	_
199-15	26192-26199	resting	_
199-16	26200-26205	state	_
199-17	26206-26216	functional	_
199-18	26217-26229	connectivity	_
199-19	26229-26230	.	_

#Text=We tested this by adding an interaction term to the regression as a 4th step in the regression.
200-1	26231-26233	We	_
200-2	26234-26240	tested	_
200-3	26241-26245	this	_
200-4	26246-26248	by	_
200-5	26249-26255	adding	_
200-6	26256-26258	an	_
200-7	26259-26270	interaction	_
200-8	26271-26275	term	_
200-9	26276-26278	to	_
200-10	26279-26282	the	_
200-11	26283-26293	regression	_
200-12	26294-26296	as	_
200-13	26297-26298	a	_
200-14	26299-26302	4th	_
200-15	26303-26307	step	_
200-16	26308-26310	in	_
200-17	26311-26314	the	_
200-18	26315-26325	regression	_
200-19	26325-26326	.	_

#Text=This interaction term failed to reach significance (t = 0.62, p = 0.54).
201-1	26327-26331	This	_
201-2	26332-26343	interaction	_
201-3	26344-26348	term	_
201-4	26349-26355	failed	_
201-5	26356-26358	to	_
201-6	26359-26364	reach	_
201-7	26365-26377	significance	_
201-8	26378-26379	(	_
201-9	26379-26380	t	_
201-10	26380-26381	 	_
201-11	26381-26382	=	_
201-12	26382-26383	 	_
201-13	26383-26387	0.62	_
201-14	26387-26388	,	_
201-15	26389-26390	p	_
201-16	26390-26391	 	_
201-17	26391-26392	=	_
201-18	26392-26393	 	_
201-19	26393-26397	0.54	_
201-20	26397-26398	)	_
201-21	26398-26399	.	_

#Text=Thus, it appears that sensory processing and between-network resting state functional connectivity independently contribute to SSRT performance.
202-1	26400-26404	Thus	_
202-2	26404-26405	,	_
202-3	26406-26408	it	_
202-4	26409-26416	appears	_
202-5	26417-26421	that	_
202-6	26422-26429	sensory	_
202-7	26430-26440	processing	_
202-8	26441-26444	and	_
202-9	26445-26460	between-network	_
202-10	26461-26468	resting	_
202-11	26469-26474	state	_
202-12	26475-26485	functional	_
202-13	26486-26498	connectivity	_
202-14	26499-26512	independently	_
202-15	26513-26523	contribute	_
202-16	26524-26526	to	_
202-17	26527-26531	SSRT	_
202-18	26532-26543	performance	_
202-19	26543-26544	.	_

#Text=Patients had significantly lower network homogeneity than controls (F7,21 = 4.24, p = 0.005, partial η2 = 0.59, d = 2.42).
203-1	26545-26553	Patients	_
203-2	26554-26557	had	_
203-3	26558-26571	significantly	_
203-4	26572-26577	lower	_
203-5	26578-26585	network	_
203-6	26586-26597	homogeneity	_
203-7	26598-26602	than	_
203-8	26603-26611	controls	_
203-9	26612-26613	(	_
203-10	26613-26618	F7,21	_
203-11	26618-26619	 	_
203-12	26619-26620	=	_
203-13	26620-26621	 	_
203-14	26621-26625	4.24	_
203-15	26625-26626	,	_
203-16	26627-26628	p	_
203-17	26628-26629	 	_
203-18	26629-26630	=	_
203-19	26630-26631	 	_
203-20	26631-26636	0.005	_
203-21	26636-26637	,	_
203-22	26638-26645	partial	_
203-23	26646-26648	η2	_
203-24	26648-26649	 	_
203-25	26649-26650	=	_
203-26	26650-26651	 	_
203-27	26651-26655	0.59	_
203-28	26655-26656	,	_
203-29	26657-26658	d	_
203-30	26658-26659	 	_
203-31	26659-26660	=	_
203-32	26660-26661	 	_
203-33	26661-26665	2.42	_
203-34	26665-26666	)	_
203-35	26666-26667	.	_

#Text=Whole-brain global brain connectivity also differed between groups (t28 = −5.06, p < 0.001), consistent with published results.
204-1	26668-26679	Whole-brain	_
204-2	26680-26686	global	_
204-3	26687-26692	brain	_
204-4	26693-26705	connectivity	_
204-5	26706-26710	also	_
204-6	26711-26719	differed	_
204-7	26720-26727	between	_
204-8	26728-26734	groups	_
204-9	26735-26736	(	_
204-10	26736-26739	t28	_
204-11	26739-26740	 	_
204-12	26740-26741	=	_
204-13	26741-26742	 	_
204-14	26742-26743	−	_
204-15	26743-26747	5.06	_
204-16	26747-26748	,	_
204-17	26749-26750	p	_
204-18	26750-26751	 	_
204-19	26751-26752	<	_
204-20	26752-26753	 	_
204-21	26753-26758	0.001	_
204-22	26758-26759	)	_
204-23	26759-26760	,	_
204-24	26761-26771	consistent	_
204-25	26772-26776	with	_
204-26	26777-26786	published	_
204-27	26787-26794	results	_
204-28	26794-26795	.	_

#Text=Each network showed significantly lower network homogeneity in patients than controls (F1,27 > 8.04, p < 0.009, 0.23 < partial η2 < 0.54, 1.09 < d < 2.17, Fig. 3B).
205-1	26796-26800	Each	_
205-2	26801-26808	network	_
205-3	26809-26815	showed	_
205-4	26816-26829	significantly	_
205-5	26830-26835	lower	_
205-6	26836-26843	network	_
205-7	26844-26855	homogeneity	_
205-8	26856-26858	in	_
205-9	26859-26867	patients	_
205-10	26868-26872	than	_
205-11	26873-26881	controls	_
205-12	26882-26883	(	_
205-13	26883-26888	F1,27	_
205-14	26888-26889	 	_
205-15	26889-26890	>	_
205-16	26890-26891	 	_
205-17	26891-26895	8.04	_
205-18	26895-26896	,	_
205-19	26897-26898	p	_
205-20	26898-26899	 	_
205-21	26899-26900	<	_
205-22	26900-26901	 	_
205-23	26901-26906	0.009	_
205-24	26906-26907	,	_
205-25	26908-26912	0.23	_
205-26	26912-26913	 	_
205-27	26913-26914	<	_
205-28	26914-26915	 	_
205-29	26915-26922	partial	_
205-30	26923-26925	η2	_
205-31	26925-26926	 	_
205-32	26926-26927	<	_
205-33	26927-26928	 	_
205-34	26928-26932	0.54	_
205-35	26932-26933	,	_
205-36	26934-26938	1.09	_
205-37	26938-26939	 	_
205-38	26939-26940	<	_
205-39	26940-26941	 	_
205-40	26941-26942	d	_
205-41	26942-26943	 	_
205-42	26943-26944	<	_
205-43	26944-26945	 	_
205-44	26945-26949	2.17	_
205-45	26949-26950	,	_
205-46	26951-26954	Fig	_
205-47	26954-26955	.	_
205-48	26956-26958	3B	_
205-49	26958-26959	)	_
205-50	26959-26960	.	_

#Text=Controlling for group, GBC did not correlate with SSRT, N1, N2, nor with P3 amplitudes for successful stops.
206-1	26961-26972	Controlling	_
206-2	26973-26976	for	_
206-3	26977-26982	group	_
206-4	26982-26983	,	_
206-5	26984-26987	GBC	_
206-6	26988-26991	did	_
206-7	26992-26995	not	_
206-8	26996-27005	correlate	_
206-9	27006-27010	with	_
206-10	27011-27015	SSRT	_
206-11	27015-27016	,	_
206-12	27017-27019	N1	_
206-13	27019-27020	,	_
206-14	27021-27023	N2	_
206-15	27023-27024	,	_
206-16	27025-27028	nor	_
206-17	27029-27033	with	_
206-18	27034-27036	P3	_
206-19	27037-27047	amplitudes	_
206-20	27048-27051	for	_
206-21	27052-27062	successful	_
206-22	27063-27068	stops	_
206-23	27068-27069	.	_

#Text=Across groups, N1 amplitudes correlated negatively with network homogeneity for the somatomotor, dorsal attention, and ventral attention networks (rs < −0.39, ps < 0.033), but these correlations were not significant within group or controlling for group.
207-1	27070-27076	Across	_
207-2	27077-27083	groups	_
207-3	27083-27084	,	_
207-4	27085-27087	N1	_
207-5	27088-27098	amplitudes	_
207-6	27099-27109	correlated	_
207-7	27110-27120	negatively	_
207-8	27121-27125	with	_
207-9	27126-27133	network	_
207-10	27134-27145	homogeneity	_
207-11	27146-27149	for	_
207-12	27150-27153	the	_
207-13	27154-27165	somatomotor	_
207-14	27165-27166	,	_
207-15	27167-27173	dorsal	_
207-16	27174-27183	attention	_
207-17	27183-27184	,	_
207-18	27185-27188	and	_
207-19	27189-27196	ventral	_
207-20	27197-27206	attention	_
207-21	27207-27215	networks	_
207-22	27216-27217	(	_
207-23	27217-27219	rs	_
207-24	27219-27220	 	_
207-25	27220-27221	<	_
207-26	27221-27222	 	_
207-27	27222-27223	−	_
207-28	27223-27227	0.39	_
207-29	27227-27228	,	_
207-30	27229-27231	ps	_
207-31	27231-27232	 	_
207-32	27232-27233	<	_
207-33	27233-27234	 	_
207-34	27234-27239	0.033	_
207-35	27239-27240	)	_
207-36	27240-27241	,	_
207-37	27242-27245	but	_
207-38	27246-27251	these	_
207-39	27252-27264	correlations	_
207-40	27265-27269	were	_
207-41	27270-27273	not	_
207-42	27274-27285	significant	_
207-43	27286-27292	within	_
207-44	27293-27298	group	_
207-45	27299-27301	or	_
207-46	27302-27313	controlling	_
207-47	27314-27317	for	_
207-48	27318-27323	group	_
207-49	27323-27324	.	_

#Text=Similarly, SSRT correlated negatively with network homogeneity for visual, somatomotor, dorsal attention, ventral attention, and default mode networks (r < −0.40, p < 0.027), but again, these correlations were not significant within group or controlling for group.
208-1	27325-27334	Similarly	_
208-2	27334-27335	,	_
208-3	27336-27340	SSRT	_
208-4	27341-27351	correlated	_
208-5	27352-27362	negatively	_
208-6	27363-27367	with	_
208-7	27368-27375	network	_
208-8	27376-27387	homogeneity	_
208-9	27388-27391	for	_
208-10	27392-27398	visual	_
208-11	27398-27399	,	_
208-12	27400-27411	somatomotor	_
208-13	27411-27412	,	_
208-14	27413-27419	dorsal	_
208-15	27420-27429	attention	_
208-16	27429-27430	,	_
208-17	27431-27438	ventral	_
208-18	27439-27448	attention	_
208-19	27448-27449	,	_
208-20	27450-27453	and	_
208-21	27454-27461	default	_
208-22	27462-27466	mode	_
208-23	27467-27475	networks	_
208-24	27476-27477	(	_
208-25	27477-27478	r	_
208-26	27478-27479	 	_
208-27	27479-27480	<	_
208-28	27480-27481	 	_
208-29	27481-27482	−	_
208-30	27482-27486	0.40	_
208-31	27486-27487	,	_
208-32	27488-27489	p	_
208-33	27489-27490	 	_
208-34	27490-27491	<	_
208-35	27491-27492	 	_
208-36	27492-27497	0.027	_
208-37	27497-27498	)	_
208-38	27498-27499	,	_
208-39	27500-27503	but	_
208-40	27504-27509	again	_
208-41	27509-27510	,	_
208-42	27511-27516	these	_
208-43	27517-27529	correlations	_
208-44	27530-27534	were	_
208-45	27535-27538	not	_
208-46	27539-27550	significant	_
208-47	27551-27557	within	_
208-48	27558-27563	group	_
208-49	27564-27566	or	_
208-50	27567-27578	controlling	_
208-51	27579-27582	for	_
208-52	27583-27588	group	_
208-53	27588-27589	.	_

#Text=When global signal was not used as a covariate in RSFC preprocessing, the results of this regression were not significant for any of the RSFCs suggesting that relative, rather than absolute, connectivity was critical.
209-1	27590-27594	When	_
209-2	27595-27601	global	_
209-3	27602-27608	signal	_
209-4	27609-27612	was	_
209-5	27613-27616	not	_
209-6	27617-27621	used	_
209-7	27622-27624	as	_
209-8	27625-27626	a	_
209-9	27627-27636	covariate	_
209-10	27637-27639	in	_
209-11	27640-27644	RSFC	_
209-12	27645-27658	preprocessing	_
209-13	27658-27659	,	_
209-14	27660-27663	the	_
209-15	27664-27671	results	_
209-16	27672-27674	of	_
209-17	27675-27679	this	_
209-18	27680-27690	regression	_
209-19	27691-27695	were	_
209-20	27696-27699	not	_
209-21	27700-27711	significant	_
209-22	27712-27715	for	_
209-23	27716-27719	any	_
209-24	27720-27722	of	_
209-25	27723-27726	the	_
209-26	27727-27732	RSFCs	_
209-27	27733-27743	suggesting	_
209-28	27744-27748	that	_
209-29	27749-27757	relative	_
209-30	27757-27758	,	_
209-31	27759-27765	rather	_
209-32	27766-27770	than	_
209-33	27771-27779	absolute	_
209-34	27779-27780	,	_
209-35	27781-27793	connectivity	_
209-36	27794-27797	was	_
209-37	27798-27806	critical	_
209-38	27806-27807	.	_

#Text=Cross domain correlations
#Text=Visual/FP RSFC correlated negatively with P3 amplitude (partial r27 = −0.45, p = 0.015), and Visual/FP RSFC correlated positively with SSRT (partial r27 = 0.46, p = 0.013).
210-1	27808-27813	Cross	_
210-2	27814-27820	domain	_
210-3	27821-27833	correlations	_
210-4	27834-27840	Visual	_
210-5	27840-27841	/	_
210-6	27841-27843	FP	_
210-7	27844-27848	RSFC	_
210-8	27849-27859	correlated	_
210-9	27860-27870	negatively	_
210-10	27871-27875	with	_
210-11	27876-27878	P3	_
210-12	27879-27888	amplitude	_
210-13	27889-27890	(	_
210-14	27890-27897	partial	_
210-15	27898-27901	r27	_
210-16	27901-27902	 	_
210-17	27902-27903	=	_
210-18	27903-27904	 	_
210-19	27904-27905	−	_
210-20	27905-27909	0.45	_
210-21	27909-27910	,	_
210-22	27911-27912	p	_
210-23	27912-27913	 	_
210-24	27913-27914	=	_
210-25	27914-27915	 	_
210-26	27915-27920	0.015	_
210-27	27920-27921	)	_
210-28	27921-27922	,	_
210-29	27923-27926	and	_
210-30	27927-27933	Visual	_
210-31	27933-27934	/	_
210-32	27934-27936	FP	_
210-33	27937-27941	RSFC	_
210-34	27942-27952	correlated	_
210-35	27953-27963	positively	_
210-36	27964-27968	with	_
210-37	27969-27973	SSRT	_
210-38	27974-27975	(	_
210-39	27975-27982	partial	_
210-40	27983-27986	r27	_
210-41	27986-27987	 	_
210-42	27987-27988	=	_
210-43	27988-27989	 	_
210-44	27989-27993	0.46	_
210-45	27993-27994	,	_
210-46	27995-27996	p	_
210-47	27996-27997	 	_
210-48	27997-27998	=	_
210-49	27998-27999	 	_
210-50	27999-28004	0.013	_
210-51	28004-28005	)	_
210-52	28005-28006	.	_

#Text=As opposed to the significant correlations between both SSRT and P3 and Visual/FP RSFC networks, no significant correlations were observed between these measures and RSFC between visual and other brain networks (|partial r27| < 0.30, ps > 0.11).
211-1	28007-28009	As	_
211-2	28010-28017	opposed	_
211-3	28018-28020	to	_
211-4	28021-28024	the	_
211-5	28025-28036	significant	_
211-6	28037-28049	correlations	_
211-7	28050-28057	between	_
211-8	28058-28062	both	_
211-9	28063-28067	SSRT	_
211-10	28068-28071	and	_
211-11	28072-28074	P3	_
211-12	28075-28078	and	_
211-13	28079-28085	Visual	_
211-14	28085-28086	/	_
211-15	28086-28088	FP	_
211-16	28089-28093	RSFC	_
211-17	28094-28102	networks	_
211-18	28102-28103	,	_
211-19	28104-28106	no	_
211-20	28107-28118	significant	_
211-21	28119-28131	correlations	_
211-22	28132-28136	were	_
211-23	28137-28145	observed	_
211-24	28146-28153	between	_
211-25	28154-28159	these	_
211-26	28160-28168	measures	_
211-27	28169-28172	and	_
211-28	28173-28177	RSFC	_
211-29	28178-28185	between	_
211-30	28186-28192	visual	_
211-31	28193-28196	and	_
211-32	28197-28202	other	_
211-33	28203-28208	brain	_
211-34	28209-28217	networks	_
211-35	28218-28219	(	_
211-36	28219-28220	|	_
211-37	28220-28227	partial	_
211-38	28228-28231	r27	_
211-39	28231-28232	|	_
211-40	28232-28233	 	_
211-41	28233-28234	<	_
211-42	28234-28235	 	_
211-43	28235-28239	0.30	_
211-44	28239-28240	,	_
211-45	28241-28243	ps	_
211-46	28243-28244	 	_
211-47	28244-28245	>	_
211-48	28245-28246	 	_
211-49	28246-28250	0.11	_
211-50	28250-28251	)	_
211-51	28251-28252	.	_

#Text=Thus, poorer performance, and reduced P3 amplitude were correlated with greater interaction between visual and FP networks.
212-1	28253-28257	Thus	_
212-2	28257-28258	,	_
212-3	28259-28265	poorer	_
212-4	28266-28277	performance	_
212-5	28277-28278	,	_
212-6	28279-28282	and	_
212-7	28283-28290	reduced	_
212-8	28291-28293	P3	_
212-9	28294-28303	amplitude	_
212-10	28304-28308	were	_
212-11	28309-28319	correlated	_
212-12	28320-28324	with	_
212-13	28325-28332	greater	_
212-14	28333-28344	interaction	_
212-15	28345-28352	between	_
212-16	28353-28359	visual	_
212-17	28360-28363	and	_
212-18	28364-28366	FP	_
212-19	28367-28375	networks	_
212-20	28375-28376	.	_

#Text=Medication and psychopathology correlates
#Text=Medication effects
#Text=No correlations between chlorpromazine equivalent medication doses and ERP stop amplitudes were significant (|r19| < 0.43, p > 0.05).
213-1	28377-28387	Medication	_
213-2	28388-28391	and	_
213-3	28392-28407	psychopathology	_
213-4	28408-28418	correlates	_
213-5	28419-28429	Medication	_
213-6	28430-28437	effects	_
213-7	28438-28440	No	_
213-8	28441-28453	correlations	_
213-9	28454-28461	between	_
213-10	28462-28476	chlorpromazine	_
213-11	28477-28487	equivalent	_
213-12	28488-28498	medication	_
213-13	28499-28504	doses	_
213-14	28505-28508	and	_
213-15	28509-28512	ERP	_
213-16	28513-28517	stop	_
213-17	28518-28528	amplitudes	_
213-18	28529-28533	were	_
213-19	28534-28545	significant	_
213-20	28546-28547	(	_
213-21	28547-28548	|	_
213-22	28548-28551	r19	_
213-23	28551-28552	|	_
213-24	28552-28553	 	_
213-25	28553-28554	<	_
213-26	28554-28555	 	_
213-27	28555-28559	0.43	_
213-28	28559-28560	,	_
213-29	28561-28562	p	_
213-30	28562-28563	 	_
213-31	28563-28564	>	_
213-32	28564-28565	 	_
213-33	28565-28569	0.05	_
213-34	28569-28570	)	_
213-35	28570-28571	.	_

#Text=Psychopathology symptoms
#Text=Positive PANSS factor scores correlated with SSRT (r19 = 0.47, p = 0.031), and with N1 amplitudes to successful go and successful and unsuccessful stop trials (r19 > 0.44, ps < 0.044).
214-1	28572-28587	Psychopathology	_
214-2	28588-28596	symptoms	_
214-3	28597-28605	Positive	_
214-4	28606-28611	PANSS	_
214-5	28612-28618	factor	_
214-6	28619-28625	scores	_
214-7	28626-28636	correlated	_
214-8	28637-28641	with	_
214-9	28642-28646	SSRT	_
214-10	28647-28648	(	_
214-11	28648-28651	r19	_
214-12	28651-28652	 	_
214-13	28652-28653	=	_
214-14	28653-28654	 	_
214-15	28654-28658	0.47	_
214-16	28658-28659	,	_
214-17	28660-28661	p	_
214-18	28661-28662	 	_
214-19	28662-28663	=	_
214-20	28663-28664	 	_
214-21	28664-28669	0.031	_
214-22	28669-28670	)	_
214-23	28670-28671	,	_
214-24	28672-28675	and	_
214-25	28676-28680	with	_
214-26	28681-28683	N1	_
214-27	28684-28694	amplitudes	_
214-28	28695-28697	to	_
214-29	28698-28708	successful	_
214-30	28709-28711	go	_
214-31	28712-28715	and	_
214-32	28716-28726	successful	_
214-33	28727-28730	and	_
214-34	28731-28743	unsuccessful	_
214-35	28744-28748	stop	_
214-36	28749-28755	trials	_
214-37	28756-28757	(	_
214-38	28757-28760	r19	_
214-39	28760-28761	 	_
214-40	28761-28762	>	_
214-41	28762-28763	 	_
214-42	28763-28767	0.44	_
214-43	28767-28768	,	_
214-44	28769-28771	ps	_
214-45	28771-28772	 	_
214-46	28772-28773	<	_
214-47	28773-28774	 	_
214-48	28774-28779	0.044	_
214-49	28779-28780	)	_
214-50	28780-28781	.	_

#Text=PANSS Cognitive factor scores correlated negatively with go accuracy (r19 = −0.69, p = 0.001) and P3 go amplitude (r19 = −0.50, p = 0.02).
215-1	28782-28787	PANSS	_
215-2	28788-28797	Cognitive	_
215-3	28798-28804	factor	_
215-4	28805-28811	scores	_
215-5	28812-28822	correlated	_
215-6	28823-28833	negatively	_
215-7	28834-28838	with	_
215-8	28839-28841	go	_
215-9	28842-28850	accuracy	_
215-10	28851-28852	(	_
215-11	28852-28855	r19	_
215-12	28855-28856	 	_
215-13	28856-28857	=	_
215-14	28857-28858	 	_
215-15	28858-28859	−	_
215-16	28859-28863	0.69	_
215-17	28863-28864	,	_
215-18	28865-28866	p	_
215-19	28866-28867	 	_
215-20	28867-28868	=	_
215-21	28868-28869	 	_
215-22	28869-28874	0.001	_
215-23	28874-28875	)	_
215-24	28876-28879	and	_
215-25	28880-28882	P3	_
215-26	28883-28885	go	_
215-27	28886-28895	amplitude	_
215-28	28896-28897	(	_
215-29	28897-28900	r19	_
215-30	28900-28901	 	_
215-31	28901-28902	=	_
215-32	28902-28903	 	_
215-33	28903-28904	−	_
215-34	28904-28908	0.50	_
215-35	28908-28909	,	_
215-36	28910-28911	p	_
215-37	28911-28912	 	_
215-38	28912-28913	=	_
215-39	28913-28914	 	_
215-40	28914-28918	0.02	_
215-41	28918-28919	)	_
215-42	28919-28920	.	_

#Text=Neuropsychological correlates
#Text=Patients performed more poorly than controls on all tests, as expected (data not shown).
216-1	28921-28939	Neuropsychological	_
216-2	28940-28950	correlates	_
216-3	28951-28959	Patients	_
216-4	28960-28969	performed	_
216-5	28970-28974	more	_
216-6	28975-28981	poorly	_
216-7	28982-28986	than	_
216-8	28987-28995	controls	_
216-9	28996-28998	on	_
216-10	28999-29002	all	_
216-11	29003-29008	tests	_
216-12	29008-29009	,	_
216-13	29010-29012	as	_
216-14	29013-29021	expected	_
216-15	29022-29023	(	_
216-16	29023-29027	data	_
216-17	29028-29031	not	_
216-18	29032-29037	shown	_
216-19	29037-29038	)	_
216-20	29038-29039	.	_

#Text=However, controlling for group, there were no signficiant correlations between SSRT and neuropsychological performance.
217-1	29040-29047	However	_
217-2	29047-29048	,	_
217-3	29049-29060	controlling	_
217-4	29061-29064	for	_
217-5	29065-29070	group	_
217-6	29070-29071	,	_
217-7	29072-29077	there	_
217-8	29078-29082	were	_
217-9	29083-29085	no	_
217-10	29086-29097	signficiant	_
217-11	29098-29110	correlations	_
217-12	29111-29118	between	_
217-13	29119-29123	SSRT	_
217-14	29124-29127	and	_
217-15	29128-29146	neuropsychological	_
217-16	29147-29158	performance	_
217-17	29158-29159	.	_

#Text=N1 amplitude correlated with the working memory index from both the WMS-III and the MATRICS (see Supplementary Table 3).
218-1	29160-29162	N1	_
218-2	29163-29172	amplitude	_
218-3	29173-29183	correlated	_
218-4	29184-29188	with	_
218-5	29189-29192	the	_
218-6	29193-29200	working	_
218-7	29201-29207	memory	_
218-8	29208-29213	index	_
218-9	29214-29218	from	_
218-10	29219-29223	both	_
218-11	29224-29227	the	_
218-12	29228-29235	WMS-III	_
218-13	29236-29239	and	_
218-14	29240-29243	the	_
218-15	29244-29251	MATRICS	_
218-16	29252-29253	(	_
218-17	29253-29256	see	_
218-18	29257-29270	Supplementary	_
218-19	29271-29276	Table	_
218-20	29277-29278	3	_
218-21	29278-29279	)	_
218-22	29279-29280	.	_

#Text=Discussion
#Text=This study evaluated network alterations revealed by RSFC that could underlie response inhibition impairment in Sz, and is the first of its kind to do so in combination with ERP methods.
219-1	29281-29291	Discussion	_
219-2	29292-29296	This	_
219-3	29297-29302	study	_
219-4	29303-29312	evaluated	_
219-5	29313-29320	network	_
219-6	29321-29332	alterations	_
219-7	29333-29341	revealed	_
219-8	29342-29344	by	_
219-9	29345-29349	RSFC	_
219-10	29350-29354	that	_
219-11	29355-29360	could	_
219-12	29361-29369	underlie	_
219-13	29370-29378	response	_
219-14	29379-29389	inhibition	_
219-15	29390-29400	impairment	_
219-16	29401-29403	in	_
219-17	29404-29406	Sz	_
219-18	29406-29407	,	_
219-19	29408-29411	and	_
219-20	29412-29414	is	_
219-21	29415-29418	the	_
219-22	29419-29424	first	_
219-23	29425-29427	of	_
219-24	29428-29431	its	_
219-25	29432-29436	kind	_
219-26	29437-29439	to	_
219-27	29440-29442	do	_
219-28	29443-29445	so	_
219-29	29446-29448	in	_
219-30	29449-29460	combination	_
219-31	29461-29465	with	_
219-32	29466-29469	ERP	_
219-33	29470-29477	methods	_
219-34	29477-29478	.	_

#Text=In addition to confirming the deficit, two specific predictors of impaired performance were identified: 1) visual N1, which reflects stimulus-driven activation of visual sensory cortex, and 2) reduced strength of functional connectivity between visual and frontoparietal networks.
220-1	29479-29481	In	_
220-2	29482-29490	addition	_
220-3	29491-29493	to	_
220-4	29494-29504	confirming	_
220-5	29505-29508	the	_
220-6	29509-29516	deficit	_
220-7	29516-29517	,	_
220-8	29518-29521	two	_
220-9	29522-29530	specific	_
220-10	29531-29541	predictors	_
220-11	29542-29544	of	_
220-12	29545-29553	impaired	_
220-13	29554-29565	performance	_
220-14	29566-29570	were	_
220-15	29571-29581	identified	_
220-16	29581-29582	:	_
220-17	29583-29584	1	_
220-18	29584-29585	)	_
220-19	29586-29592	visual	_
220-20	29593-29595	N1	_
220-21	29595-29596	,	_
220-22	29597-29602	which	_
220-23	29603-29611	reflects	_
220-24	29612-29627	stimulus-driven	_
220-25	29628-29638	activation	_
220-26	29639-29641	of	_
220-27	29642-29648	visual	_
220-28	29649-29656	sensory	_
220-29	29657-29663	cortex	_
220-30	29663-29664	,	_
220-31	29665-29668	and	_
220-32	29669-29670	2	_
220-33	29670-29671	)	_
220-34	29672-29679	reduced	_
220-35	29680-29688	strength	_
220-36	29689-29691	of	_
220-37	29692-29702	functional	_
220-38	29703-29715	connectivity	_
220-39	29716-29723	between	_
220-40	29724-29730	visual	_
220-41	29731-29734	and	_
220-42	29735-29749	frontoparietal	_
220-43	29750-29758	networks	_
220-44	29758-29759	.	_

#Text=By contrast, although reduced network homogeneity was seen in patients across networks, it did not correlate significantly with performance.
221-1	29760-29762	By	_
221-2	29763-29771	contrast	_
221-3	29771-29772	,	_
221-4	29773-29781	although	_
221-5	29782-29789	reduced	_
221-6	29790-29797	network	_
221-7	29798-29809	homogeneity	_
221-8	29810-29813	was	_
221-9	29814-29818	seen	_
221-10	29819-29821	in	_
221-11	29822-29830	patients	_
221-12	29831-29837	across	_
221-13	29838-29846	networks	_
221-14	29846-29847	,	_
221-15	29848-29850	it	_
221-16	29851-29854	did	_
221-17	29855-29858	not	_
221-18	29859-29868	correlate	_
221-19	29869-29882	significantly	_
221-20	29883-29887	with	_
221-21	29888-29899	performance	_
221-22	29899-29900	.	_

#Text=In addition to providing evidence for potential mechanisms that could underlie cognitive control impairments in Sz, this study demonstrates the utility of combining neurophysiological measures, which are especially sensitive to cortical “input” dysfunction in Sz, with RSFC, which provided additional information about impaired cortico-cortical interaction.
222-1	29901-29903	In	_
222-2	29904-29912	addition	_
222-3	29913-29915	to	_
222-4	29916-29925	providing	_
222-5	29926-29934	evidence	_
222-6	29935-29938	for	_
222-7	29939-29948	potential	_
222-8	29949-29959	mechanisms	_
222-9	29960-29964	that	_
222-10	29965-29970	could	_
222-11	29971-29979	underlie	_
222-12	29980-29989	cognitive	_
222-13	29990-29997	control	_
222-14	29998-30009	impairments	_
222-15	30010-30012	in	_
222-16	30013-30015	Sz	_
222-17	30015-30016	,	_
222-18	30017-30021	this	_
222-19	30022-30027	study	_
222-20	30028-30040	demonstrates	_
222-21	30041-30044	the	_
222-22	30045-30052	utility	_
222-23	30053-30055	of	_
222-24	30056-30065	combining	_
222-25	30066-30084	neurophysiological	_
222-26	30085-30093	measures	_
222-27	30093-30094	,	_
222-28	30095-30100	which	_
222-29	30101-30104	are	_
222-30	30105-30115	especially	_
222-31	30116-30125	sensitive	_
222-32	30126-30128	to	_
222-33	30129-30137	cortical	_
222-34	30138-30139	“	_
222-35	30139-30144	input	_
222-36	30144-30145	”	_
222-37	30146-30157	dysfunction	_
222-38	30158-30160	in	_
222-39	30161-30163	Sz	_
222-40	30163-30164	,	_
222-41	30165-30169	with	_
222-42	30170-30174	RSFC	_
222-43	30174-30175	,	_
222-44	30176-30181	which	_
222-45	30182-30190	provided	_
222-46	30191-30201	additional	_
222-47	30202-30213	information	_
222-48	30214-30219	about	_
222-49	30220-30228	impaired	_
222-50	30229-30245	cortico-cortical	_
222-51	30246-30257	interaction	_
222-52	30257-30258	.	_

#Text=In the present study, as in prior studies (reviewed in), patients showed highly significant deficits in visual N1 generation.
223-1	30259-30261	In	_
223-2	30262-30265	the	_
223-3	30266-30273	present	_
223-4	30274-30279	study	_
223-5	30279-30280	,	_
223-6	30281-30283	as	_
223-7	30284-30286	in	_
223-8	30287-30292	prior	_
223-9	30293-30300	studies	_
223-10	30301-30302	(	_
223-11	30302-30310	reviewed	_
223-12	30311-30313	in	_
223-13	30313-30314	)	_
223-14	30314-30315	,	_
223-15	30316-30324	patients	_
223-16	30325-30331	showed	_
223-17	30332-30338	highly	_
223-18	30339-30350	significant	_
223-19	30351-30359	deficits	_
223-20	30360-30362	in	_
223-21	30363-30369	visual	_
223-22	30370-30372	N1	_
223-23	30373-30383	generation	_
223-24	30383-30384	.	_

#Text=When simple stimuli such as sine-wave gratings are used to elicit sensory components in Sz, deficits are observed preferentially to low contrast, low spatial frequency stimuli, suggesting differential involvement of the magnocellular visual system, which projects primarily to the dorsal visual stream.
224-1	30385-30389	When	_
224-2	30390-30396	simple	_
224-3	30397-30404	stimuli	_
224-4	30405-30409	such	_
224-5	30410-30412	as	_
224-6	30413-30422	sine-wave	_
224-7	30423-30431	gratings	_
224-8	30432-30435	are	_
224-9	30436-30440	used	_
224-10	30441-30443	to	_
224-11	30444-30450	elicit	_
224-12	30451-30458	sensory	_
224-13	30459-30469	components	_
224-14	30470-30472	in	_
224-15	30473-30475	Sz	_
224-16	30475-30476	,	_
224-17	30477-30485	deficits	_
224-18	30486-30489	are	_
224-19	30490-30498	observed	_
224-20	30499-30513	preferentially	_
224-21	30514-30516	to	_
224-22	30517-30520	low	_
224-23	30521-30529	contrast	_
224-24	30529-30530	,	_
224-25	30531-30534	low	_
224-26	30535-30542	spatial	_
224-27	30543-30552	frequency	_
224-28	30553-30560	stimuli	_
224-29	30560-30561	,	_
224-30	30562-30572	suggesting	_
224-31	30573-30585	differential	_
224-32	30586-30597	involvement	_
224-33	30598-30600	of	_
224-34	30601-30604	the	_
224-35	30605-30618	magnocellular	_
224-36	30619-30625	visual	_
224-37	30626-30632	system	_
224-38	30632-30633	,	_
224-39	30634-30639	which	_
224-40	30640-30648	projects	_
224-41	30649-30658	primarily	_
224-42	30659-30661	to	_
224-43	30662-30665	the	_
224-44	30666-30672	dorsal	_
224-45	30673-30679	visual	_
224-46	30680-30686	stream	_
224-47	30686-30687	.	_

#Text=The stimuli in the present study consisted of letters, which contain both low and high spatial frequency information.
225-1	30688-30691	The	_
225-2	30692-30699	stimuli	_
225-3	30700-30702	in	_
225-4	30703-30706	the	_
225-5	30707-30714	present	_
225-6	30715-30720	study	_
225-7	30721-30730	consisted	_
225-8	30731-30733	of	_
225-9	30734-30741	letters	_
225-10	30741-30742	,	_
225-11	30743-30748	which	_
225-12	30749-30756	contain	_
225-13	30757-30761	both	_
225-14	30762-30765	low	_
225-15	30766-30769	and	_
225-16	30770-30774	high	_
225-17	30775-30782	spatial	_
225-18	30783-30792	frequency	_
225-19	30793-30804	information	_
225-20	30804-30805	.	_

#Text=Nevertheless, significant engagement of the magnocellular pathway is shown by the activation of extracalcarine visual regions in both ERP topographies.
226-1	30806-30818	Nevertheless	_
226-2	30818-30819	,	_
226-3	30820-30831	significant	_
226-4	30832-30842	engagement	_
226-5	30843-30845	of	_
226-6	30846-30849	the	_
226-7	30850-30863	magnocellular	_
226-8	30864-30871	pathway	_
226-9	30872-30874	is	_
226-10	30875-30880	shown	_
226-11	30881-30883	by	_
226-12	30884-30887	the	_
226-13	30888-30898	activation	_
226-14	30899-30901	of	_
226-15	30902-30916	extracalcarine	_
226-16	30917-30923	visual	_
226-17	30924-30931	regions	_
226-18	30932-30934	in	_
226-19	30935-30939	both	_
226-20	30940-30943	ERP	_
226-21	30944-30956	topographies	_
226-22	30956-30957	.	_

#Text=Consistent with the importance of activation of dorsal visual areas, numerically smaller (i.e., less negative) N1 potentials correlated significantly with prolonged SSRT both across groups and within patients alone (Fig. 1C).
227-1	30958-30968	Consistent	_
227-2	30969-30973	with	_
227-3	30974-30977	the	_
227-4	30978-30988	importance	_
227-5	30989-30991	of	_
227-6	30992-31002	activation	_
227-7	31003-31005	of	_
227-8	31006-31012	dorsal	_
227-9	31013-31019	visual	_
227-10	31020-31025	areas	_
227-11	31025-31026	,	_
227-12	31027-31038	numerically	_
227-13	31039-31046	smaller	_
227-14	31047-31048	(	_
227-15	31048-31051	i.e	_
227-16	31051-31052	.	_
227-17	31052-31053	,	_
227-18	31054-31058	less	_
227-19	31059-31067	negative	_
227-20	31067-31068	)	_
227-21	31069-31071	N1	_
227-22	31072-31082	potentials	_
227-23	31083-31093	correlated	_
227-24	31094-31107	significantly	_
227-25	31108-31112	with	_
227-26	31113-31122	prolonged	_
227-27	31123-31127	SSRT	_
227-28	31128-31132	both	_
227-29	31133-31139	across	_
227-30	31140-31146	groups	_
227-31	31147-31150	and	_
227-32	31151-31157	within	_
227-33	31158-31166	patients	_
227-34	31167-31172	alone	_
227-35	31173-31174	(	_
227-36	31174-31177	Fig	_
227-37	31177-31178	.	_
227-38	31179-31181	1C	_
227-39	31181-31182	)	_
227-40	31182-31183	.	_

#Text=The dorsal visual stream is preferentially involved in “vision for action” as opposed to “vision for identification” and thus may play a critical role in processing information in tasks wherein simple stimulus features are used to determine rapid, stimulus-driven responses.
228-1	31184-31187	The	_
228-2	31188-31194	dorsal	_
228-3	31195-31201	visual	_
228-4	31202-31208	stream	_
228-5	31209-31211	is	_
228-6	31212-31226	preferentially	_
228-7	31227-31235	involved	_
228-8	31236-31238	in	_
228-9	31239-31240	“	_
228-10	31240-31246	vision	_
228-11	31247-31250	for	_
228-12	31251-31257	action	_
228-13	31257-31258	”	_
228-14	31259-31261	as	_
228-15	31262-31269	opposed	_
228-16	31270-31272	to	_
228-17	31273-31274	“	_
228-18	31274-31280	vision	_
228-19	31281-31284	for	_
228-20	31285-31299	identification	_
228-21	31299-31300	”	_
228-22	31301-31304	and	_
228-23	31305-31309	thus	_
228-24	31310-31313	may	_
228-25	31314-31318	play	_
228-26	31319-31320	a	_
228-27	31321-31329	critical	_
228-28	31330-31334	role	_
228-29	31335-31337	in	_
228-30	31338-31348	processing	_
228-31	31349-31360	information	_
228-32	31361-31363	in	_
228-33	31364-31369	tasks	_
228-34	31370-31377	wherein	_
228-35	31378-31384	simple	_
228-36	31385-31393	stimulus	_
228-37	31394-31402	features	_
228-38	31403-31406	are	_
228-39	31407-31411	used	_
228-40	31412-31414	to	_
228-41	31415-31424	determine	_
228-42	31425-31430	rapid	_
228-43	31430-31431	,	_
228-44	31432-31447	stimulus-driven	_
228-45	31448-31457	responses	_
228-46	31457-31458	.	_

#Text=In addition to sensory contributions, interaction between the visual and frontoparietal networks significantly predicted SSRT performance.
229-1	31459-31461	In	_
229-2	31462-31470	addition	_
229-3	31471-31473	to	_
229-4	31474-31481	sensory	_
229-5	31482-31495	contributions	_
229-6	31495-31496	,	_
229-7	31497-31508	interaction	_
229-8	31509-31516	between	_
229-9	31517-31520	the	_
229-10	31521-31527	visual	_
229-11	31528-31531	and	_
229-12	31532-31546	frontoparietal	_
229-13	31547-31555	networks	_
229-14	31556-31569	significantly	_
229-15	31570-31579	predicted	_
229-16	31580-31584	SSRT	_
229-17	31585-31596	performance	_
229-18	31596-31597	.	_

#Text=Interestingly, RSFC was negative, suggesting that the networks were operating in an anticorrelated manner (i.e., potentially out of phase).
230-1	31598-31611	Interestingly	_
230-2	31611-31612	,	_
230-3	31613-31617	RSFC	_
230-4	31618-31621	was	_
230-5	31622-31630	negative	_
230-6	31630-31631	,	_
230-7	31632-31642	suggesting	_
230-8	31643-31647	that	_
230-9	31648-31651	the	_
230-10	31652-31660	networks	_
230-11	31661-31665	were	_
230-12	31666-31675	operating	_
230-13	31676-31678	in	_
230-14	31679-31681	an	_
230-15	31682-31696	anticorrelated	_
230-16	31697-31703	manner	_
230-17	31704-31705	(	_
230-18	31705-31708	i.e	_
230-19	31708-31709	.	_
230-20	31709-31710	,	_
230-21	31711-31722	potentially	_
230-22	31723-31726	out	_
230-23	31727-31729	of	_
230-24	31730-31735	phase	_
230-25	31735-31736	)	_
230-26	31736-31737	.	_

#Text=Furthermore, greater negative connectivity correlated with better performance.
231-1	31738-31749	Furthermore	_
231-2	31749-31750	,	_
231-3	31751-31758	greater	_
231-4	31759-31767	negative	_
231-5	31768-31780	connectivity	_
231-6	31781-31791	correlated	_
231-7	31792-31796	with	_
231-8	31797-31803	better	_
231-9	31804-31815	performance	_
231-10	31815-31816	.	_

#Text=The importance of the N1 in explaining group differences in performance is highlighted in the multiple regression analysis, where Group was not significant when both N1 and Visual/FP RSFC is included in the model (Table 3).
232-1	31817-31820	The	_
232-2	31821-31831	importance	_
232-3	31832-31834	of	_
232-4	31835-31838	the	_
232-5	31839-31841	N1	_
232-6	31842-31844	in	_
232-7	31845-31855	explaining	_
232-8	31856-31861	group	_
232-9	31862-31873	differences	_
232-10	31874-31876	in	_
232-11	31877-31888	performance	_
232-12	31889-31891	is	_
232-13	31892-31903	highlighted	_
232-14	31904-31906	in	_
232-15	31907-31910	the	_
232-16	31911-31919	multiple	_
232-17	31920-31930	regression	_
232-18	31931-31939	analysis	_
232-19	31939-31940	,	_
232-20	31941-31946	where	_
232-21	31947-31952	Group	_
232-22	31953-31956	was	_
232-23	31957-31960	not	_
232-24	31961-31972	significant	_
232-25	31973-31977	when	_
232-26	31978-31982	both	_
232-27	31983-31985	N1	_
232-28	31986-31989	and	_
232-29	31990-31996	Visual	_
232-30	31996-31997	/	_
232-31	31997-31999	FP	_
232-32	32000-32004	RSFC	_
232-33	32005-32007	is	_
232-34	32008-32016	included	_
232-35	32017-32019	in	_
232-36	32020-32023	the	_
232-37	32024-32029	model	_
232-38	32030-32031	(	_
232-39	32031-32036	Table	_
232-40	32037-32038	3	_
232-41	32038-32039	)	_
232-42	32039-32040	.	_

#Text=When predicted SSRT values were calculated simply based on the N1 and Visual/FP RSFC measures, a highly significant correlation was observed across the groups (Fig. 3D).
233-1	32041-32045	When	_
233-2	32046-32055	predicted	_
233-3	32056-32060	SSRT	_
233-4	32061-32067	values	_
233-5	32068-32072	were	_
233-6	32073-32083	calculated	_
233-7	32084-32090	simply	_
233-8	32091-32096	based	_
233-9	32097-32099	on	_
233-10	32100-32103	the	_
233-11	32104-32106	N1	_
233-12	32107-32110	and	_
233-13	32111-32117	Visual	_
233-14	32117-32118	/	_
233-15	32118-32120	FP	_
233-16	32121-32125	RSFC	_
233-17	32126-32134	measures	_
233-18	32134-32135	,	_
233-19	32136-32137	a	_
233-20	32138-32144	highly	_
233-21	32145-32156	significant	_
233-22	32157-32168	correlation	_
233-23	32169-32172	was	_
233-24	32173-32181	observed	_
233-25	32182-32188	across	_
233-26	32189-32192	the	_
233-27	32193-32199	groups	_
233-28	32200-32201	(	_
233-29	32201-32204	Fig	_
233-30	32204-32205	.	_
233-31	32206-32208	3D	_
233-32	32208-32209	)	_
233-33	32209-32210	.	_

#Text=Thus, both impaired sensory processing and RSFC may contribute in parallel to cognitive dysfunction in schizophrenia, and parallel neurophysiological and fMRI analyses may be required to best assess these interactions.
234-1	32211-32215	Thus	_
234-2	32215-32216	,	_
234-3	32217-32221	both	_
234-4	32222-32230	impaired	_
234-5	32231-32238	sensory	_
234-6	32239-32249	processing	_
234-7	32250-32253	and	_
234-8	32254-32258	RSFC	_
234-9	32259-32262	may	_
234-10	32263-32273	contribute	_
234-11	32274-32276	in	_
234-12	32277-32285	parallel	_
234-13	32286-32288	to	_
234-14	32289-32298	cognitive	_
234-15	32299-32310	dysfunction	_
234-16	32311-32313	in	_
234-17	32314-32327	schizophrenia	_
234-18	32327-32328	,	_
234-19	32329-32332	and	_
234-20	32333-32341	parallel	_
234-21	32342-32360	neurophysiological	_
234-22	32361-32364	and	_
234-23	32365-32369	fMRI	_
234-24	32370-32378	analyses	_
234-25	32379-32382	may	_
234-26	32383-32385	be	_
234-27	32386-32394	required	_
234-28	32395-32397	to	_
234-29	32398-32402	best	_
234-30	32403-32409	assess	_
234-31	32410-32415	these	_
234-32	32416-32428	interactions	_
234-33	32428-32429	.	_

#Text=This independence is supported by the failure to detect a signficiant N1 X Visual/FP RSFC interaction.
235-1	32430-32434	This	_
235-2	32435-32447	independence	_
235-3	32448-32450	is	_
235-4	32451-32460	supported	_
235-5	32461-32463	by	_
235-6	32464-32467	the	_
235-7	32468-32475	failure	_
235-8	32476-32478	to	_
235-9	32479-32485	detect	_
235-10	32486-32487	a	_
235-11	32488-32499	signficiant	_
235-12	32500-32502	N1	_
235-13	32503-32504	X	_
235-14	32505-32511	Visual	_
235-15	32511-32512	/	_
235-16	32512-32514	FP	_
235-17	32515-32519	RSFC	_
235-18	32520-32531	interaction	_
235-19	32531-32532	.	_

#Text=Our electrophysiological data suggest that patients have deficits on response inhibition tasks during both sensory registration and post-decision/monitoring stages.
236-1	32533-32536	Our	_
236-2	32537-32557	electrophysiological	_
236-3	32558-32562	data	_
236-4	32563-32570	suggest	_
236-5	32571-32575	that	_
236-6	32576-32584	patients	_
236-7	32585-32589	have	_
236-8	32590-32598	deficits	_
236-9	32599-32601	on	_
236-10	32602-32610	response	_
236-11	32611-32621	inhibition	_
236-12	32622-32627	tasks	_
236-13	32628-32634	during	_
236-14	32635-32639	both	_
236-15	32640-32647	sensory	_
236-16	32648-32660	registration	_
236-17	32661-32664	and	_
236-18	32665-32678	post-decision	_
236-19	32678-32679	/	_
236-20	32679-32689	monitoring	_
236-21	32690-32696	stages	_
236-22	32696-32697	.	_

#Text=N1 deficits during successful and unsuccessful stop trials suggest impairment in Sz at early stages of sensory processing.
237-1	32698-32700	N1	_
237-2	32701-32709	deficits	_
237-3	32710-32716	during	_
237-4	32717-32727	successful	_
237-5	32728-32731	and	_
237-6	32732-32744	unsuccessful	_
237-7	32745-32749	stop	_
237-8	32750-32756	trials	_
237-9	32757-32764	suggest	_
237-10	32765-32775	impairment	_
237-11	32776-32778	in	_
237-12	32779-32781	Sz	_
237-13	32782-32784	at	_
237-14	32785-32790	early	_
237-15	32791-32797	stages	_
237-16	32798-32800	of	_
237-17	32801-32808	sensory	_
237-18	32809-32819	processing	_
237-19	32819-32820	.	_

#Text=These findings are consistent with a large literature suggesting that sensory deficits in Sz contribute to poor cognitive function (;;) and, as suggested by the current data, to response inhibition deficits.
238-1	32821-32826	These	_
238-2	32827-32835	findings	_
238-3	32836-32839	are	_
238-4	32840-32850	consistent	_
238-5	32851-32855	with	_
238-6	32856-32857	a	_
238-7	32858-32863	large	_
238-8	32864-32874	literature	_
238-9	32875-32885	suggesting	_
238-10	32886-32890	that	_
238-11	32891-32898	sensory	_
238-12	32899-32907	deficits	_
238-13	32908-32910	in	_
238-14	32911-32913	Sz	_
238-15	32914-32924	contribute	_
238-16	32925-32927	to	_
238-17	32928-32932	poor	_
238-18	32933-32942	cognitive	_
238-19	32943-32951	function	_
238-20	32952-32953	(	_
238-21	32953-32954	;	_
238-22	32954-32955	;	_
238-23	32955-32956	)	_
238-24	32957-32960	and	_
238-25	32960-32961	,	_
238-26	32962-32964	as	_
238-27	32965-32974	suggested	_
238-28	32975-32977	by	_
238-29	32978-32981	the	_
238-30	32982-32989	current	_
238-31	32990-32994	data	_
238-32	32994-32995	,	_
238-33	32996-32998	to	_
238-34	32999-33007	response	_
238-35	33008-33018	inhibition	_
238-36	33019-33027	deficits	_
238-37	33027-33028	.	_

#Text=The reduced N2 to unsuccessful stops and reduced P3 to successful stops in patients may reflect reduced response monitoring.
239-1	33029-33032	The	_
239-2	33033-33040	reduced	_
239-3	33041-33043	N2	_
239-4	33044-33046	to	_
239-5	33047-33059	unsuccessful	_
239-6	33060-33065	stops	_
239-7	33066-33069	and	_
239-8	33070-33077	reduced	_
239-9	33078-33080	P3	_
239-10	33081-33083	to	_
239-11	33084-33094	successful	_
239-12	33095-33100	stops	_
239-13	33101-33103	in	_
239-14	33104-33112	patients	_
239-15	33113-33116	may	_
239-16	33117-33124	reflect	_
239-17	33125-33132	reduced	_
239-18	33133-33141	response	_
239-19	33142-33152	monitoring	_
239-20	33152-33153	.	_

#Text=The frontoparietal network has been posited to reflect active, adaptive online cognitive control.
240-1	33154-33157	The	_
240-2	33158-33172	frontoparietal	_
240-3	33173-33180	network	_
240-4	33181-33184	has	_
240-5	33185-33189	been	_
240-6	33190-33197	posited	_
240-7	33198-33200	to	_
240-8	33201-33208	reflect	_
240-9	33209-33215	active	_
240-10	33215-33216	,	_
240-11	33217-33225	adaptive	_
240-12	33226-33232	online	_
240-13	33233-33242	cognitive	_
240-14	33243-33250	control	_
240-15	33250-33251	.	_

#Text=Its relationship to task performance is consistent with prior fMRI studies of the stop task (;;).
241-1	33252-33255	Its	_
241-2	33256-33268	relationship	_
241-3	33269-33271	to	_
241-4	33272-33276	task	_
241-5	33277-33288	performance	_
241-6	33289-33291	is	_
241-7	33292-33302	consistent	_
241-8	33303-33307	with	_
241-9	33308-33313	prior	_
241-10	33314-33318	fMRI	_
241-11	33319-33326	studies	_
241-12	33327-33329	of	_
241-13	33330-33333	the	_
241-14	33334-33338	stop	_
241-15	33339-33343	task	_
241-16	33344-33345	(	_
241-17	33345-33346	;	_
241-18	33346-33347	;	_
241-19	33347-33348	)	_
241-20	33348-33349	.	_

#Text=Here, we evaluated two aspects of frontoparietal connectivity potentially related to impaired response inhibition in schizophrenia: within-network connectivity (network homogeneity), and between-network connectivity.
242-1	33350-33354	Here	_
242-2	33354-33355	,	_
242-3	33356-33358	we	_
242-4	33359-33368	evaluated	_
242-5	33369-33372	two	_
242-6	33373-33380	aspects	_
242-7	33381-33383	of	_
242-8	33384-33398	frontoparietal	_
242-9	33399-33411	connectivity	_
242-10	33412-33423	potentially	_
242-11	33424-33431	related	_
242-12	33432-33434	to	_
242-13	33435-33443	impaired	_
242-14	33444-33452	response	_
242-15	33453-33463	inhibition	_
242-16	33464-33466	in	_
242-17	33467-33480	schizophrenia	_
242-18	33480-33481	:	_
242-19	33482-33496	within-network	_
242-20	33497-33509	connectivity	_
242-21	33510-33511	(	_
242-22	33511-33518	network	_
242-23	33519-33530	homogeneity	_
242-24	33530-33531	)	_
242-25	33531-33532	,	_
242-26	33533-33536	and	_
242-27	33537-33552	between-network	_
242-28	33553-33565	connectivity	_
242-29	33565-33566	.	_

#Text=Interestingly, only the between-network connectivity findings were related to task performance.
243-1	33567-33580	Interestingly	_
243-2	33580-33581	,	_
243-3	33582-33586	only	_
243-4	33587-33590	the	_
243-5	33591-33606	between-network	_
243-6	33607-33619	connectivity	_
243-7	33620-33628	findings	_
243-8	33629-33633	were	_
243-9	33634-33641	related	_
243-10	33642-33644	to	_
243-11	33645-33649	task	_
243-12	33650-33661	performance	_
243-13	33661-33662	.	_

#Text=MRI scans were done in no temporal relationship to the ERP which in some ways makes the pattern of results even more impressive.
244-1	33663-33666	MRI	_
244-2	33667-33672	scans	_
244-3	33673-33677	were	_
244-4	33678-33682	done	_
244-5	33683-33685	in	_
244-6	33686-33688	no	_
244-7	33689-33697	temporal	_
244-8	33698-33710	relationship	_
244-9	33711-33713	to	_
244-10	33714-33717	the	_
244-11	33718-33721	ERP	_
244-12	33722-33727	which	_
244-13	33728-33730	in	_
244-14	33731-33735	some	_
244-15	33736-33740	ways	_
244-16	33741-33746	makes	_
244-17	33747-33750	the	_
244-18	33751-33758	pattern	_
244-19	33759-33761	of	_
244-20	33762-33769	results	_
244-21	33770-33774	even	_
244-22	33775-33779	more	_
244-23	33780-33790	impressive	_
244-24	33790-33791	.	_

#Text=We note that resting state functional connectivity patterns have shown moderate to good long-term stability.
245-1	33792-33794	We	_
245-2	33795-33799	note	_
245-3	33800-33804	that	_
245-4	33805-33812	resting	_
245-5	33813-33818	state	_
245-6	33819-33829	functional	_
245-7	33830-33842	connectivity	_
245-8	33843-33851	patterns	_
245-9	33852-33856	have	_
245-10	33857-33862	shown	_
245-11	33863-33871	moderate	_
245-12	33872-33874	to	_
245-13	33875-33879	good	_
245-14	33880-33889	long-term	_
245-15	33890-33899	stability	_
245-16	33899-33900	.	_

#Text=Our results thus complement those of, who showed that although frontoparietal and cingulo-opercular network homogeneity correlated with neuropsychological performance across schizophrenia and control groups, they did not explain group differences in performance.
246-1	33901-33904	Our	_
246-2	33905-33912	results	_
246-3	33913-33917	thus	_
246-4	33918-33928	complement	_
246-5	33929-33934	those	_
246-6	33935-33937	of	_
246-7	33937-33938	,	_
246-8	33939-33942	who	_
246-9	33943-33949	showed	_
246-10	33950-33954	that	_
246-11	33955-33963	although	_
246-12	33964-33978	frontoparietal	_
246-13	33979-33982	and	_
246-14	33983-34000	cingulo-opercular	_
246-15	34001-34008	network	_
246-16	34009-34020	homogeneity	_
246-17	34021-34031	correlated	_
246-18	34032-34036	with	_
246-19	34037-34055	neuropsychological	_
246-20	34056-34067	performance	_
246-21	34068-34074	across	_
246-22	34075-34088	schizophrenia	_
246-23	34089-34092	and	_
246-24	34093-34100	control	_
246-25	34101-34107	groups	_
246-26	34107-34108	,	_
246-27	34109-34113	they	_
246-28	34114-34117	did	_
246-29	34118-34121	not	_
246-30	34122-34129	explain	_
246-31	34130-34135	group	_
246-32	34136-34147	differences	_
246-33	34148-34150	in	_
246-34	34151-34162	performance	_
246-35	34162-34163	.	_

#Text=The present results may suggest that disruption in the dorsal stream between abnormal visual and frontoparietal networks has negative consequences for response inhibition.
247-1	34164-34167	The	_
247-2	34168-34175	present	_
247-3	34176-34183	results	_
247-4	34184-34187	may	_
247-5	34188-34195	suggest	_
247-6	34196-34200	that	_
247-7	34201-34211	disruption	_
247-8	34212-34214	in	_
247-9	34215-34218	the	_
247-10	34219-34225	dorsal	_
247-11	34226-34232	stream	_
247-12	34233-34240	between	_
247-13	34241-34249	abnormal	_
247-14	34250-34256	visual	_
247-15	34257-34260	and	_
247-16	34261-34275	frontoparietal	_
247-17	34276-34284	networks	_
247-18	34285-34288	has	_
247-19	34289-34297	negative	_
247-20	34298-34310	consequences	_
247-21	34311-34314	for	_
247-22	34315-34323	response	_
247-23	34324-34334	inhibition	_
247-24	34334-34335	.	_

#Text=More generally, they suggest that between-network RSFC interactions may be as or more important than network homogeneity in explaining between-group differences in cognition, and suggest the need for further studies involving sensory processing/RSFC interactions.
248-1	34336-34340	More	_
248-2	34341-34350	generally	_
248-3	34350-34351	,	_
248-4	34352-34356	they	_
248-5	34357-34364	suggest	_
248-6	34365-34369	that	_
248-7	34370-34385	between-network	_
248-8	34386-34390	RSFC	_
248-9	34391-34403	interactions	_
248-10	34404-34407	may	_
248-11	34408-34410	be	_
248-12	34411-34413	as	_
248-13	34414-34416	or	_
248-14	34417-34421	more	_
248-15	34422-34431	important	_
248-16	34432-34436	than	_
248-17	34437-34444	network	_
248-18	34445-34456	homogeneity	_
248-19	34457-34459	in	_
248-20	34460-34470	explaining	_
248-21	34471-34484	between-group	_
248-22	34485-34496	differences	_
248-23	34497-34499	in	_
248-24	34500-34509	cognition	_
248-25	34509-34510	,	_
248-26	34511-34514	and	_
248-27	34515-34522	suggest	_
248-28	34523-34526	the	_
248-29	34527-34531	need	_
248-30	34532-34535	for	_
248-31	34536-34543	further	_
248-32	34544-34551	studies	_
248-33	34552-34561	involving	_
248-34	34562-34569	sensory	_
248-35	34570-34580	processing	_
248-36	34580-34581	/	_
248-37	34581-34585	RSFC	_
248-38	34586-34598	interactions	_
248-39	34598-34599	.	_

#Text=This paper utilized networks first proposed by based on data from HCP pipeline validation studies.
249-1	34600-34604	This	_
249-2	34605-34610	paper	_
249-3	34611-34619	utilized	_
249-4	34620-34628	networks	_
249-5	34629-34634	first	_
249-6	34635-34643	proposed	_
249-7	34644-34646	by	_
249-8	34647-34652	based	_
249-9	34653-34655	on	_
249-10	34656-34660	data	_
249-11	34661-34665	from	_
249-12	34666-34669	HCP	_
249-13	34670-34678	pipeline	_
249-14	34679-34689	validation	_
249-15	34690-34697	studies	_
249-16	34697-34698	.	_

#Text=Analyses of high resolution HCP data has further subdivided the cortex into 180 functional domains, and further improvements in spatial resolution may lead to even finer parcellations.
250-1	34699-34707	Analyses	_
250-2	34708-34710	of	_
250-3	34711-34715	high	_
250-4	34716-34726	resolution	_
250-5	34727-34730	HCP	_
250-6	34731-34735	data	_
250-7	34736-34739	has	_
250-8	34740-34747	further	_
250-9	34748-34758	subdivided	_
250-10	34759-34762	the	_
250-11	34763-34769	cortex	_
250-12	34770-34774	into	_
250-13	34775-34778	180	_
250-14	34779-34789	functional	_
250-15	34790-34797	domains	_
250-16	34797-34798	,	_
250-17	34799-34802	and	_
250-18	34803-34810	further	_
250-19	34811-34823	improvements	_
250-20	34824-34826	in	_
250-21	34827-34834	spatial	_
250-22	34835-34845	resolution	_
250-23	34846-34849	may	_
250-24	34850-34854	lead	_
250-25	34855-34857	to	_
250-26	34858-34862	even	_
250-27	34863-34868	finer	_
250-28	34869-34882	parcellations	_
250-29	34882-34883	.	_

#Text=Nevertheless, the present study demonstrates the utility of using even relatively low-resolution networks, and suggests that higher imaging resolutions can achieve more fine-grained analyses of dysfunctional interactions in Sz.
251-1	34884-34896	Nevertheless	_
251-2	34896-34897	,	_
251-3	34898-34901	the	_
251-4	34902-34909	present	_
251-5	34910-34915	study	_
251-6	34916-34928	demonstrates	_
251-7	34929-34932	the	_
251-8	34933-34940	utility	_
251-9	34941-34943	of	_
251-10	34944-34949	using	_
251-11	34950-34954	even	_
251-12	34955-34965	relatively	_
251-13	34966-34980	low-resolution	_
251-14	34981-34989	networks	_
251-15	34989-34990	,	_
251-16	34991-34994	and	_
251-17	34995-35003	suggests	_
251-18	35004-35008	that	_
251-19	35009-35015	higher	_
251-20	35016-35023	imaging	_
251-21	35024-35035	resolutions	_
251-22	35036-35039	can	_
251-23	35040-35047	achieve	_
251-24	35048-35052	more	_
251-25	35053-35065	fine-grained	_
251-26	35066-35074	analyses	_
251-27	35075-35077	of	_
251-28	35078-35091	dysfunctional	_
251-29	35092-35104	interactions	_
251-30	35105-35107	in	_
251-31	35108-35110	Sz	_
251-32	35110-35111	.	_

#Text=For the present study, we relied primarily on resting state analyses in which we normalized by global signal regression.
252-1	35112-35115	For	_
252-2	35116-35119	the	_
252-3	35120-35127	present	_
252-4	35128-35133	study	_
252-5	35133-35134	,	_
252-6	35135-35137	we	_
252-7	35138-35144	relied	_
252-8	35145-35154	primarily	_
252-9	35155-35157	on	_
252-10	35158-35165	resting	_
252-11	35166-35171	state	_
252-12	35172-35180	analyses	_
252-13	35181-35183	in	_
252-14	35184-35189	which	_
252-15	35190-35192	we	_
252-16	35193-35203	normalized	_
252-17	35204-35206	by	_
252-18	35207-35213	global	_
252-19	35214-35220	signal	_
252-20	35221-35231	regression	_
252-21	35231-35232	.	_

#Text=The ideal approach to normalization of connectivity data is controversial, given potential between-group differences in global signal and their possible contribution to negative RSFC values (anticorrelations).
253-1	35233-35236	The	_
253-2	35237-35242	ideal	_
253-3	35243-35251	approach	_
253-4	35252-35254	to	_
253-5	35255-35268	normalization	_
253-6	35269-35271	of	_
253-7	35272-35284	connectivity	_
253-8	35285-35289	data	_
253-9	35290-35292	is	_
253-10	35293-35306	controversial	_
253-11	35306-35307	,	_
253-12	35308-35313	given	_
253-13	35314-35323	potential	_
253-14	35324-35337	between-group	_
253-15	35338-35349	differences	_
253-16	35350-35352	in	_
253-17	35353-35359	global	_
253-18	35360-35366	signal	_
253-19	35367-35370	and	_
253-20	35371-35376	their	_
253-21	35377-35385	possible	_
253-22	35386-35398	contribution	_
253-23	35399-35401	to	_
253-24	35402-35410	negative	_
253-25	35411-35415	RSFC	_
253-26	35416-35422	values	_
253-27	35423-35424	(	_
253-28	35424-35440	anticorrelations	_
253-29	35440-35441	)	_
253-30	35441-35442	.	_

#Text=However, we found no group difference in the global signal.
254-1	35443-35450	However	_
254-2	35450-35451	,	_
254-3	35452-35454	we	_
254-4	35455-35460	found	_
254-5	35461-35463	no	_
254-6	35464-35469	group	_
254-7	35470-35480	difference	_
254-8	35481-35483	in	_
254-9	35484-35487	the	_
254-10	35488-35494	global	_
254-11	35495-35501	signal	_
254-12	35501-35502	.	_

#Text=When nonnormalized data were used, the results were not significant suggesting that relative, rather than absolute, connectivity was the critical factor.
255-1	35503-35507	When	_
255-2	35508-35521	nonnormalized	_
255-3	35522-35526	data	_
255-4	35527-35531	were	_
255-5	35532-35536	used	_
255-6	35536-35537	,	_
255-7	35538-35541	the	_
255-8	35542-35549	results	_
255-9	35550-35554	were	_
255-10	35555-35558	not	_
255-11	35559-35570	significant	_
255-12	35571-35581	suggesting	_
255-13	35582-35586	that	_
255-14	35587-35595	relative	_
255-15	35595-35596	,	_
255-16	35597-35603	rather	_
255-17	35604-35608	than	_
255-18	35609-35617	absolute	_
255-19	35617-35618	,	_
255-20	35619-35631	connectivity	_
255-21	35632-35635	was	_
255-22	35636-35639	the	_
255-23	35640-35648	critical	_
255-24	35649-35655	factor	_
255-25	35655-35656	.	_

#Text=In addition to N1 deficits, significant impairments were also observed in the N2 and P3 components, providing additional insights into mechanisms underlying response inhibition impairments in schizophrenia.
256-1	35657-35659	In	_
256-2	35660-35668	addition	_
256-3	35669-35671	to	_
256-4	35672-35674	N1	_
256-5	35675-35683	deficits	_
256-6	35683-35684	,	_
256-7	35685-35696	significant	_
256-8	35697-35708	impairments	_
256-9	35709-35713	were	_
256-10	35714-35718	also	_
256-11	35719-35727	observed	_
256-12	35728-35730	in	_
256-13	35731-35734	the	_
256-14	35735-35737	N2	_
256-15	35738-35741	and	_
256-16	35742-35744	P3	_
256-17	35745-35755	components	_
256-18	35755-35756	,	_
256-19	35757-35766	providing	_
256-20	35767-35777	additional	_
256-21	35778-35786	insights	_
256-22	35787-35791	into	_
256-23	35792-35802	mechanisms	_
256-24	35803-35813	underlying	_
256-25	35814-35822	response	_
256-26	35823-35833	inhibition	_
256-27	35834-35845	impairments	_
256-28	35846-35848	in	_
256-29	35849-35862	schizophrenia	_
256-30	35862-35863	.	_

#Text=As opposed to the N1, the N2 component was only observed to unsuccessful stops, suggesting that it may be involved primarily in response monitoring, rather than response selection.
257-1	35864-35866	As	_
257-2	35867-35874	opposed	_
257-3	35875-35877	to	_
257-4	35878-35881	the	_
257-5	35882-35884	N1	_
257-6	35884-35885	,	_
257-7	35886-35889	the	_
257-8	35890-35892	N2	_
257-9	35893-35902	component	_
257-10	35903-35906	was	_
257-11	35907-35911	only	_
257-12	35912-35920	observed	_
257-13	35921-35923	to	_
257-14	35924-35936	unsuccessful	_
257-15	35937-35942	stops	_
257-16	35942-35943	,	_
257-17	35944-35954	suggesting	_
257-18	35955-35959	that	_
257-19	35960-35962	it	_
257-20	35963-35966	may	_
257-21	35967-35969	be	_
257-22	35970-35978	involved	_
257-23	35979-35988	primarily	_
257-24	35989-35991	in	_
257-25	35992-36000	response	_
257-26	36001-36011	monitoring	_
257-27	36011-36012	,	_
257-28	36013-36019	rather	_
257-29	36020-36024	than	_
257-30	36025-36033	response	_
257-31	36034-36043	selection	_
257-32	36043-36044	.	_

#Text=As with the N1, N2 amplitude was significantly reduced in Sz.
258-1	36045-36047	As	_
258-2	36048-36052	with	_
258-3	36053-36056	the	_
258-4	36057-36059	N1	_
258-5	36059-36060	,	_
258-6	36061-36063	N2	_
258-7	36064-36073	amplitude	_
258-8	36074-36077	was	_
258-9	36078-36091	significantly	_
258-10	36092-36099	reduced	_
258-11	36100-36102	in	_
258-12	36103-36105	Sz	_
258-13	36105-36106	.	_

#Text=Nevertheless, N2 did not correlate with SSRT.
259-1	36107-36119	Nevertheless	_
259-2	36119-36120	,	_
259-3	36121-36123	N2	_
259-4	36124-36127	did	_
259-5	36128-36131	not	_
259-6	36132-36141	correlate	_
259-7	36142-36146	with	_
259-8	36147-36151	SSRT	_
259-9	36151-36152	.	_

#Text=Thus, the N2 may represent the beginning of a heterogeneous set of processes associated with response monitoring and evaluation.
260-1	36153-36157	Thus	_
260-2	36157-36158	,	_
260-3	36159-36162	the	_
260-4	36163-36165	N2	_
260-5	36166-36169	may	_
260-6	36170-36179	represent	_
260-7	36180-36183	the	_
260-8	36184-36193	beginning	_
260-9	36194-36196	of	_
260-10	36197-36198	a	_
260-11	36199-36212	heterogeneous	_
260-12	36213-36216	set	_
260-13	36217-36219	of	_
260-14	36220-36229	processes	_
260-15	36230-36240	associated	_
260-16	36241-36245	with	_
260-17	36246-36254	response	_
260-18	36255-36265	monitoring	_
260-19	36266-36269	and	_
260-20	36270-36280	evaluation	_
260-21	36280-36281	.	_

#Text=The N2 did not occur after SSRT latency but did occur after the presumed decision to respond given corticospinal transmission time (~20 ms).We suggest that the N2 marks a transition in processes from stop preparation to detection of stop failure.
261-1	36282-36285	The	_
261-2	36286-36288	N2	_
261-3	36289-36292	did	_
261-4	36293-36296	not	_
261-5	36297-36302	occur	_
261-6	36303-36308	after	_
261-7	36309-36313	SSRT	_
261-8	36314-36321	latency	_
261-9	36322-36325	but	_
261-10	36326-36329	did	_
261-11	36330-36335	occur	_
261-12	36336-36341	after	_
261-13	36342-36345	the	_
261-14	36346-36354	presumed	_
261-15	36355-36363	decision	_
261-16	36364-36366	to	_
261-17	36367-36374	respond	_
261-18	36375-36380	given	_
261-19	36381-36394	corticospinal	_
261-20	36395-36407	transmission	_
261-21	36408-36412	time	_
261-22	36413-36414	(	_
261-23	36414-36415	~	_
261-24	36415-36417	20	_
261-25	36417-36418	 	_
261-26	36418-36420	ms	_
261-27	36420-36421	)	_
261-28	36421-36422	.	_
261-29	36422-36424	We	_
261-30	36425-36432	suggest	_
261-31	36433-36437	that	_
261-32	36438-36441	the	_
261-33	36442-36444	N2	_
261-34	36445-36450	marks	_
261-35	36451-36452	a	_
261-36	36453-36463	transition	_
261-37	36464-36466	in	_
261-38	36467-36476	processes	_
261-39	36477-36481	from	_
261-40	36482-36486	stop	_
261-41	36487-36498	preparation	_
261-42	36499-36501	to	_
261-43	36502-36511	detection	_
261-44	36512-36514	of	_
261-45	36515-36519	stop	_
261-46	36520-36527	failure	_
261-47	36527-36528	.	_

#Text=The fact that it occurred only to unsuccessful stops but not successful gos also argues against its obligatory involvement in motor decision.
262-1	36529-36532	The	_
262-2	36533-36537	fact	_
262-3	36538-36542	that	_
262-4	36543-36545	it	_
262-5	36546-36554	occurred	_
262-6	36555-36559	only	_
262-7	36560-36562	to	_
262-8	36563-36575	unsuccessful	_
262-9	36576-36581	stops	_
262-10	36582-36585	but	_
262-11	36586-36589	not	_
262-12	36590-36600	successful	_
262-13	36601-36604	gos	_
262-14	36605-36609	also	_
262-15	36610-36616	argues	_
262-16	36617-36624	against	_
262-17	36625-36628	its	_
262-18	36629-36639	obligatory	_
262-19	36640-36651	involvement	_
262-20	36652-36654	in	_
262-21	36655-36660	motor	_
262-22	36661-36669	decision	_
262-23	36669-36670	.	_

#Text=Highly significant reductions were also observed in P3 amplitude in Sz, which did correlate significantly with SSRT.
263-1	36671-36677	Highly	_
263-2	36678-36689	significant	_
263-3	36690-36700	reductions	_
263-4	36701-36705	were	_
263-5	36706-36710	also	_
263-6	36711-36719	observed	_
263-7	36720-36722	in	_
263-8	36723-36725	P3	_
263-9	36726-36735	amplitude	_
263-10	36736-36738	in	_
263-11	36739-36741	Sz	_
263-12	36741-36742	,	_
263-13	36743-36748	which	_
263-14	36749-36752	did	_
263-15	36753-36762	correlate	_
263-16	36763-36776	significantly	_
263-17	36777-36781	with	_
263-18	36782-36786	SSRT	_
263-19	36786-36787	.	_

#Text=P3 latency also exceeded the SSRT, suggesting that, like N2, P3 reflected performance monitoring, rather than response decision.
264-1	36788-36790	P3	_
264-2	36791-36798	latency	_
264-3	36799-36803	also	_
264-4	36804-36812	exceeded	_
264-5	36813-36816	the	_
264-6	36817-36821	SSRT	_
264-7	36821-36822	,	_
264-8	36823-36833	suggesting	_
264-9	36834-36838	that	_
264-10	36838-36839	,	_
264-11	36840-36844	like	_
264-12	36845-36847	N2	_
264-13	36847-36848	,	_
264-14	36849-36851	P3	_
264-15	36852-36861	reflected	_
264-16	36862-36873	performance	_
264-17	36874-36884	monitoring	_
264-18	36884-36885	,	_
264-19	36886-36892	rather	_
264-20	36893-36897	than	_
264-21	36898-36906	response	_
264-22	36907-36915	decision	_
264-23	36915-36916	.	_

#Text=Strikingly, however, the P3 for successful stops was virtually absent for participants with SSRTs exceeding 250 ms.
265-1	36917-36927	Strikingly	_
265-2	36927-36928	,	_
265-3	36929-36936	however	_
265-4	36936-36937	,	_
265-5	36938-36941	the	_
265-6	36942-36944	P3	_
265-7	36945-36948	for	_
265-8	36949-36959	successful	_
265-9	36960-36965	stops	_
265-10	36966-36969	was	_
265-11	36970-36979	virtually	_
265-12	36980-36986	absent	_
265-13	36987-36990	for	_
265-14	36991-37003	participants	_
265-15	37004-37008	with	_
265-16	37009-37014	SSRTs	_
265-17	37015-37024	exceeding	_
265-18	37025-37028	250	_
265-19	37028-37029	 	_
265-20	37029-37031	ms	_
265-21	37031-37032	.	_

#Text=Thus, longer SSRTs may reflect the use of strategies that do not involve circuits involved in P3 generation.
266-1	37033-37037	Thus	_
266-2	37037-37038	,	_
266-3	37039-37045	longer	_
266-4	37046-37051	SSRTs	_
266-5	37052-37055	may	_
266-6	37056-37063	reflect	_
266-7	37064-37067	the	_
266-8	37068-37071	use	_
266-9	37072-37074	of	_
266-10	37075-37085	strategies	_
266-11	37086-37090	that	_
266-12	37091-37093	do	_
266-13	37094-37097	not	_
266-14	37098-37105	involve	_
266-15	37106-37114	circuits	_
266-16	37115-37123	involved	_
266-17	37124-37126	in	_
266-18	37127-37129	P3	_
266-19	37130-37140	generation	_
266-20	37140-37141	.	_

#Text=Values that exceeded this threshold were primarily observed among patients, whose performance was more affected than controls by loss of anticorrelation between networks.
267-1	37142-37148	Values	_
267-2	37149-37153	that	_
267-3	37154-37162	exceeded	_
267-4	37163-37167	this	_
267-5	37168-37177	threshold	_
267-6	37178-37182	were	_
267-7	37183-37192	primarily	_
267-8	37193-37201	observed	_
267-9	37202-37207	among	_
267-10	37208-37216	patients	_
267-11	37216-37217	,	_
267-12	37218-37223	whose	_
267-13	37224-37235	performance	_
267-14	37236-37239	was	_
267-15	37240-37244	more	_
267-16	37245-37253	affected	_
267-17	37254-37258	than	_
267-18	37259-37267	controls	_
267-19	37268-37270	by	_
267-20	37271-37275	loss	_
267-21	37276-37278	of	_
267-22	37279-37294	anticorrelation	_
267-23	37295-37302	between	_
267-24	37303-37311	networks	_
267-25	37311-37312	.	_

#Text=Although we did not directly examine the interplay between resting state and ERP measures, it is useful to consider the observed relationships.
268-1	37313-37321	Although	_
268-2	37322-37324	we	_
268-3	37325-37328	did	_
268-4	37329-37332	not	_
268-5	37333-37341	directly	_
268-6	37342-37349	examine	_
268-7	37350-37353	the	_
268-8	37354-37363	interplay	_
268-9	37364-37371	between	_
268-10	37372-37379	resting	_
268-11	37380-37385	state	_
268-12	37386-37389	and	_
268-13	37390-37393	ERP	_
268-14	37394-37402	measures	_
268-15	37402-37403	,	_
268-16	37404-37406	it	_
268-17	37407-37409	is	_
268-18	37410-37416	useful	_
268-19	37417-37419	to	_
268-20	37420-37428	consider	_
268-21	37429-37432	the	_
268-22	37433-37441	observed	_
268-23	37442-37455	relationships	_
268-24	37455-37456	.	_

#Text=The ERP data reflect behaviors that occur on a millisecond scale (3–10 Hz), whereas RSFC occurs on a tens-to-hundreds of seconds timescale (0.01–0.1 Hz).
269-1	37457-37460	The	_
269-2	37461-37464	ERP	_
269-3	37465-37469	data	_
269-4	37470-37477	reflect	_
269-5	37478-37487	behaviors	_
269-6	37488-37492	that	_
269-7	37493-37498	occur	_
269-8	37499-37501	on	_
269-9	37502-37503	a	_
269-10	37504-37515	millisecond	_
269-11	37516-37521	scale	_
269-12	37522-37523	(	_
269-13	37523-37524	3	_
269-14	37524-37525	–	_
269-15	37525-37527	10	_
269-16	37527-37528	 	_
269-17	37528-37530	Hz	_
269-18	37530-37531	)	_
269-19	37531-37532	,	_
269-20	37533-37540	whereas	_
269-21	37541-37545	RSFC	_
269-22	37546-37552	occurs	_
269-23	37553-37555	on	_
269-24	37556-37557	a	_
269-25	37558-37574	tens-to-hundreds	_
269-26	37575-37577	of	_
269-27	37578-37585	seconds	_
269-28	37586-37595	timescale	_
269-29	37596-37597	(	_
269-30	37597-37601	0.01	_
269-31	37601-37602	–	_
269-32	37602-37605	0.1	_
269-33	37605-37606	 	_
269-34	37606-37608	Hz	_
269-35	37608-37609	)	_
269-36	37609-37610	.	_

#Text=It may be that activity occurring on the shorter time scale constrains the kinds of computations that occur in a longer time frame.
270-1	37611-37613	It	_
270-2	37614-37617	may	_
270-3	37618-37620	be	_
270-4	37621-37625	that	_
270-5	37626-37634	activity	_
270-6	37635-37644	occurring	_
270-7	37645-37647	on	_
270-8	37648-37651	the	_
270-9	37652-37659	shorter	_
270-10	37660-37664	time	_
270-11	37665-37670	scale	_
270-12	37671-37681	constrains	_
270-13	37682-37685	the	_
270-14	37686-37691	kinds	_
270-15	37692-37694	of	_
270-16	37695-37707	computations	_
270-17	37708-37712	that	_
270-18	37713-37718	occur	_
270-19	37719-37721	in	_
270-20	37722-37723	a	_
270-21	37724-37730	longer	_
270-22	37731-37735	time	_
270-23	37736-37741	frame	_
270-24	37741-37742	.	_

#Text=Alternatively, the resting state RSFC may be trait-like phenomenon that constrains how brain activity patterns occur over a millisecond time frame.
271-1	37743-37756	Alternatively	_
271-2	37756-37757	,	_
271-3	37758-37761	the	_
271-4	37762-37769	resting	_
271-5	37770-37775	state	_
271-6	37776-37780	RSFC	_
271-7	37781-37784	may	_
271-8	37785-37787	be	_
271-9	37788-37798	trait-like	_
271-10	37799-37809	phenomenon	_
271-11	37810-37814	that	_
271-12	37815-37825	constrains	_
271-13	37826-37829	how	_
271-14	37830-37835	brain	_
271-15	37836-37844	activity	_
271-16	37845-37853	patterns	_
271-17	37854-37859	occur	_
271-18	37860-37864	over	_
271-19	37865-37866	a	_
271-20	37867-37878	millisecond	_
271-21	37879-37883	time	_
271-22	37884-37889	frame	_
271-23	37889-37890	.	_

#Text=It will be useful to conduct analyses using psychophysiological interaction, dynamic causal modeling, and/or neuromodulatory interventions to disentangle these mechanisms.
272-1	37891-37893	It	_
272-2	37894-37898	will	_
272-3	37899-37901	be	_
272-4	37902-37908	useful	_
272-5	37909-37911	to	_
272-6	37912-37919	conduct	_
272-7	37920-37928	analyses	_
272-8	37929-37934	using	_
272-9	37935-37954	psychophysiological	_
272-10	37955-37966	interaction	_
272-11	37966-37967	,	_
272-12	37968-37975	dynamic	_
272-13	37976-37982	causal	_
272-14	37983-37991	modeling	_
272-15	37991-37992	,	_
272-16	37993-37996	and	_
272-17	37996-37997	/	_
272-18	37997-37999	or	_
272-19	38000-38015	neuromodulatory	_
272-20	38016-38029	interventions	_
272-21	38030-38032	to	_
272-22	38033-38044	disentangle	_
272-23	38045-38050	these	_
272-24	38051-38061	mechanisms	_
272-25	38061-38062	.	_

#Text=Moreover, it may be useful to assess phase-amplitude coupling between EEG- and RSFC-related frequencies, given that other aspects of phase-amplitude coupling are abnormal in Sz (;).
273-1	38063-38071	Moreover	_
273-2	38071-38072	,	_
273-3	38073-38075	it	_
273-4	38076-38079	may	_
273-5	38080-38082	be	_
273-6	38083-38089	useful	_
273-7	38090-38092	to	_
273-8	38093-38099	assess	_
273-9	38100-38115	phase-amplitude	_
273-10	38116-38124	coupling	_
273-11	38125-38132	between	_
273-12	38133-38136	EEG	_
273-13	38136-38137	-	_
273-14	38138-38141	and	_
273-15	38142-38154	RSFC-related	_
273-16	38155-38166	frequencies	_
273-17	38166-38167	,	_
273-18	38168-38173	given	_
273-19	38174-38178	that	_
273-20	38179-38184	other	_
273-21	38185-38192	aspects	_
273-22	38193-38195	of	_
273-23	38196-38211	phase-amplitude	_
273-24	38212-38220	coupling	_
273-25	38221-38224	are	_
273-26	38225-38233	abnormal	_
273-27	38234-38236	in	_
273-28	38237-38239	Sz	_
273-29	38240-38241	(	_
273-30	38241-38242	;	_
273-31	38242-38243	)	_
273-32	38243-38244	.	_

#Text=For each of the 7 resting state networks, we found reduced network homogeneity, suggesting reduced temporal correlation of voxels within the network.
274-1	38245-38248	For	_
274-2	38249-38253	each	_
274-3	38254-38256	of	_
274-4	38257-38260	the	_
274-5	38261-38262	7	_
274-6	38263-38270	resting	_
274-7	38271-38276	state	_
274-8	38277-38285	networks	_
274-9	38285-38286	,	_
274-10	38287-38289	we	_
274-11	38290-38295	found	_
274-12	38296-38303	reduced	_
274-13	38304-38311	network	_
274-14	38312-38323	homogeneity	_
274-15	38323-38324	,	_
274-16	38325-38335	suggesting	_
274-17	38336-38343	reduced	_
274-18	38344-38352	temporal	_
274-19	38353-38364	correlation	_
274-20	38365-38367	of	_
274-21	38368-38374	voxels	_
274-22	38375-38381	within	_
274-23	38382-38385	the	_
274-24	38386-38393	network	_
274-25	38393-38394	.	_

#Text=A possible implication of these reductions is that brain networks in schizophrenia are disrupted, possibly as a consequence of abnormal brain structural connectivity, as reflected in reduced white matter integrity in the disorder (e.g.,), which correlated with poor sensory (;), emotional, and cognitive performance.
275-1	38395-38396	A	_
275-2	38397-38405	possible	_
275-3	38406-38417	implication	_
275-4	38418-38420	of	_
275-5	38421-38426	these	_
275-6	38427-38437	reductions	_
275-7	38438-38440	is	_
275-8	38441-38445	that	_
275-9	38446-38451	brain	_
275-10	38452-38460	networks	_
275-11	38461-38463	in	_
275-12	38464-38477	schizophrenia	_
275-13	38478-38481	are	_
275-14	38482-38491	disrupted	_
275-15	38491-38492	,	_
275-16	38493-38501	possibly	_
275-17	38502-38504	as	_
275-18	38505-38506	a	_
275-19	38507-38518	consequence	_
275-20	38519-38521	of	_
275-21	38522-38530	abnormal	_
275-22	38531-38536	brain	_
275-23	38537-38547	structural	_
275-24	38548-38560	connectivity	_
275-25	38560-38561	,	_
275-26	38562-38564	as	_
275-27	38565-38574	reflected	_
275-28	38575-38577	in	_
275-29	38578-38585	reduced	_
275-30	38586-38591	white	_
275-31	38592-38598	matter	_
275-32	38599-38608	integrity	_
275-33	38609-38611	in	_
275-34	38612-38615	the	_
275-35	38616-38624	disorder	_
275-36	38625-38626	(	_
275-37	38626-38629	e.g	_
275-38	38629-38630	.	_
275-39	38630-38631	,	_
275-40	38631-38632	)	_
275-41	38632-38633	,	_
275-42	38634-38639	which	_
275-43	38640-38650	correlated	_
275-44	38651-38655	with	_
275-45	38656-38660	poor	_
275-46	38661-38668	sensory	_
275-47	38669-38670	(	_
275-48	38670-38671	;	_
275-49	38671-38672	)	_
275-50	38672-38673	,	_
275-51	38674-38683	emotional	_
275-52	38683-38684	,	_
275-53	38685-38688	and	_
275-54	38689-38698	cognitive	_
275-55	38699-38710	performance	_
275-56	38710-38711	.	_

#Text=Deficits in N1 amplitude did not correlate with performance on tests of general cognitive function (Working Memory Index) and thus are unlikely to be driven by generalized cognitive impairment as opposed to specific visual system dysfunction.
276-1	38712-38720	Deficits	_
276-2	38721-38723	in	_
276-3	38724-38726	N1	_
276-4	38727-38736	amplitude	_
276-5	38737-38740	did	_
276-6	38741-38744	not	_
276-7	38745-38754	correlate	_
276-8	38755-38759	with	_
276-9	38760-38771	performance	_
276-10	38772-38774	on	_
276-11	38775-38780	tests	_
276-12	38781-38783	of	_
276-13	38784-38791	general	_
276-14	38792-38801	cognitive	_
276-15	38802-38810	function	_
276-16	38811-38812	(	_
276-17	38812-38819	Working	_
276-18	38820-38826	Memory	_
276-19	38827-38832	Index	_
276-20	38832-38833	)	_
276-21	38834-38837	and	_
276-22	38838-38842	thus	_
276-23	38843-38846	are	_
276-24	38847-38855	unlikely	_
276-25	38856-38858	to	_
276-26	38859-38861	be	_
276-27	38862-38868	driven	_
276-28	38869-38871	by	_
276-29	38872-38883	generalized	_
276-30	38884-38893	cognitive	_
276-31	38894-38904	impairment	_
276-32	38905-38907	as	_
276-33	38908-38915	opposed	_
276-34	38916-38918	to	_
276-35	38919-38927	specific	_
276-36	38928-38934	visual	_
276-37	38935-38941	system	_
276-38	38942-38953	dysfunction	_
276-39	38953-38954	.	_

#Text=Significant correlations controlling for group, however, suggest that deficits in N1, which reflect initial stages of visual stimulus processing, may contribute to impaired neurocognitive performance in schizophrenia, as we have suggested in the past.
277-1	38955-38966	Significant	_
277-2	38967-38979	correlations	_
277-3	38980-38991	controlling	_
277-4	38992-38995	for	_
277-5	38996-39001	group	_
277-6	39001-39002	,	_
277-7	39003-39010	however	_
277-8	39010-39011	,	_
277-9	39012-39019	suggest	_
277-10	39020-39024	that	_
277-11	39025-39033	deficits	_
277-12	39034-39036	in	_
277-13	39037-39039	N1	_
277-14	39039-39040	,	_
277-15	39041-39046	which	_
277-16	39047-39054	reflect	_
277-17	39055-39062	initial	_
277-18	39063-39069	stages	_
277-19	39070-39072	of	_
277-20	39073-39079	visual	_
277-21	39080-39088	stimulus	_
277-22	39089-39099	processing	_
277-23	39099-39100	,	_
277-24	39101-39104	may	_
277-25	39105-39115	contribute	_
277-26	39116-39118	to	_
277-27	39119-39127	impaired	_
277-28	39128-39142	neurocognitive	_
277-29	39143-39154	performance	_
277-30	39155-39157	in	_
277-31	39158-39171	schizophrenia	_
277-32	39171-39172	,	_
277-33	39173-39175	as	_
277-34	39176-39178	we	_
277-35	39179-39183	have	_
277-36	39184-39193	suggested	_
277-37	39194-39196	in	_
277-38	39197-39200	the	_
277-39	39201-39205	past	_
277-40	39205-39206	.	_

#Text=Despite the novel ERP/fMRI findings, a few limitations should be noted.
278-1	39207-39214	Despite	_
278-2	39215-39218	the	_
278-3	39219-39224	novel	_
278-4	39225-39228	ERP	_
278-5	39228-39229	/	_
278-6	39229-39233	fMRI	_
278-7	39234-39242	findings	_
278-8	39242-39243	,	_
278-9	39244-39245	a	_
278-10	39246-39249	few	_
278-11	39250-39261	limitations	_
278-12	39262-39268	should	_
278-13	39269-39271	be	_
278-14	39272-39277	noted	_
278-15	39277-39278	.	_

#Text=First, data from a number of participants were rejected because of noisy data or poor performance.
279-1	39279-39284	First	_
279-2	39284-39285	,	_
279-3	39286-39290	data	_
279-4	39291-39295	from	_
279-5	39296-39297	a	_
279-6	39298-39304	number	_
279-7	39305-39307	of	_
279-8	39308-39320	participants	_
279-9	39321-39325	were	_
279-10	39326-39334	rejected	_
279-11	39335-39342	because	_
279-12	39343-39345	of	_
279-13	39346-39351	noisy	_
279-14	39352-39356	data	_
279-15	39357-39359	or	_
279-16	39360-39364	poor	_
279-17	39365-39376	performance	_
279-18	39376-39377	.	_

#Text=However, we used published criteria to determine whom to include.
280-1	39378-39385	However	_
280-2	39385-39386	,	_
280-3	39387-39389	we	_
280-4	39390-39394	used	_
280-5	39395-39404	published	_
280-6	39405-39413	criteria	_
280-7	39414-39416	to	_
280-8	39417-39426	determine	_
280-9	39427-39431	whom	_
280-10	39432-39434	to	_
280-11	39435-39442	include	_
280-12	39442-39443	.	_

#Text=Our data have excellent signal to noise characteristics, which were further improved using ICA, and the included and excluded participants did not differ on demographic variables.
281-1	39444-39447	Our	_
281-2	39448-39452	data	_
281-3	39453-39457	have	_
281-4	39458-39467	excellent	_
281-5	39468-39474	signal	_
281-6	39475-39477	to	_
281-7	39478-39483	noise	_
281-8	39484-39499	characteristics	_
281-9	39499-39500	,	_
281-10	39501-39506	which	_
281-11	39507-39511	were	_
281-12	39512-39519	further	_
281-13	39520-39528	improved	_
281-14	39529-39534	using	_
281-15	39535-39538	ICA	_
281-16	39538-39539	,	_
281-17	39540-39543	and	_
281-18	39544-39547	the	_
281-19	39548-39556	included	_
281-20	39557-39560	and	_
281-21	39561-39569	excluded	_
281-22	39570-39582	participants	_
281-23	39583-39586	did	_
281-24	39587-39590	not	_
281-25	39591-39597	differ	_
281-26	39598-39600	on	_
281-27	39601-39612	demographic	_
281-28	39613-39622	variables	_
281-29	39622-39623	.	_

#Text=The N2 results were somewhat unexpected, in that we did not find a correlation with SSRT.
282-1	39624-39627	The	_
282-2	39628-39630	N2	_
282-3	39631-39638	results	_
282-4	39639-39643	were	_
282-5	39644-39652	somewhat	_
282-6	39653-39663	unexpected	_
282-7	39663-39664	,	_
282-8	39665-39667	in	_
282-9	39668-39672	that	_
282-10	39673-39675	we	_
282-11	39676-39679	did	_
282-12	39680-39683	not	_
282-13	39684-39688	find	_
282-14	39689-39690	a	_
282-15	39691-39702	correlation	_
282-16	39703-39707	with	_
282-17	39708-39712	SSRT	_
282-18	39712-39713	.	_

#Text=An examination of scalp topography suggested that only 2 channels showed substantial activity in the predicted regions for N2, but we cannot rule out the possibility that N2 measures were derived from less data than the N1 and P3, and thus may have had lower reliability than those peaks.
283-1	39714-39716	An	_
283-2	39717-39728	examination	_
283-3	39729-39731	of	_
283-4	39732-39737	scalp	_
283-5	39738-39748	topography	_
283-6	39749-39758	suggested	_
283-7	39759-39763	that	_
283-8	39764-39768	only	_
283-9	39769-39770	2	_
283-10	39771-39779	channels	_
283-11	39780-39786	showed	_
283-12	39787-39798	substantial	_
283-13	39799-39807	activity	_
283-14	39808-39810	in	_
283-15	39811-39814	the	_
283-16	39815-39824	predicted	_
283-17	39825-39832	regions	_
283-18	39833-39836	for	_
283-19	39837-39839	N2	_
283-20	39839-39840	,	_
283-21	39841-39844	but	_
283-22	39845-39847	we	_
283-23	39848-39854	cannot	_
283-24	39855-39859	rule	_
283-25	39860-39863	out	_
283-26	39864-39867	the	_
283-27	39868-39879	possibility	_
283-28	39880-39884	that	_
283-29	39885-39887	N2	_
283-30	39888-39896	measures	_
283-31	39897-39901	were	_
283-32	39902-39909	derived	_
283-33	39910-39914	from	_
283-34	39915-39919	less	_
283-35	39920-39924	data	_
283-36	39925-39929	than	_
283-37	39930-39933	the	_
283-38	39934-39936	N1	_
283-39	39937-39940	and	_
283-40	39941-39943	P3	_
283-41	39943-39944	,	_
283-42	39945-39948	and	_
283-43	39949-39953	thus	_
283-44	39954-39957	may	_
283-45	39958-39962	have	_
283-46	39963-39966	had	_
283-47	39967-39972	lower	_
283-48	39973-39984	reliability	_
283-49	39985-39989	than	_
283-50	39990-39995	those	_
283-51	39996-40001	peaks	_
283-52	40001-40002	.	_

#Text=Another limitation is that we did not measure simple RT, which would have allowed us to examine the specific role of speeded responses.
284-1	40003-40010	Another	_
284-2	40011-40021	limitation	_
284-3	40022-40024	is	_
284-4	40025-40029	that	_
284-5	40030-40032	we	_
284-6	40033-40036	did	_
284-7	40037-40040	not	_
284-8	40041-40048	measure	_
284-9	40049-40055	simple	_
284-10	40056-40058	RT	_
284-11	40058-40059	,	_
284-12	40060-40065	which	_
284-13	40066-40071	would	_
284-14	40072-40076	have	_
284-15	40077-40084	allowed	_
284-16	40085-40087	us	_
284-17	40088-40090	to	_
284-18	40091-40098	examine	_
284-19	40099-40102	the	_
284-20	40103-40111	specific	_
284-21	40112-40116	role	_
284-22	40117-40119	of	_
284-23	40120-40127	speeded	_
284-24	40128-40137	responses	_
284-25	40137-40138	.	_

#Text=Future studies should examine simple RT task as a control condition.
285-1	40139-40145	Future	_
285-2	40146-40153	studies	_
285-3	40154-40160	should	_
285-4	40161-40168	examine	_
285-5	40169-40175	simple	_
285-6	40176-40178	RT	_
285-7	40179-40183	task	_
285-8	40184-40186	as	_
285-9	40187-40188	a	_
285-10	40189-40196	control	_
285-11	40197-40206	condition	_
285-12	40206-40207	.	_

#Text=Also, all patients were taking antipsychotic medication.
286-1	40208-40212	Also	_
286-2	40212-40213	,	_
286-3	40214-40217	all	_
286-4	40218-40226	patients	_
286-5	40227-40231	were	_
286-6	40232-40238	taking	_
286-7	40239-40252	antipsychotic	_
286-8	40253-40263	medication	_
286-9	40263-40264	.	_

#Text=In the future, it will be important to study unmedicated patients or those with limited antipsychotic exposure.
287-1	40265-40267	In	_
287-2	40268-40271	the	_
287-3	40272-40278	future	_
287-4	40278-40279	,	_
287-5	40280-40282	it	_
287-6	40283-40287	will	_
287-7	40288-40290	be	_
287-8	40291-40300	important	_
287-9	40301-40303	to	_
287-10	40304-40309	study	_
287-11	40310-40321	unmedicated	_
287-12	40322-40330	patients	_
287-13	40331-40333	or	_
287-14	40334-40339	those	_
287-15	40340-40344	with	_
287-16	40345-40352	limited	_
287-17	40353-40366	antipsychotic	_
287-18	40367-40375	exposure	_
287-19	40375-40376	.	_

#Text=In addition, our sample size was relatively small.
288-1	40377-40379	In	_
288-2	40380-40388	addition	_
288-3	40388-40389	,	_
288-4	40390-40393	our	_
288-5	40394-40400	sample	_
288-6	40401-40405	size	_
288-7	40406-40409	was	_
288-8	40410-40420	relatively	_
288-9	40421-40426	small	_
288-10	40426-40427	.	_

#Text=However, our effect sizes were large and our results were largely consistent with, while adding to, extant literature.
289-1	40428-40435	However	_
289-2	40435-40436	,	_
289-3	40437-40440	our	_
289-4	40441-40447	effect	_
289-5	40448-40453	sizes	_
289-6	40454-40458	were	_
289-7	40459-40464	large	_
289-8	40465-40468	and	_
289-9	40469-40472	our	_
289-10	40473-40480	results	_
289-11	40481-40485	were	_
289-12	40486-40493	largely	_
289-13	40494-40504	consistent	_
289-14	40505-40509	with	_
289-15	40509-40510	,	_
289-16	40511-40516	while	_
289-17	40517-40523	adding	_
289-18	40524-40526	to	_
289-19	40526-40527	,	_
289-20	40528-40534	extant	_
289-21	40535-40545	literature	_
289-22	40545-40546	.	_

#Text=We also did not use latency adjustment techniques (such as ADJAR) to differentiate potentially overlapping ERP components.
290-1	40547-40549	We	_
290-2	40550-40554	also	_
290-3	40555-40558	did	_
290-4	40559-40562	not	_
290-5	40563-40566	use	_
290-6	40567-40574	latency	_
290-7	40575-40585	adjustment	_
290-8	40586-40596	techniques	_
290-9	40597-40598	(	_
290-10	40598-40602	such	_
290-11	40603-40605	as	_
290-12	40606-40611	ADJAR	_
290-13	40611-40612	)	_
290-14	40613-40615	to	_
290-15	40616-40629	differentiate	_
290-16	40630-40641	potentially	_
290-17	40642-40653	overlapping	_
290-18	40654-40657	ERP	_
290-19	40658-40668	components	_
290-20	40668-40669	.	_

#Text=However, we had a wide range of SSDs between go and stop signals, which would have disrupted any non-time-locked activity, and indeed the baselines for the grand averages were flat (see Figs. 1C and 2C/D), suggesting that baseline activity was not accounting for the observed effects.
291-1	40670-40677	However	_
291-2	40677-40678	,	_
291-3	40679-40681	we	_
291-4	40682-40685	had	_
291-5	40686-40687	a	_
291-6	40688-40692	wide	_
291-7	40693-40698	range	_
291-8	40699-40701	of	_
291-9	40702-40706	SSDs	_
291-10	40707-40714	between	_
291-11	40715-40717	go	_
291-12	40718-40721	and	_
291-13	40722-40726	stop	_
291-14	40727-40734	signals	_
291-15	40734-40735	,	_
291-16	40736-40741	which	_
291-17	40742-40747	would	_
291-18	40748-40752	have	_
291-19	40753-40762	disrupted	_
291-20	40763-40766	any	_
291-21	40767-40782	non-time-locked	_
291-22	40783-40791	activity	_
291-23	40791-40792	,	_
291-24	40793-40796	and	_
291-25	40797-40803	indeed	_
291-26	40804-40807	the	_
291-27	40808-40817	baselines	_
291-28	40818-40821	for	_
291-29	40822-40825	the	_
291-30	40826-40831	grand	_
291-31	40832-40840	averages	_
291-32	40841-40845	were	_
291-33	40846-40850	flat	_
291-34	40851-40852	(	_
291-35	40852-40855	see	_
291-36	40856-40860	Figs	_
291-37	40860-40861	.	_
291-38	40862-40864	1C	_
291-39	40865-40868	and	_
291-40	40869-40871	2C	_
291-41	40871-40872	/	_
291-42	40872-40873	D	_
291-43	40873-40874	)	_
291-44	40874-40875	,	_
291-45	40876-40886	suggesting	_
291-46	40887-40891	that	_
291-47	40892-40900	baseline	_
291-48	40901-40909	activity	_
291-49	40910-40913	was	_
291-50	40914-40917	not	_
291-51	40918-40928	accounting	_
291-52	40929-40932	for	_
291-53	40933-40936	the	_
291-54	40937-40945	observed	_
291-55	40946-40953	effects	_
291-56	40953-40954	.	_

#Text=In conclusion, patients with Sz show response inhibition deficits that are associated in parallel with 1) reduced visual sensory response, and 2) greater dependence on anticorrelation between visual and frontoparietal task-control networks.
292-1	40955-40957	In	_
292-2	40958-40968	conclusion	_
292-3	40968-40969	,	_
292-4	40970-40978	patients	_
292-5	40979-40983	with	_
292-6	40984-40986	Sz	_
292-7	40987-40991	show	_
292-8	40992-41000	response	_
292-9	41001-41011	inhibition	_
292-10	41012-41020	deficits	_
292-11	41021-41025	that	_
292-12	41026-41029	are	_
292-13	41030-41040	associated	_
292-14	41041-41043	in	_
292-15	41044-41052	parallel	_
292-16	41053-41057	with	_
292-17	41058-41059	1	_
292-18	41059-41060	)	_
292-19	41061-41068	reduced	_
292-20	41069-41075	visual	_
292-21	41076-41083	sensory	_
292-22	41084-41092	response	_
292-23	41092-41093	,	_
292-24	41094-41097	and	_
292-25	41098-41099	2	_
292-26	41099-41100	)	_
292-27	41101-41108	greater	_
292-28	41109-41119	dependence	_
292-29	41120-41122	on	_
292-30	41123-41138	anticorrelation	_
292-31	41139-41146	between	_
292-32	41147-41153	visual	_
292-33	41154-41157	and	_
292-34	41158-41172	frontoparietal	_
292-35	41173-41185	task-control	_
292-36	41186-41194	networks	_
292-37	41194-41195	.	_

#Text=P3 reduction was observed after the stop process, suggesting that this component reflects deficient response monitoring, which may also contribute to impaired inhibitory function.
293-1	41196-41198	P3	_
293-2	41199-41208	reduction	_
293-3	41209-41212	was	_
293-4	41213-41221	observed	_
293-5	41222-41227	after	_
293-6	41228-41231	the	_
293-7	41232-41236	stop	_
293-8	41237-41244	process	_
293-9	41244-41245	,	_
293-10	41246-41256	suggesting	_
293-11	41257-41261	that	_
293-12	41262-41266	this	_
293-13	41267-41276	component	_
293-14	41277-41285	reflects	_
293-15	41286-41295	deficient	_
293-16	41296-41304	response	_
293-17	41305-41315	monitoring	_
293-18	41315-41316	,	_
293-19	41317-41322	which	_
293-20	41323-41326	may	_
293-21	41327-41331	also	_
293-22	41332-41342	contribute	_
293-23	41343-41345	to	_
293-24	41346-41354	impaired	_
293-25	41355-41365	inhibitory	_
293-26	41366-41374	function	_
293-27	41374-41375	.	_

#Text=Response inhibition deficits are present in a range of disorders, including Sz, but also ADHD.
294-1	41376-41384	Response	_
294-2	41385-41395	inhibition	_
294-3	41396-41404	deficits	_
294-4	41405-41408	are	_
294-5	41409-41416	present	_
294-6	41417-41419	in	_
294-7	41420-41421	a	_
294-8	41422-41427	range	_
294-9	41428-41430	of	_
294-10	41431-41440	disorders	_
294-11	41440-41441	,	_
294-12	41442-41451	including	_
294-13	41452-41454	Sz	_
294-14	41454-41455	,	_
294-15	41456-41459	but	_
294-16	41460-41464	also	_
294-17	41465-41469	ADHD	_
294-18	41469-41470	.	_

#Text=Nevertheless, neurophysiological patterns during continuous performance tests may differ considerably across disorders.
295-1	41471-41483	Nevertheless	_
295-2	41483-41484	,	_
295-3	41485-41503	neurophysiological	_
295-4	41504-41512	patterns	_
295-5	41513-41519	during	_
295-6	41520-41530	continuous	_
295-7	41531-41542	performance	_
295-8	41543-41548	tests	_
295-9	41549-41552	may	_
295-10	41553-41559	differ	_
295-11	41560-41572	considerably	_
295-12	41573-41579	across	_
295-13	41580-41589	disorders	_
295-14	41589-41590	.	_

#Text=The fractionation of electrophysiological and neuroimaging mechanisms demonstrated underlying biomarkers that may help distinguish among clinical groups, and to mapping of cognitive control deficits reflected by response inhibition at the physiological and distributed circuit units of analysis.
296-1	41591-41594	The	_
296-2	41595-41608	fractionation	_
296-3	41609-41611	of	_
296-4	41612-41632	electrophysiological	_
296-5	41633-41636	and	_
296-6	41637-41649	neuroimaging	_
296-7	41650-41660	mechanisms	_
296-8	41661-41673	demonstrated	_
296-9	41674-41684	underlying	_
296-10	41685-41695	biomarkers	_
296-11	41696-41700	that	_
296-12	41701-41704	may	_
296-13	41705-41709	help	_
296-14	41710-41721	distinguish	_
296-15	41722-41727	among	_
296-16	41728-41736	clinical	_
296-17	41737-41743	groups	_
296-18	41743-41744	,	_
296-19	41745-41748	and	_
296-20	41749-41751	to	_
296-21	41752-41759	mapping	_
296-22	41760-41762	of	_
296-23	41763-41772	cognitive	_
296-24	41773-41780	control	_
296-25	41781-41789	deficits	_
296-26	41790-41799	reflected	_
296-27	41800-41802	by	_
296-28	41803-41811	response	_
296-29	41812-41822	inhibition	_
296-30	41823-41825	at	_
296-31	41826-41829	the	_
296-32	41830-41843	physiological	_
296-33	41844-41847	and	_
296-34	41848-41859	distributed	_
296-35	41860-41867	circuit	_
296-36	41868-41873	units	_
296-37	41874-41876	of	_
296-38	41877-41885	analysis	_
296-39	41885-41886	.	_

#Text=Funding
#Text=This work was supported by  R21MH084031 to MJH and R01MH049334 to DCJ.
297-1	41887-41894	Funding	_
297-2	41895-41899	This	_
297-3	41900-41904	work	_
297-4	41905-41908	was	_
297-5	41909-41918	supported	_
297-6	41919-41921	by	_
297-7	41923-41934	R21MH084031	_
297-8	41935-41937	to	_
297-9	41938-41941	MJH	_
297-10	41942-41945	and	_
297-11	41946-41957	R01MH049334	_
297-12	41958-41960	to	_
297-13	41961-41964	DCJ	_
297-14	41964-41965	.	_

#Text=MRI scanner funded by  grant 1S10RR022972-01.
298-1	41966-41969	MRI	_
298-2	41970-41977	scanner	_
298-3	41978-41984	funded	_
298-4	41985-41987	by	_
298-5	41989-41994	grant	_
298-6	41995-42007	1S10RR022972	_
298-7	42007-42008	-	_
298-8	42008-42010	01	_
298-9	42010-42011	.	_

#Text=References
#Text=MRI study of white matter diffusion anisotropy in schizophrenia
#Text=Triangulating a cognitive control network using diffusion-weighted magnetic resonance imaging (MRI) and functional MRI
#Text=Inhibition and the right inferior frontal cortex: one decade on
#Text=Functional connectivity in the motor cortex of resting human brain using echo-planar mri
#Text=Early-stage visual processing and cortical amplification deficits in schizophrenia
#Text=Visual white matter integrity in schizophrenia
#Text=Contributions of low and high spatial frequency processing to impaired object recognition circuitry in schizophrenia
#Text=Insights into the neural basis of response inhibition from cognitive and clinical neuroscience
#Text=DPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI
#Text=
#Text=Identifying the brain's most globally connected regions
#Text=Variable global dysconnectivity and individual differences in schizophrenia
#Text=Engagement of large-scale networks is related to individual differences in inhibitory control
#Text=Toward new approaches to psychotic disorders: the NIMH research domain criteria project
#Text=EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis
#Text=Cortical sources of the early components of the visual evoked potential
#Text=Early sensory contributions to contextual encoding deficits in schizophrenia
#Text=Dissociating inhibition, attention, and response control in the Frontoparietal network using functional magnetic resonance imaging
#Text=Distinct brain networks for adaptive and stable task control in humans
#Text=Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit
#Text=Psychophysiological and modulatory interactions in neuroimaging
#Text=Dynamic causal modelling
#Text=
#Text=A multi-modal parcellation of human cerebral cortex
#Text=Separate visual pathways for perception and action
#Text=Save the global: global signal connectivity as a tool for studying clinical populations with functional magnetic resonance imaging
#Text=Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior
#Text=Stop-signal response inhibition in schizophrenia: behavioural, event-related potential and functional neuroimaging data
#Text=When doors of perception close: bottom-up models of disrupted cognition in schizophrenia
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Neural substrates of auditory emotion recognition deficits in schizophrenia
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia
#Text=Differentiating suicide attempters from suicide ideators: a critical frontier for suicidology research
#Text=Predictive suppression of cortical excitability and its deficit in schizophrenia
#Text=The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents
#Text=Voxelwise correlational analyses of white matter integrity in multiple cognitive domains in schizophrenia
#Text=Five-factor model of schizophrenia initial validation
#Text=Inhibitory control and psychopathology: a meta-analysis of studies using the stop signal task
#Text=
#Text=On the ability to inhibit thought and action: a theory of an act of control
#Text=
#Text=Error detection failures in schizophrenia: ERPs and FMRI
#Text=The impact of global signal regression on resting state correlations: are anti-correlated networks introduced?
299-1	42012-42022	References	_
299-2	42023-42026	MRI	_
299-3	42027-42032	study	_
299-4	42033-42035	of	_
299-5	42036-42041	white	_
299-6	42042-42048	matter	_
299-7	42049-42058	diffusion	_
299-8	42059-42069	anisotropy	_
299-9	42070-42072	in	_
299-10	42073-42086	schizophrenia	_
299-11	42087-42100	Triangulating	_
299-12	42101-42102	a	_
299-13	42103-42112	cognitive	_
299-14	42113-42120	control	_
299-15	42121-42128	network	_
299-16	42129-42134	using	_
299-17	42135-42153	diffusion-weighted	_
299-18	42154-42162	magnetic	_
299-19	42163-42172	resonance	_
299-20	42173-42180	imaging	_
299-21	42181-42182	(	_
299-22	42182-42185	MRI	_
299-23	42185-42186	)	_
299-24	42187-42190	and	_
299-25	42191-42201	functional	_
299-26	42202-42205	MRI	_
299-27	42206-42216	Inhibition	_
299-28	42217-42220	and	_
299-29	42221-42224	the	_
299-30	42225-42230	right	_
299-31	42231-42239	inferior	_
299-32	42240-42247	frontal	_
299-33	42248-42254	cortex	_
299-34	42254-42255	:	_
299-35	42256-42259	one	_
299-36	42260-42266	decade	_
299-37	42267-42269	on	_
299-38	42270-42280	Functional	_
299-39	42281-42293	connectivity	_
299-40	42294-42296	in	_
299-41	42297-42300	the	_
299-42	42301-42306	motor	_
299-43	42307-42313	cortex	_
299-44	42314-42316	of	_
299-45	42317-42324	resting	_
299-46	42325-42330	human	_
299-47	42331-42336	brain	_
299-48	42337-42342	using	_
299-49	42343-42354	echo-planar	_
299-50	42355-42358	mri	_
299-51	42359-42370	Early-stage	_
299-52	42371-42377	visual	_
299-53	42378-42388	processing	_
299-54	42389-42392	and	_
299-55	42393-42401	cortical	_
299-56	42402-42415	amplification	_
299-57	42416-42424	deficits	_
299-58	42425-42427	in	_
299-59	42428-42441	schizophrenia	_
299-60	42442-42448	Visual	_
299-61	42449-42454	white	_
299-62	42455-42461	matter	_
299-63	42462-42471	integrity	_
299-64	42472-42474	in	_
299-65	42475-42488	schizophrenia	_
299-66	42489-42502	Contributions	_
299-67	42503-42505	of	_
299-68	42506-42509	low	_
299-69	42510-42513	and	_
299-70	42514-42518	high	_
299-71	42519-42526	spatial	_
299-72	42527-42536	frequency	_
299-73	42537-42547	processing	_
299-74	42548-42550	to	_
299-75	42551-42559	impaired	_
299-76	42560-42566	object	_
299-77	42567-42578	recognition	_
299-78	42579-42588	circuitry	_
299-79	42589-42591	in	_
299-80	42592-42605	schizophrenia	_
299-81	42606-42614	Insights	_
299-82	42615-42619	into	_
299-83	42620-42623	the	_
299-84	42624-42630	neural	_
299-85	42631-42636	basis	_
299-86	42637-42639	of	_
299-87	42640-42648	response	_
299-88	42649-42659	inhibition	_
299-89	42660-42664	from	_
299-90	42665-42674	cognitive	_
299-91	42675-42678	and	_
299-92	42679-42687	clinical	_
299-93	42688-42700	neuroscience	_
299-94	42701-42707	DPARSF	_
299-95	42707-42708	:	_
299-96	42709-42710	a	_
299-97	42711-42717	MATLAB	_
299-98	42718-42725	toolbox	_
299-99	42726-42729	for	_
299-100	42730-42731	“	_
299-101	42731-42739	pipeline	_
299-102	42739-42740	”	_
299-103	42741-42745	data	_
299-104	42746-42754	analysis	_
299-105	42755-42757	of	_
299-106	42758-42771	resting-state	_
299-107	42772-42776	fMRI	_
299-108	42778-42789	Identifying	_
299-109	42790-42793	the	_
299-110	42794-42801	brain's	_
299-111	42802-42806	most	_
299-112	42807-42815	globally	_
299-113	42816-42825	connected	_
299-114	42826-42833	regions	_
299-115	42834-42842	Variable	_
299-116	42843-42849	global	_
299-117	42850-42865	dysconnectivity	_
299-118	42866-42869	and	_
299-119	42870-42880	individual	_
299-120	42881-42892	differences	_
299-121	42893-42895	in	_
299-122	42896-42909	schizophrenia	_
299-123	42910-42920	Engagement	_
299-124	42921-42923	of	_
299-125	42924-42935	large-scale	_
299-126	42936-42944	networks	_
299-127	42945-42947	is	_
299-128	42948-42955	related	_
299-129	42956-42958	to	_
299-130	42959-42969	individual	_
299-131	42970-42981	differences	_
299-132	42982-42984	in	_
299-133	42985-42995	inhibitory	_
299-134	42996-43003	control	_
299-135	43004-43010	Toward	_
299-136	43011-43014	new	_
299-137	43015-43025	approaches	_
299-138	43026-43028	to	_
299-139	43029-43038	psychotic	_
299-140	43039-43048	disorders	_
299-141	43048-43049	:	_
299-142	43050-43053	the	_
299-143	43054-43058	NIMH	_
299-144	43059-43067	research	_
299-145	43068-43074	domain	_
299-146	43075-43083	criteria	_
299-147	43084-43091	project	_
299-148	43092-43098	EEGLAB	_
299-149	43098-43099	:	_
299-150	43100-43102	an	_
299-151	43103-43107	open	_
299-152	43108-43114	source	_
299-153	43115-43122	toolbox	_
299-154	43123-43126	for	_
299-155	43127-43135	analysis	_
299-156	43136-43138	of	_
299-157	43139-43151	single-trial	_
299-158	43152-43155	EEG	_
299-159	43156-43164	dynamics	_
299-160	43165-43174	including	_
299-161	43175-43186	independent	_
299-162	43187-43196	component	_
299-163	43197-43205	analysis	_
299-164	43206-43214	Cortical	_
299-165	43215-43222	sources	_
299-166	43223-43225	of	_
299-167	43226-43229	the	_
299-168	43230-43235	early	_
299-169	43236-43246	components	_
299-170	43247-43249	of	_
299-171	43250-43253	the	_
299-172	43254-43260	visual	_
299-173	43261-43267	evoked	_
299-174	43268-43277	potential	_
299-175	43278-43283	Early	_
299-176	43284-43291	sensory	_
299-177	43292-43305	contributions	_
299-178	43306-43308	to	_
299-179	43309-43319	contextual	_
299-180	43320-43328	encoding	_
299-181	43329-43337	deficits	_
299-182	43338-43340	in	_
299-183	43341-43354	schizophrenia	_
299-184	43355-43367	Dissociating	_
299-185	43368-43378	inhibition	_
299-186	43378-43379	,	_
299-187	43380-43389	attention	_
299-188	43389-43390	,	_
299-189	43391-43394	and	_
299-190	43395-43403	response	_
299-191	43404-43411	control	_
299-192	43412-43414	in	_
299-193	43415-43418	the	_
299-194	43419-43433	Frontoparietal	_
299-195	43434-43441	network	_
299-196	43442-43447	using	_
299-197	43448-43458	functional	_
299-198	43459-43467	magnetic	_
299-199	43468-43477	resonance	_
299-200	43478-43485	imaging	_
299-201	43486-43494	Distinct	_
299-202	43495-43500	brain	_
299-203	43501-43509	networks	_
299-204	43510-43513	for	_
299-205	43514-43522	adaptive	_
299-206	43523-43526	and	_
299-207	43527-43533	stable	_
299-208	43534-43538	task	_
299-209	43539-43546	control	_
299-210	43547-43549	in	_
299-211	43550-43556	humans	_
299-212	43557-43567	Behavioral	_
299-213	43568-43576	response	_
299-214	43577-43587	inhibition	_
299-215	43588-43590	in	_
299-216	43591-43600	psychotic	_
299-217	43601-43610	disorders	_
299-218	43610-43611	:	_
299-219	43612-43622	diagnostic	_
299-220	43623-43634	specificity	_
299-221	43634-43635	,	_
299-222	43636-43647	familiality	_
299-223	43648-43651	and	_
299-224	43652-43660	relation	_
299-225	43661-43663	to	_
299-226	43664-43675	generalized	_
299-227	43676-43685	cognitive	_
299-228	43686-43693	deficit	_
299-229	43694-43713	Psychophysiological	_
299-230	43714-43717	and	_
299-231	43718-43728	modulatory	_
299-232	43729-43741	interactions	_
299-233	43742-43744	in	_
299-234	43745-43757	neuroimaging	_
299-235	43758-43765	Dynamic	_
299-236	43766-43772	causal	_
299-237	43773-43782	modelling	_
299-238	43784-43785	A	_
299-239	43786-43797	multi-modal	_
299-240	43798-43810	parcellation	_
299-241	43811-43813	of	_
299-242	43814-43819	human	_
299-243	43820-43828	cerebral	_
299-244	43829-43835	cortex	_
299-245	43836-43844	Separate	_
299-246	43845-43851	visual	_
299-247	43852-43860	pathways	_
299-248	43861-43864	for	_
299-249	43865-43875	perception	_
299-250	43876-43879	and	_
299-251	43880-43886	action	_
299-252	43887-43891	Save	_
299-253	43892-43895	the	_
299-254	43896-43902	global	_
299-255	43902-43903	:	_
299-256	43904-43910	global	_
299-257	43911-43917	signal	_
299-258	43918-43930	connectivity	_
299-259	43931-43933	as	_
299-260	43934-43935	a	_
299-261	43936-43940	tool	_
299-262	43941-43944	for	_
299-263	43945-43953	studying	_
299-264	43954-43962	clinical	_
299-265	43963-43974	populations	_
299-266	43975-43979	with	_
299-267	43980-43990	functional	_
299-268	43991-43999	magnetic	_
299-269	44000-44009	resonance	_
299-270	44010-44017	imaging	_
299-271	44018-44026	Cortical	_
299-272	44027-44035	thinning	_
299-273	44035-44036	,	_
299-274	44037-44047	functional	_
299-275	44048-44060	connectivity	_
299-276	44060-44061	,	_
299-277	44062-44065	and	_
299-278	44066-44078	mood-related	_
299-279	44079-44090	impulsivity	_
299-280	44091-44093	in	_
299-281	44094-44107	schizophrenia	_
299-282	44107-44108	:	_
299-283	44109-44121	relationship	_
299-284	44122-44124	to	_
299-285	44125-44135	aggressive	_
299-286	44136-44145	attitudes	_
299-287	44146-44149	and	_
299-288	44150-44158	behavior	_
299-289	44159-44170	Stop-signal	_
299-290	44171-44179	response	_
299-291	44180-44190	inhibition	_
299-292	44191-44193	in	_
299-293	44194-44207	schizophrenia	_
299-294	44207-44208	:	_
299-295	44209-44220	behavioural	_
299-296	44220-44221	,	_
299-297	44222-44235	event-related	_
299-298	44236-44245	potential	_
299-299	44246-44249	and	_
299-300	44250-44260	functional	_
299-301	44261-44273	neuroimaging	_
299-302	44274-44278	data	_
299-303	44279-44283	When	_
299-304	44284-44289	doors	_
299-305	44290-44292	of	_
299-306	44293-44303	perception	_
299-307	44304-44309	close	_
299-308	44309-44310	:	_
299-309	44311-44320	bottom-up	_
299-310	44321-44327	models	_
299-311	44328-44330	of	_
299-312	44331-44340	disrupted	_
299-313	44341-44350	cognition	_
299-314	44351-44353	in	_
299-315	44354-44367	schizophrenia	_
299-316	44368-44376	Improved	_
299-317	44377-44389	optimization	_
299-318	44390-44393	for	_
299-319	44394-44397	the	_
299-320	44398-44404	robust	_
299-321	44405-44408	and	_
299-322	44409-44417	accurate	_
299-323	44418-44424	linear	_
299-324	44425-44437	registration	_
299-325	44438-44441	and	_
299-326	44442-44448	motion	_
299-327	44449-44459	correction	_
299-328	44460-44462	of	_
299-329	44463-44468	brain	_
299-330	44469-44475	images	_
299-331	44476-44482	Neural	_
299-332	44483-44493	substrates	_
299-333	44494-44496	of	_
299-334	44497-44505	auditory	_
299-335	44506-44513	emotion	_
299-336	44514-44525	recognition	_
299-337	44526-44534	deficits	_
299-338	44535-44537	in	_
299-339	44538-44551	schizophrenia	_
299-340	44552-44555	The	_
299-341	44556-44564	positive	_
299-342	44565-44568	and	_
299-343	44569-44577	negative	_
299-344	44578-44586	syndrome	_
299-345	44587-44592	scale	_
299-346	44593-44594	(	_
299-347	44594-44599	PANSS	_
299-348	44599-44600	)	_
299-349	44601-44604	for	_
299-350	44605-44618	schizophrenia	_
299-351	44619-44631	Hierarchical	_
299-352	44632-44644	organization	_
299-353	44645-44647	of	_
299-354	44648-44653	gamma	_
299-355	44654-44657	and	_
299-356	44658-44663	theta	_
299-357	44664-44675	oscillatory	_
299-358	44676-44684	dynamics	_
299-359	44685-44687	in	_
299-360	44688-44701	schizophrenia	_
299-361	44702-44717	Differentiating	_
299-362	44718-44725	suicide	_
299-363	44726-44736	attempters	_
299-364	44737-44741	from	_
299-365	44742-44749	suicide	_
299-366	44750-44758	ideators	_
299-367	44758-44759	:	_
299-368	44760-44761	a	_
299-369	44762-44770	critical	_
299-370	44771-44779	frontier	_
299-371	44780-44783	for	_
299-372	44784-44795	suicidology	_
299-373	44796-44804	research	_
299-374	44805-44815	Predictive	_
299-375	44816-44827	suppression	_
299-376	44828-44830	of	_
299-377	44831-44839	cortical	_
299-378	44840-44852	excitability	_
299-379	44853-44856	and	_
299-380	44857-44860	its	_
299-381	44861-44868	deficit	_
299-382	44869-44871	in	_
299-383	44872-44885	schizophrenia	_
299-384	44886-44889	The	_
299-385	44890-44896	neural	_
299-386	44897-44907	substrates	_
299-387	44908-44910	of	_
299-388	44911-44919	impaired	_
299-389	44920-44928	prosodic	_
299-390	44929-44938	detection	_
299-391	44939-44941	in	_
299-392	44942-44955	schizophrenia	_
299-393	44956-44959	and	_
299-394	44960-44963	its	_
299-395	44964-44973	sensorial	_
299-396	44974-44985	antecedents	_
299-397	44986-44995	Voxelwise	_
299-398	44996-45009	correlational	_
299-399	45010-45018	analyses	_
299-400	45019-45021	of	_
299-401	45022-45027	white	_
299-402	45028-45034	matter	_
299-403	45035-45044	integrity	_
299-404	45045-45047	in	_
299-405	45048-45056	multiple	_
299-406	45057-45066	cognitive	_
299-407	45067-45074	domains	_
299-408	45075-45077	in	_
299-409	45078-45091	schizophrenia	_
299-410	45092-45103	Five-factor	_
299-411	45104-45109	model	_
299-412	45110-45112	of	_
299-413	45113-45126	schizophrenia	_
299-414	45127-45134	initial	_
299-415	45135-45145	validation	_
299-416	45146-45156	Inhibitory	_
299-417	45157-45164	control	_
299-418	45165-45168	and	_
299-419	45169-45184	psychopathology	_
299-420	45184-45185	:	_
299-421	45186-45187	a	_
299-422	45188-45201	meta-analysis	_
299-423	45202-45204	of	_
299-424	45205-45212	studies	_
299-425	45213-45218	using	_
299-426	45219-45222	the	_
299-427	45223-45227	stop	_
299-428	45228-45234	signal	_
299-429	45235-45239	task	_
299-430	45241-45243	On	_
299-431	45244-45247	the	_
299-432	45248-45255	ability	_
299-433	45256-45258	to	_
299-434	45259-45266	inhibit	_
299-435	45267-45274	thought	_
299-436	45275-45278	and	_
299-437	45279-45285	action	_
299-438	45285-45286	:	_
299-439	45287-45288	a	_
299-440	45289-45295	theory	_
299-441	45296-45298	of	_
299-442	45299-45301	an	_
299-443	45302-45305	act	_
299-444	45306-45308	of	_
299-445	45309-45316	control	_
299-446	45318-45323	Error	_
299-447	45324-45333	detection	_
299-448	45334-45342	failures	_
299-449	45343-45345	in	_
299-450	45346-45359	schizophrenia	_
299-451	45359-45360	:	_
299-452	45361-45365	ERPs	_
299-453	45366-45369	and	_
299-454	45370-45374	FMRI	_
299-455	45375-45378	The	_
299-456	45379-45385	impact	_
299-457	45386-45388	of	_
299-458	45389-45395	global	_
299-459	45396-45402	signal	_
299-460	45403-45413	regression	_
299-461	45414-45416	on	_
299-462	45417-45424	resting	_
299-463	45425-45430	state	_
299-464	45431-45443	correlations	_
299-465	45443-45444	:	_
299-466	45445-45448	are	_
299-467	45449-45464	anti-correlated	_
299-468	45465-45473	networks	_
299-469	45474-45484	introduced	_
299-470	45484-45485	?	_

#Text=Impulsivity across the psychosis spectrum: correlates of cortical volume, suicidal history, and social and global function
#Text=Comparison of large-scale human brain functional and anatomical networks in schizophrenia
#Text=Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls
#Text=The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity
#Text=Roles of multiscale brain activity fluctuations in shaping the variability and dynamics of psychophysical performance
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection
#Text=Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia
#Text=Common inhibitory prefrontal activation during inhibition of hand and foot responses
#Text=Response inhibition and response monitoring in a saccadic double-step task in schizophrenia
#Text=
#Text=
#Text=Electrophysiological indices of information processing in methylphenidate responders
#Text=Distortion of ERP averages due to overlap from temporally adjacent ERPs: analysis and correction
#Text=Chlorpromazine equivalent doses for the newer atypical antipsychotics
#Text=Response inhibition and psychopathology: a meta-analysis of go/no-go task performance
#Text=A comprehensive assessment of regional variation in the impact of head micromovements on functional connectomics
#Text=Altered global brain signal in schizophrenia
#Text=The organization of the human cerebral cortex estimated by intrinsic functional connectivity
#Text=The oscillating brain: complex and reliable
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2018.01.001.
300-1	45486-45497	Impulsivity	_
300-2	45498-45504	across	_
300-3	45505-45508	the	_
300-4	45509-45518	psychosis	_
300-5	45519-45527	spectrum	_
300-6	45527-45528	:	_
300-7	45529-45539	correlates	_
300-8	45540-45542	of	_
300-9	45543-45551	cortical	_
300-10	45552-45558	volume	_
300-11	45558-45559	,	_
300-12	45560-45568	suicidal	_
300-13	45569-45576	history	_
300-14	45576-45577	,	_
300-15	45578-45581	and	_
300-16	45582-45588	social	_
300-17	45589-45592	and	_
300-18	45593-45599	global	_
300-19	45600-45608	function	_
300-20	45609-45619	Comparison	_
300-21	45620-45622	of	_
300-22	45623-45634	large-scale	_
300-23	45635-45640	human	_
300-24	45641-45646	brain	_
300-25	45647-45657	functional	_
300-26	45658-45661	and	_
300-27	45662-45672	anatomical	_
300-28	45673-45681	networks	_
300-29	45682-45684	in	_
300-30	45685-45698	schizophrenia	_
300-31	45699-45710	Self-report	_
300-32	45711-45714	and	_
300-33	45715-45725	laboratory	_
300-34	45726-45734	measures	_
300-35	45735-45737	of	_
300-36	45738-45749	impulsivity	_
300-37	45750-45752	in	_
300-38	45753-45761	patients	_
300-39	45762-45766	with	_
300-40	45767-45780	schizophrenia	_
300-41	45781-45783	or	_
300-42	45784-45799	schizoaffective	_
300-43	45800-45808	disorder	_
300-44	45809-45812	and	_
300-45	45813-45820	healthy	_
300-46	45821-45829	controls	_
300-47	45830-45833	The	_
300-48	45834-45841	MATRICS	_
300-49	45842-45851	consensus	_
300-50	45852-45861	cognitive	_
300-51	45862-45869	battery	_
300-52	45869-45870	,	_
300-53	45871-45875	part	_
300-54	45876-45877	1	_
300-55	45877-45878	:	_
300-56	45879-45883	test	_
300-57	45884-45893	selection	_
300-58	45893-45894	,	_
300-59	45895-45906	reliability	_
300-60	45906-45907	,	_
300-61	45908-45911	and	_
300-62	45912-45920	validity	_
300-63	45921-45926	Roles	_
300-64	45927-45929	of	_
300-65	45930-45940	multiscale	_
300-66	45941-45946	brain	_
300-67	45947-45955	activity	_
300-68	45956-45968	fluctuations	_
300-69	45969-45971	in	_
300-70	45972-45979	shaping	_
300-71	45980-45983	the	_
300-72	45984-45995	variability	_
300-73	45996-45999	and	_
300-74	46000-46008	dynamics	_
300-75	46009-46011	of	_
300-76	46012-46026	psychophysical	_
300-77	46027-46038	performance	_
300-78	46039-46047	Spurious	_
300-79	46048-46051	but	_
300-80	46052-46062	systematic	_
300-81	46063-46075	correlations	_
300-82	46076-46078	in	_
300-83	46079-46089	functional	_
300-84	46090-46102	connectivity	_
300-85	46103-46106	MRI	_
300-86	46107-46115	networks	_
300-87	46116-46121	arise	_
300-88	46122-46126	from	_
300-89	46127-46134	subject	_
300-90	46135-46141	motion	_
300-91	46142-46147	Right	_
300-92	46148-46156	inferior	_
300-93	46157-46167	prefrontal	_
300-94	46168-46174	cortex	_
300-95	46175-46183	mediates	_
300-96	46184-46192	response	_
300-97	46193-46203	inhibition	_
300-98	46204-46209	while	_
300-99	46210-46216	mesial	_
300-100	46217-46227	prefrontal	_
300-101	46228-46234	cortex	_
300-102	46235-46237	is	_
300-103	46238-46249	responsible	_
300-104	46250-46253	for	_
300-105	46254-46259	error	_
300-106	46260-46269	detection	_
300-107	46270-46285	Fronto-parietal	_
300-108	46286-46289	and	_
300-109	46290-46307	cingulo-opercular	_
300-110	46308-46315	network	_
300-111	46316-46325	integrity	_
300-112	46326-46329	and	_
300-113	46330-46339	cognition	_
300-114	46340-46342	in	_
300-115	46343-46349	health	_
300-116	46350-46353	and	_
300-117	46354-46367	schizophrenia	_
300-118	46368-46374	Common	_
300-119	46375-46385	inhibitory	_
300-120	46386-46396	prefrontal	_
300-121	46397-46407	activation	_
300-122	46408-46414	during	_
300-123	46415-46425	inhibition	_
300-124	46426-46428	of	_
300-125	46429-46433	hand	_
300-126	46434-46437	and	_
300-127	46438-46442	foot	_
300-128	46443-46452	responses	_
300-129	46453-46461	Response	_
300-130	46462-46472	inhibition	_
300-131	46473-46476	and	_
300-132	46477-46485	response	_
300-133	46486-46496	monitoring	_
300-134	46497-46499	in	_
300-135	46500-46501	a	_
300-136	46502-46510	saccadic	_
300-137	46511-46522	double-step	_
300-138	46523-46527	task	_
300-139	46528-46530	in	_
300-140	46531-46544	schizophrenia	_
300-141	46547-46567	Electrophysiological	_
300-142	46568-46575	indices	_
300-143	46576-46578	of	_
300-144	46579-46590	information	_
300-145	46591-46601	processing	_
300-146	46602-46604	in	_
300-147	46605-46620	methylphenidate	_
300-148	46621-46631	responders	_
300-149	46632-46642	Distortion	_
300-150	46643-46645	of	_
300-151	46646-46649	ERP	_
300-152	46650-46658	averages	_
300-153	46659-46662	due	_
300-154	46663-46665	to	_
300-155	46666-46673	overlap	_
300-156	46674-46678	from	_
300-157	46679-46689	temporally	_
300-158	46690-46698	adjacent	_
300-159	46699-46703	ERPs	_
300-160	46703-46704	:	_
300-161	46705-46713	analysis	_
300-162	46714-46717	and	_
300-163	46718-46728	correction	_
300-164	46729-46743	Chlorpromazine	_
300-165	46744-46754	equivalent	_
300-166	46755-46760	doses	_
300-167	46761-46764	for	_
300-168	46765-46768	the	_
300-169	46769-46774	newer	_
300-170	46775-46783	atypical	_
300-171	46784-46798	antipsychotics	_
300-172	46799-46807	Response	_
300-173	46808-46818	inhibition	_
300-174	46819-46822	and	_
300-175	46823-46838	psychopathology	_
300-176	46838-46839	:	_
300-177	46840-46841	a	_
300-178	46842-46855	meta-analysis	_
300-179	46856-46858	of	_
300-180	46859-46861	go	_
300-181	46861-46862	/	_
300-182	46862-46867	no-go	_
300-183	46868-46872	task	_
300-184	46873-46884	performance	_
300-185	46885-46886	A	_
300-186	46887-46900	comprehensive	_
300-187	46901-46911	assessment	_
300-188	46912-46914	of	_
300-189	46915-46923	regional	_
300-190	46924-46933	variation	_
300-191	46934-46936	in	_
300-192	46937-46940	the	_
300-193	46941-46947	impact	_
300-194	46948-46950	of	_
300-195	46951-46955	head	_
300-196	46956-46970	micromovements	_
300-197	46971-46973	on	_
300-198	46974-46984	functional	_
300-199	46985-46997	connectomics	_
300-200	46998-47005	Altered	_
300-201	47006-47012	global	_
300-202	47013-47018	brain	_
300-203	47019-47025	signal	_
300-204	47026-47028	in	_
300-205	47029-47042	schizophrenia	_
300-206	47043-47046	The	_
300-207	47047-47059	organization	_
300-208	47060-47062	of	_
300-209	47063-47066	the	_
300-210	47067-47072	human	_
300-211	47073-47081	cerebral	_
300-212	47082-47088	cortex	_
300-213	47089-47098	estimated	_
300-214	47099-47101	by	_
300-215	47102-47111	intrinsic	_
300-216	47112-47122	functional	_
300-217	47123-47135	connectivity	_
300-218	47136-47139	The	_
300-219	47140-47151	oscillating	_
300-220	47152-47157	brain	_
300-221	47157-47158	:	_
300-222	47159-47166	complex	_
300-223	47167-47170	and	_
300-224	47171-47179	reliable	_
300-225	47180-47193	Supplementary	_
300-226	47194-47198	data	_
300-227	47199-47212	Supplementary	_
300-228	47213-47217	data	_
300-229	47218-47220	to	_
300-230	47221-47225	this	_
300-231	47226-47233	article	_
300-232	47234-47237	can	_
300-233	47238-47240	be	_
300-234	47241-47246	found	_
300-235	47247-47253	online	_
300-236	47254-47256	at	_
300-237	47257-47262	https	_
300-238	47262-47263	:	_
300-239	47263-47264	/	_
300-240	47264-47265	/	_
300-241	47265-47272	doi.org	_
300-242	47272-47273	/	_
300-243	47273-47280	10.1016	_
300-244	47280-47281	/	_
300-245	47281-47287	j.nicl	_
300-246	47287-47299	.2018.01.001	_
300-247	47299-47300	.	_
